diff --git a/trait-representation-migration/remove_background_trait_links.py b/trait-representation-migration/remove_background_trait_links.py new file mode 100755 index 0000000..97a24a2 --- /dev/null +++ b/trait-representation-migration/remove_background_trait_links.py @@ -0,0 +1,213 @@ +# Activate Python venv for the script - uncomment to run script on commandline +# activate_this_file = "/path/to/bin/activate_this.py" +# execfile(activate_this_file, dict(__file__ = activate_this_file)) + +import cx_Oracle +import contextlib +import argparse +import sys +from tqdm import tqdm +import csv +import os.path + +sys.path.insert(0, '/path/to/gwas_data_sources') +import gwas_data_sources + +import datetime + + +def read_file(filename): + ''' + Read file. + + Args: + filename: Name of file provided as a commandline argument. + + Returns: + data_map: Dictionary with the STUDY_ID as the key and a + list of EFO_IDs as the dictionary value. + ''' + + with open(filename, 'r') as file: + lines = file.readlines()[1:] + + return lines + + +def process_file_contents(file_data, efo_map, cursor): + ''' + Extract fields of interest from the file and clean-up values. + + Args: + file_data: Contents of the file. + ''' + + count = 0 + + for line in file_data: + formatted_line = line.split('\t') + + study_accession = formatted_line[2].strip() + study_id = _get_study_id(study_accession) + + background_column = formatted_line[4].strip() + + delimiter = '||' + + if not background_column == '': + count += 1 + # print('\nCount: {} StudyID: {} Accession: {}'.format(count, study_id, study_accession)) + + if delimiter in background_column: + background_column = background_column.split(delimiter) + + for background_trait in background_column: + # Get the EFO_ID + background_trait_id = efo_map[background_trait.strip().lower()] + # print('TID: {}'.format(background_trait_id)) + _execute_delete_query(cursor, study_id, background_trait_id) + else: + # Get the EFO_ID + background_trait_id = efo_map[background_column.strip().lower()] + # print('TID: {}'.format(background_trait_id)) + _execute_delete_query(cursor, study_id, background_trait_id) + + +def database_connection(DATABASE_NAME): + ''' + Connect to the database and returns a cursor object. + + Args: + database_name (str): The name of the database. + + Raises: + DatabaseError: Error reponse if unable to connect to the database. + + Returns: + cursor: Database cursor object. + ''' + + try: + ip, port, sid, username, password = gwas_data_sources.get_db_properties(DATABASE_NAME) + dsn_tns = cx_Oracle.makedsn(ip, port, sid) + connection = cx_Oracle.connect(username, password, dsn_tns) + + cursor = connection.cursor() + + return connection, cursor + + except cx_Oracle.DatabaseError, exception: + print exception + + +def get_efo_id_map(cursor): + ''' + Get mapping of term labels to EFO IDs. + + Args: + cursor (object): Database cursor object. + + + Returns: + efo_map: A mapping of term labels to it's EFO ID + ''' + efo_map = {} + + efo_sql = ''' + SELECT ID, LOWER(TRAIT) + FROM EFO_TRAIT + ''' + + cursor.execute(efo_sql) + efo_data = cursor.fetchall() + + for row in tqdm(efo_data, desc='Build EFO map'): + # Key is Trait, Value is ID + efo_map[row[1]] = row[0] + + return efo_map + + +def _get_study_id(accession): + ''' + Query the STUDY table with the accession to get the Study ID. + + Args: + accession (str): study accession parsed from input file + + Returns: + study_id (int): STUDY.ID, the primary key for the row with the study accession. + ''' + + study_sql = ''' + SELECT ID + FROM STUDY + WHERE ACCESSION_ID = '{}' + '''.format(accession) + + cursor.execute(study_sql) + study_id = cursor.fetchone() + + return study_id[0] + + + +def _execute_delete_query(cursor, study_id, efo_trait_id): + ''' + Delete row from STUDY_EFO_TRAIT table. + + Args: + query (str): The query to run. + + Raises: + ''' + + study_efo_trait_delete_sql = ''' + DELETE FROM STUDY_EFO_TRAIT + WHERE STUDY_ID = '{}' AND EFO_TRAIT_ID = '{}' + '''.format(study_id, efo_trait_id) + + cursor.execute(study_efo_trait_delete_sql) + + # commit or rollback changes + if args.mode == 'production': + cursor.execute('COMMIT') + else: + cursor.execute('ROLLBACK') + + +if __name__ == '__main__': + ''' + Remove background trait link to Studies. + ''' + + # Commandline arguments + parser = argparse.ArgumentParser() + parser.add_argument('--filename', default='study_background_traits-ALL.txt', + help='Name of data file (default: study_background_traits).') + parser.add_argument('--database', default='DEV3', choices=['DEV3', 'SPOTPRO'], + help='Run as (default: DEV3).') + parser.add_argument('--mode', default='debug', choices=['debug', 'production'], + help='Run as (default: debug).') + args = parser.parse_args() + + global DATABASE_NAME + DATABASE_NAME = args.database + + # Get database connection + conn, cursor = database_connection(args.database) + + # Create map of Trait labels and EFO_IDs + efo_map = get_efo_id_map(cursor) + + # Read data file + data = read_file(args.filename) + + # Format column values and remove STUDY_EFO_TRAIT link + process_file_contents(data, efo_map, cursor) + + # Close database connection + conn.close() + + + diff --git a/trait-representation-migration/study_background_traits-ALL.txt b/trait-representation-migration/study_background_traits-ALL.txt new file mode 100644 index 0000000..9bdf57e --- /dev/null +++ b/trait-representation-migration/study_background_traits-ALL.txt @@ -0,0 +1,1518 @@ +DISEASE/TRAIT MAPPED_TRAIT STUDY ACCESSION Other Background +Cannabis use (age at onset) Cannabis use|| age at onset GCST006386 Cannabis use|| age at onset +Cannabis use (age at onset) Cannabis use|| age at onset GCST002917 Cannabis use|| age at onset +Schizophrenia (age at onset) schizophrenia|| age at onset GCST001115 schizophrenia|| age at onset +Parkinson's disease in GBA mutation carriers (age at onset) Parkinson's disease|| GBA carrier status|| age at onset GCST003060 age at onset|| Parkinson's disease GBA carrier status +Bipolar disorder (age of onset and psychotic symptoms) age at onset|| psychotic symptoms|| bipolar disorder GCST000969 age at onset|| psychotic symptoms|| bipolar disorder +Curve progression in adolescent idiopathic scoliosis adolescent idiopathic scoliosis|| disease progression measurement GCST004981 adolescent idiopathic scoliosis|| disease progression measurement +Severe progression in rheumatoid arthritis rheumatoid arthritis|| disease progression measurement GCST004998 rheumatoid arthritis|| disease progression measurement +Liver transplant-free survival in primary sclerosing cholangitis (time to event) event free survival time|| sclerosing cholangitis GCST005859 event free survival time|| sclerosing cholangitis +Cholangiocarcinoma in primary sclerosing cholangitis (time to event) event free survival time|| cholangiocarcinoma|| sclerosing cholangitis GCST005860 event free survival time|| cholangiocarcinoma|| sclerosing cholangitis +Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy diffuse large B-cell lymphoma|| event free survival time|| response to immunochemotherapy GCST003178 diffuse large B-cell lymphoma|| event free survival time|| response to immunochemotherapy +Breast cancer (survival) event free survival time|| survival time|| breast carcinoma GCST001373 event free survival time|| survival time|| breast carcinoma +Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event) event free survival time|| type I diabetes mellitus|| carrier status|| autoantibody measurement GCST006197 event free survival time|| type I diabetes mellitus|| autoantibody measurement carrier status +Overall survival in osteosarcoma osteosarcoma|| overall survival GCST005158 osteosarcoma|| overall survival +Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab) progression free survival|| metastatic colorectal cancer|| response to cetuximab|| response to CAPOX-B GCST003058 progression free survival|| metastatic colorectal cancer|| response to cetuximab|| response to CAPOX-B +Progression free survival in metastatic colorectal cancer (chemotherapy interaction) progression free survival|| metastatic colorectal cancer|| response to cetuximab|| response to CAPOX-B GCST003057 progression free survival|| metastatic colorectal cancer|| response to cetuximab|| response to CAPOX-B +Breast cancer (survival) survival time|| breast carcinoma GCST005106 survival time|| breast carcinoma +Breast cancer (survival) survival time|| breast carcinoma GCST002727 survival time|| breast carcinoma +Breast cancer (survival) estrogen-receptor negative breast cancer|| survival time|| estrogen-receptor positive breast cancer|| breast carcinoma GCST002861 survival time|| estrogen-receptor negative breast cancer|| estrogen-receptor positive breast cancer|| breast carcinoma +Survival in breast cancer (estrogen-receptor positive) event free survival time|| estrogen-receptor positive breast cancer GCST005901 event free survival time|| estrogen-receptor positive breast cancer +Survival in endocrine treated breast cancer (estrogen-receptor positive) event free survival time|| estrogen-receptor positive breast cancer|| response to endocrine therapy GCST005900 event free survival time|| estrogen-receptor positive breast cancer|| response to endocrine therapy +Survival in colorectal cancer (distant metastatic) metastasis measurement|| colorectal cancer|| survival time GCST003230 metastasis measurement|| colorectal cancer|| survival time +Survival in colorectal cancer (non-distant metastatic) metastasis measurement|| colorectal cancer|| survival time GCST003231 metastasis measurement|| colorectal cancer|| survival time +Survival in breast cancer (TP53 expression interaction) overall survival|| breast carcinoma|| TP53 mutation status GCST004229 overall survival|| breast carcinoma|| TP53 mutation status +Survival in TP53 positive breast cancer overall survival|| TP53 Positive Breast Carcinoma GCST004228 overall survival|| TP53 Positive Breast Carcinoma +Survival in pancreatic cancer overall survival|| pancreatic carcinoma GCST004485 overall survival|| pancreatic carcinoma +Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin overall survival|| ovarian carcinoma|| response to cisplatin|| response to paclitaxel GCST004896 overall survival|| ovarian carcinoma|| response to cisplatin|| response to paclitaxel +Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel progression free survival|| response to carboplatin|| ovarian carcinoma|| response to paclitaxel GCST003328 progression free survival|| response to carboplatin|| ovarian carcinoma|| response to paclitaxel +Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel progression free survival|| ovarian carcinoma|| response to cisplatin|| response to paclitaxel GCST004897 progression free survival|| ovarian carcinoma|| response to cisplatin|| response to paclitaxel +Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib progression free survival|| response to gefitinib|| response to erlotinib|| lung adenocarcinoma GCST003794 progression free survival|| response to gefitinib|| response to erlotinib|| lung adenocarcinoma +Survival in colorectal cancer colorectal cancer|| survival time GCST003229 colorectal cancer|| survival time +Survival in breast cancer (estrogen-receptor negative) estrogen-receptor negative breast cancer|| survival time|| breast carcinoma GCST002902 estrogen-receptor negative breast cancer|| survival time|| breast carcinoma +Survival in breast cancer (estrogen-receptor positive) survival time|| estrogen-receptor positive breast cancer|| breast carcinoma GCST002903 survival time|| estrogen-receptor positive breast cancer|| breast carcinoma +Survival in head and neck cancer head and neck malignant neoplasia|| survival time GCST003541 head and neck malignant neoplasia|| survival time +Sepsis from pneumonia (survival) survival time|| pneumonia|| septic shock|| sepsis GCST002725 survival time|| pneumonia|| septic shock|| sepsis +Survival in sporadic amyotrophic lateral sclerosis sporadic amyotrophic lateral sclerosis|| survival time GCST003632 sporadic amyotrophic lateral sclerosis|| survival time +Survival in endocrine treated breast cancer (estrogen-receptor positive) survival time|| estrogen-receptor positive breast cancer|| breast carcinoma|| response to endocrine therapy GCST002901 survival time|| estrogen-receptor positive breast cancer|| breast carcinoma|| response to endocrine therapy +Age-related cataracts (age at onset) age at onset|| age-related cataract GCST002618 age at onset|| age-related cataract +Alcohol dependence (age at onset) age at onset|| alcohol dependence GCST002477 age at onset|| alcohol dependence +Alzheimer disease and age of onset Alzheimer's disease|| age at onset GCST003427 Alzheimer's disease|| age at onset +Alzheimer's disease (age of onset) Alzheimer's disease|| age at onset GCST006120 Alzheimer's disease|| age at onset +Alzheimer's disease (age of onset) Alzheimer's disease|| age at onset GCST001280 Alzheimer's disease|| age at onset +Alzheimer's disease (survival time) Alzheimer's disease|| survival time GCST002775 Alzheimer's disease|| survival time +Amyotrophic lateral sclerosis (age of onset) amyotrophic lateral sclerosis|| age at onset GCST001663 amyotrophic lateral sclerosis|| age at onset +Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| bipolar disorder GCST004002 attention deficit hyperactivity disorder|| bipolar disorder +Frontotemporal dementia (age at onset) age at onset|| Frontotemporal dementia GCST006147 age at onset|| Frontotemporal dementia +Frontotemporal dementia (age at onset) age at onset|| Frontotemporal dementia GCST004096 age at onset|| Frontotemporal dementia +Frontotemporal dementia with GRN mutation (age at onset) age at onset|| Frontotemporal dementia GCST006149 age at onset|| Frontotemporal dementia +Multiple myeloma (survival) overall survival|| multiple myeloma GCST003051 overall survival|| multiple myeloma +Multiple sclerosis (age of onset) multiple sclerosis|| age at onset GCST000267 multiple sclerosis|| age at onset +Myopia (age of diagnosis) age at onset|| Myopia GCST006290 age at onset|| Myopia +Narcolepsy (age of onset) narcolepsy with cataplexy|| age at onset GCST002261 narcolepsy with cataplexy|| age at onset +Non-small cell lung cancer (survival) survival time|| non-small cell lung carcinoma GCST002577 survival time|| non-small cell lung carcinoma +Non-small cell lung cancer (survival) survival time|| non-small cell lung carcinoma GCST002032 survival time|| non-small cell lung carcinoma +Non-small cell lung cancer (survival) survival time|| non-small cell lung carcinoma GCST000871 survival time|| non-small cell lung carcinoma +Parkinson's disease (age of onset) Parkinson's disease|| age at onset GCST003653 Parkinson's disease|| age at onset +Parkinson's disease (age of onset) Parkinson's disease|| age at onset GCST000490 Parkinson's disease|| age at onset +"Parkinson's disease (familial, age at onset)" Parkinson's disease|| age at onset GCST003652 Parkinson's disease|| age at onset +"Parkinson's disease (non-familial, age at onset)" Parkinson's disease|| age at onset GCST003651 Parkinson's disease|| age at onset +Prostate cancer (survival) survival time|| prostate carcinoma GCST003100 survival time|| prostate carcinoma +Spherical equivalent or myopia (age of diagnosis) age at onset|| Myopia|| refractive error measurement GCST006291 age at onset|| Myopia|| refractive error measurement +Restricted and repetitive behaviours in autism spectrum disorder autism spectrum disorder|| behavior or behavioral disorder measurement GCST004377 behavior or behavioral disorder measurement autism spectrum disorder +Serum metabolite concentrations in chronic kidney disease chronic kidney disease|| serum metabolite measurement GCST005648 serum metabolite measurement chronic kidney disease +Serum metabolite ratios in chronic kidney disease chronic kidney disease|| serum metabolite measurement GCST005650 serum metabolite measurement chronic kidney disease +3-hydroxy-1-methylpropylmercapturic acid levels in smokers smoking behavior|| 3-hydroxy-1-methylpropylmercapturic acid measurement GCST002957 3-hydroxy-1-methylpropylmercapturic acid measurement smoking behavior +3-hydroxypropylmercapturic acid levels in smokers smoking behavior|| 3-hydroxypropylmercapturic acid measurement GCST002956 3-hydroxypropylmercapturic acid measurement smoking behavior +Change in HbA1c levels in response to metformin treatment in type 2 diabetes A1C measurement|| type II diabetes mellitus|| response to metformin GCST005753 A1C measurement|| response to metformin type II diabetes mellitus +Paneth cell defects in Crohn's disease abnormal paneth cell measurement|| Crohn's disease GCST004251 abnormal paneth cell measurement Crohn's disease +Acute kidney injury in critical illness Acute kidney injury|| illness severity status GCST003656 Acute kidney injury illness severity status +Acute kidney injury in coronary artery bypass surgery (creatinine rise) coronary artery bypass|| Acute kidney injury|| serum creatinine measurement GCST002982 Acute kidney injury|| serum creatinine measurement coronary artery bypass +Acute-on-chronic liver failure in hepatitis B acute-on-chronic liver failure|| hepatitis B infection GCST004165 acute-on-chronic liver failure hepatitis B infection +Adult onset asthma in ever-smokers smoking behavior|| adult onset asthma GCST004222 adult onset asthma smoking behavior +Cannabis-related aggression Cannabis use|| aggressive behavior GCST006175 aggressive behaviour Cannabis use +Aggressiveness in attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| aggressive behaviour measurement|| childhood aggressive behaviour measurement GCST003473 aggressive behaviour measurement|| childhood aggressive behaviour measurement attention deficit hyperactivity disorder +Airway responsiveness in chronic obstructive pulmonary disease airway responsiveness measurement|| chronic obstructive pulmonary disease GCST002724 airway responsiveness measurement chronic obstructive pulmonary disease +Problematic alcohol use in trauma-exposed individuals response to trauma exposure|| alcohol dependence measurement GCST005236 alcohol dependence measurement|| response to trauma exposure +Allergic rhinitis in asthma allergic rhinitis|| asthma GCST002552 allergic rhinitis asthma +Alloimmunization response to red blood cell transfusion in sickle cell anemia Sickle cell anemia|| alloimmunization|| response to red blood cell transfusion GCST002691 alloimmunization|| response to red blood cell transfusion Sickle cell anemia +Thiopurine-induced alopecia in inflammatory bowel disease Alopecia|| response to thiopurine|| inflammatory bowel disease GCST006206 Alopecia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232) Alopecia|| response to thiopurine|| inflammatory bowel disease GCST006214 Alopecia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced severe alopecia in inflammatory bowel disease Alopecia|| response to thiopurine|| inflammatory bowel disease GCST006207 Alopecia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232) Alopecia|| response to thiopurine|| inflammatory bowel disease GCST006199 Alopecia|| response to thiopurine inflammatory bowel disease +Amygdala volume in trauma-exposed individuals response to trauma exposure|| amygdala volume GCST005239 amygdala volume|| response to trauma exposure +Plasma androstenedione levels in resected early stage-receptor positive breast cancer androstenedione measurement|| estrogen-receptor positive breast cancer GCST004363 androstenedione measurement estrogen-receptor positive breast cancer +Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer androstenedione measurement|| estrogen-receptor positive breast cancer|| estrone measurement GCST004361 androstenedione measurement|| estrone measurement estrogen-receptor positive breast cancer +Anthropometric traits in newborns anthropometric measurement|| neonate GCST001964 anthropometric measurement neonate +Antibody status in Tripanosoma cruzi seropositivity antibody measurement|| Trypanosoma cruzi seropositivity GCST002280 antibody measurement Trypanosoma cruzi seropositivity +Antipsychotic drug-induced weight gain in schizophrenia schizophrenia|| antipsychotic drug related weight gain GCST003579 antipsychotic drug related weight gain schizophrenia +antipsychotic drug dosage in schizophrenia or schizoaffective disorder schizophrenia|| antipsychotic drug use measurement|| schizoaffective disorder GCST003341 antipsychotic drug use measurement schizophrenia|| schizoaffective disorder +Anti-saccade error rate in psychotic disorders antisaccade response measurement|| schizophrenia|| bipolar disorder|| schizoaffective disorder GCST005027 antisaccade response measurement schizophrenia|| bipolar disorder|| schizoaffective disorder +Anxiety in major depressive disorder unipolar depression|| anxiety GCST002202 anxiety unipolar depression +AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor AR-C124910XX measurement|| acute coronary syndrome GCST002883 AR-C124910XX measurement acute coronary syndrome +Asparaginase hypersensitivity in acute lymphoblastic leukemia asparaginase hypersensitivity|| acute lymphoblastic leukemia GCST002915 asparaginase hypersensitivity acute lymphoblastic leukemia +Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia asparaginase-induced acute pancreatitis|| acute lymphoblastic leukemia GCST003500 asparaginase-induced acute pancreatitis acute lymphoblastic leukemia +Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time) asparaginase-induced acute pancreatitis|| acute lymphoblastic leukemia GCST003501 asparaginase-induced acute pancreatitis acute lymphoblastic leukemia +Postoperative atrial fibrillation in coronary artery bypass grafting surgery coronary artery bypass|| atrial fibrillation GCST002975 atrial fibrillation coronary artery bypass +Atrioventricular septal defects in Down syndrome Atrioventricular canal defect|| Down syndrome GCST003047 Atrioventricular canal defect Down syndrome +Suicide attempts in bipolar disorder bipolar disorder|| attempted suicide GCST001015 attempted suicide bipolar disorder +Suicide attempts in major depressive disorder unipolar depression|| attempted suicide GCST002972 attempted suicide unipolar depression +Suicide attempts in depression or bipolar disorder unipolar depression|| bipolar disorder|| attempted suicide GCST002503 attempted suicide unipolar depression|| bipolar disorder +Attention function in attention deficit hyperactive disorder attention deficit hyperactivity disorder|| attention function measurement GCST003025 attention function measurement attention deficit hyperactivity disorder +Gastric parietal cell autoantibody levels in type 1 diabetes type I diabetes mellitus|| autoantibody measurement GCST004382 autoantibody measurement type I diabetes mellitus +Glutamate decarboxylase autoantibody levels in type 1 diabetes type I diabetes mellitus|| autoantibody measurement GCST004380 autoantibody measurement type I diabetes mellitus +Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes type I diabetes mellitus|| autoantibody measurement GCST004381 autoantibody measurement type I diabetes mellitus +Autoimmune hepatitis in primary sclerosing cholangitis Autoimmune Hepatitis|| sclerosing cholangitis GCST005853 Autoimmune Hepatitis sclerosing cholangitis +Infective endocarditis in Staphylococcus aureus infection bacterial endocarditis|| Staphylococcus aureus infection GCST006805 bacterial endocarditis Staphylococcus aureus infection +Behavioural changes in frontotemporal lobe dementia Frontotemporal dementia|| behavior GCST006146 behavior Frontotemporal dementia +Temperament (bipolar disorder) behavior or behavioral disorder measurement|| personality trait|| bipolar disorder GCST001419 behavior or behavioral disorder measurement|| personality trait bipolar disorder +Behavioral disturbance or psychiatric symptoms in prion disease behavioral abnormality|| prion disease GCST002863 behavioral abnormality prion disease +Cerebrospinal AB1-42 levels in Alzheimer's disease dementia Alzheimer's disease|| beta-amyloid 1-42 measurement GCST002531 beta-amyloid 1-42 measurement Alzheimer's disease +Total bilirubin levels in HIV-1 infection HIV-1 infection|| bilirubin measurement GCST002745 bilirubin measurement HIV-1 infection +Bilirubin levels in extreme obesity bilirubin measurement|| obesity GCST002628 bilirubin measurement obesity +Bilirubin levels in tenofovir-treated HIV infection bilirubin measurement|| response to tenofovir|| HIV infection GCST006074 bilirubin measurement|| response to tenofovir HIV infection +Binge eating behaviour in bipolar disorder binge eating|| bipolar disorder GCST005387 binge eating bipolar disorder +Binge eating behaviour in bipolar disorder binge eating|| bipolar disorder GCST002420 binge eating bipolar disorder +Bone mineral density x blood lead interaction in current smokers (1df test) smoking behavior|| blood lead measurement|| bone density GCST006132 blood lead measurement|| bone density smoking behavior +Bone mineral density x blood lead interaction in current smokers (2df test) smoking behavior|| blood lead measurement|| bone density GCST006133 blood lead measurement|| bone density smoking behavior +Waist circumference adjusted for BMI in active individuals BMI-adjusted waist circumference|| physical activity measurement GCST004564 BMI-adjusted waist circumference physical activity measurement +Waist circumference adjusted for BMI in inactive individuals BMI-adjusted waist circumference|| physical activity measurement GCST004565 BMI-adjusted waist circumference physical activity measurement +Waist circumference adjusted for BMI in smokers smoking behavior|| BMI-adjusted waist circumference GCST004503 BMI-adjusted waist circumference smoking behavior +Waist-to-hip ratio adjusted for BMI in active individuals BMI-adjusted waist-hip ratio|| physical activity measurement GCST004578 BMI-adjusted waist-hip ratio physical activity measurement +Waist-to-hip ratio adjusted for BMI in inactive individuals BMI-adjusted waist-hip ratio|| physical activity measurement GCST004577 BMI-adjusted waist-hip ratio physical activity measurement +Waist-to-hip ratio adjusted for BMI in smokers smoking behavior|| BMI-adjusted waist-hip ratio GCST004509 BMI-adjusted waist-hip ratio smoking behavior +Fat distribution (HIV) HIV-1 infection|| body fat distribution GCST001343 body fat distribution HIV-1 infection +Body mass index in asthmatics body mass index|| asthma GCST001945 body mass index asthma +Body mass in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| body mass index GCST000850 body mass index chronic obstructive pulmonary disease +Body mass index in physically active individuals physical activity measurement|| body mass index GCST004559 body mass index physical activity measurement +Body mass index in physically inactive individuals physical activity measurement|| body mass index GCST004560 body mass index physical activity measurement +BMI in smokers smoking behavior|| body mass index GCST004498 body mass index smoking behavior +Weight loss (gastric bypass surgery) gastric bypass|| body weight loss GCST001991 body weight loss gastric bypass +Weight loss (gastric bypass surgery) gastric bypass|| body weight loss GCST001985 body weight loss gastric bypass +Bone fracture in osteoporosis bone fracture|| osteoporosis GCST004403 bone fracture osteoporosis +Bone mineral accretion in asthma (oral corticosteroid dose interaction) bone mineral accretion measurement|| response to corticosteroid|| asthma GCST002926 bone mineral accretion measurement|| response to corticosteroid asthma +Breast Cancer in BRCA1 mutation carriers carrier status|| breast carcinoma GCST005075 breast carcinoma carrier status +Breast cancer in childhood cancer survivors breast carcinoma|| childhood cancer GCST005111 breast carcinoma childhood cancer +Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy breast carcinoma|| childhood cancer GCST005110 breast carcinoma childhood cancer +Breslow thickness in cutaneous melanoma cutaneous melanoma|| Breslow thickness GCST003639 Breslow thickness cutaneous melanoma +Bronchopulmonary dysplasia in preterm infants Bronchopulmonary dysplasia|| premature birth GCST006460 Bronchopulmonary dysplasia premature birth +C-peptide levels in type I diabetes C-peptide measurement|| type I diabetes mellitus GCST005436 C-peptide measurement type I diabetes mellitus +Fasting C-peptide levels in type I diabetes C-peptide measurement|| type I diabetes mellitus GCST005438 C-peptide measurement type I diabetes mellitus +Random C-peptide levels in type I diabetes C-peptide measurement|| type I diabetes mellitus GCST005437 C-peptide measurement type I diabetes mellitus +Stimulated C-peptide levels in type I diabetes C-peptide measurement|| type I diabetes mellitus GCST005435 C-peptide measurement type I diabetes mellitus +C-reactive protein levels in ischemic stroke Ischemic stroke|| C-reactive protein measurement GCST003211 C-reactive protein measurement Ischemic stroke +Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease smoking status measurement|| chronic obstructive pulmonary disease|| carbon monoxide exhalation measurement GCST005919 carbon monoxide exhalation measurement smoking status measurement|| chronic obstructive pulmonary disease +Cardiomyopathy in childhood cancer survivors childhood cancer|| cardiomyopathy GCST003299 cardiomyopathy childhood cancer +Anthracycline-induced cardiotoxicity in childhood cancer childhood cancer|| cardiotoxicity|| response to anthracycline-based chemotherapy GCST003062 cardiotoxicity|| response to anthracycline-based chemotherapy childhood cancer +Cardiovascular heart disease in diabetics cardiovascular disease|| type II diabetes mellitus GCST002153 cardiovascular disease type II diabetes mellitus +Cardiovascular disease in hypertension (ACE inhibitor interaction) hypertension|| cardiovascular disease|| response to angiotensin-converting enzyme inhibitor GCST003186 cardiovascular disease|| response to angiotensin-converting enzyme inhibitor hypertension +Cardiovascular disease in hypertension (calcium channel blocker interaction) hypertension|| cardiovascular disease|| response to calcium channel blocker GCST003205 cardiovascular disease|| response to calcium channel blocker hypertension +Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction) response to darapladib|| acute coronary syndrome|| coronary heart disease|| cardiovascular event measurement GCST004958 cardiovascular event measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Major coronary event in placebo-treated cardiovascular disease (time to event) acute coronary syndrome|| coronary heart disease|| cardiovascular event measurement|| response to placebo GCST004961 cardiovascular event measurement|| response to placebo acute coronary syndrome|| coronary heart disease +Cataracts in type 2 diabetes cataract|| type II diabetes mellitus GCST001736 cataract type II diabetes mellitus +Caudate volume in trauma-exposed individuals response to trauma exposure|| caudate nucleus volume GCST005240 caudate nucleus volume|| response to trauma exposure +Cerebral amyloid deposition in APOEe4 carriers (PET imaging) APOE carrier status|| cerebral amyloid deposition measurement GCST003076 cerebral amyloid deposition measurement APOE carrier status +Cerebrospinal fluid clusterin levels in APOEe4+ carriers APOE carrier status|| cerebrospinal fluid clusterin measurement GCST003131 cerebrospinal fluid clusterin measurement APOE carrier status +Chagas cardiomyopathy in Tripanosoma cruzi seropositivity Chagas cardiomyopathy|| Trypanosoma cruzi seropositivity GCST002285 Chagas cardiomyopathy Trypanosoma cruzi seropositivity +Cholangiocarcinoma in primary sclerosing cholangitis cholangiocarcinoma|| sclerosing cholangitis GCST005855 cholangiocarcinoma sclerosing cholangitis +Cholelithiasis-related traits in sickle cell anemia Sickle cell anemia|| cholelithiasis|| bilirubin measurement GCST001497 cholelithiasis|| bilirubin measurement Sickle cell anemia +Chronic bronchitis in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| chronic bronchitis GCST002621 chronic bronchitis chronic obstructive pulmonary disease +End stage renal disease in APOL1 risk genotype-negative individuals chronic kidney disease|| APOL1 risk genotype carrier status GCST006815 chronic kidney disease APOL1 risk genotype carrier status +End stage renal disease in APOL1 risk genotype-positive individuals chronic kidney disease|| APOL1 risk genotype carrier status GCST006816 chronic kidney disease APOL1 risk genotype carrier status +Chronic kidney disease in diabetes chronic kidney disease|| diabetes mellitus GCST005880 chronic kidney disease diabetes mellitus +End-stage renal disease in diabetes chronic kidney disease|| diabetes mellitus GCST005886 chronic kidney disease diabetes mellitus +End stage renal failure in renal transplantation (recipient effect) renal transplant outcome measurement|| chronic kidney disease GCST005427 chronic kidney disease renal transplant outcome measurement +End-stage renal disease in Type 1 diabetics type I diabetes mellitus|| chronic kidney disease GCST002182 chronic kidney disease type I diabetes mellitus +Chronic kidney disease in type 2 diabetes chronic kidney disease|| type II diabetes mellitus GCST005882 chronic kidney disease type II diabetes mellitus +End-stage renal disease in type 2 diabetes chronic kidney disease|| type II diabetes mellitus GCST005885 chronic kidney disease type II diabetes mellitus +Chronic kidney disease and diabetic kidney disease in diabetes chronic kidney disease|| diabetes mellitus|| diabetic nephropathy GCST005884 chronic kidney disease|| diabetic nephropathy diabetes mellitus +End-stage renal disease or diabetic nephropathy in type 1 diabetes type I diabetes mellitus|| chronic kidney disease|| diabetic nephropathy GCST002464 chronic kidney disease|| diabetic nephropathy type I diabetes mellitus +Chronic kidney disease and diabetic kidney disease in type 2 diabetes chronic kidney disease|| diabetic nephropathy|| type II diabetes mellitus GCST005883 chronic kidney disease|| diabetic nephropathy type II diabetes mellitus +Chronic mucus hypersecretion in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| chronic mucus hypersecretion GCST002612 chronic mucus hypersecretion chronic obstructive pulmonary disease +Clostridium difficile infection in multiple myeloma clostridium difficile infection|| multiple myeloma GCST005686 clostridium difficile infection multiple myeloma +Response to cognitive-behavioural therapy in anxiety disorder anxiety disorder|| cognitive behavioural therapy GCST003469 cognitive behavioural therapy anxiety disorder +Cognitive decline rate in late mild cognitive impairment cognitive impairment|| cognitive decline measurement GCST003075 cognitive decline measurement cognitive impairment +Rate of cognitive decline in mild cognitive impairment (time interaction) cognitive impairment|| cognitive decline measurement|| disease progression measurement GCST004371 cognitive decline measurement|| disease progression measurement cognitive impairment +Neurocognitive impairment in HIV-1 infection (continuous) HIV-1 infection|| cognitive impairment measurement GCST004406 cognitive impairment measurement HIV-1 infection +Neurocognitive impairment in HIV-1 infection (dichotomous) HIV-1 infection|| cognitive impairment measurement GCST004407 cognitive impairment measurement HIV-1 infection +Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| cognitive inhibition measurement GCST004336 cognitive inhibition measurement attention deficit hyperactivity disorder +Colorectal carcinoma in primary sclerosing cholangitis colorectal cancer|| sclerosing cholangitis GCST005856 colorectal cancer sclerosing cholangitis +Mucinous adenocarcinoma in colorectal cancer colorectal cancer|| colorectal mucinous adenocarcinoma GCST006411 colorectal mucinous adenocarcinoma colorectal cancer +Common carotid intima-media thickness in HIV infection common carotid intimal medial thickness|| HIV infection GCST005184 common carotid intimal medial thickness HIV infection +Carotid atherosclerosis in HIV infection HIV-1 infection|| common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease GCST000555 common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease HIV-1 infection +Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to anticonvulsant GCST002887 concentration dose ratio|| response to anticonvulsant unipolar depression|| schizophrenia|| bipolar disorder +Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antidepressant GCST002891 concentration dose ratio|| response to antidepressant unipolar depression|| schizophrenia|| bipolar disorder +Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antipsychotic drug GCST002888 concentration dose ratio|| response to antipsychotic drug unipolar depression|| schizophrenia|| bipolar disorder +Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST002026 coronary aneurysm mucocutaneous lymph node syndrome +Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST001878 coronary aneurysm mucocutaneous lymph node syndrome +Coronary artery aneurysm in Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST003560 coronary aneurysm mucocutaneous lymph node syndrome +Coronary artery aneurysm in Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST003192 coronary aneurysm mucocutaneous lymph node syndrome +Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes coronary artery calcification|| type II diabetes mellitus GCST005173 coronary artery calcification type II diabetes mellitus +Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes coronary artery calcification|| type II diabetes mellitus GCST005175 coronary artery calcification type II diabetes mellitus +Coronary artery calcified atherosclerotic plaque score in type 2 diabetes coronary artery calcification|| type II diabetes mellitus GCST005174 coronary artery calcification type II diabetes mellitus +Coronary artery disease in diabetes diabetes mellitus|| coronary artery disease GCST006405 coronary artery disease diabetes mellitus +Coronary artery disease in type 1 diabetes type I diabetes mellitus|| coronary artery disease GCST006281 coronary artery disease type I diabetes mellitus +Coronary heart disease in familial hypercholesterolemia familial hypercholesterolemia|| coronary heart disease GCST002478 coronary heart disease familial hypercholesterolemia +Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma childhood onset asthma|| cortisol measurement|| response to corticosteroid|| response to synacthen GCST005925 cortisol measurement|| response to corticosteroid|| response to synacthen childhood onset asthma +Cotinine levels in smokers with chronic obstructive pulmonary disease smoking status measurement|| cotinine measurement|| chronic obstructive pulmonary disease GCST005916 cotinine measurement smoking status measurement|| chronic obstructive pulmonary disease +Creatine kinase in statin users response to statin|| creatine kinase measurement GCST002603 creatine kinase measurement|| response to statin +Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection cryoglobulinemia|| Chronic Hepatitis C infection GCST002534 cryoglobulinemia Chronic Hepatitis C infection +Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab) cumulative dose response to bevacizumab|| chemotherapy-induced hypertension|| breast carcinoma GCST002566 cumulative dose response to bevacizumab breast carcinoma|| chemotherapy-induced hypertension +Response to paclitaxel in ovarian cancer (MTT IC50) ovarian carcinoma|| cytotoxicity measurement|| response to paclitaxel GCST003441 cytotoxicity measurement|| response to paclitaxel ovarian carcinoma +Depressive episodes in bipolar disorder depressive episode measurement|| bipolar disorder GCST003091 depressive episode measurement bipolar disorder +Depression in response to interferon-based therapy in chronic hepatitis C Chronic Hepatitis C infection|| response to interferon|| depressive symptom measurement GCST003824 depressive symptom measurement|| response to interferon Chronic Hepatitis C infection +Diabetes in response to antihypertensive drug treatment (treatment strategy interaction) response to antihypertensive drug|| diabetes mellitus|| hypertension|| response to beta blocker|| response to calcium channel blocker GCST003797 diabetes mellitus|| response to antihypertensive drug|| response to beta blocker|| response to calcium channel blocker hypertension +Foot ulcer in diabetes and neuropathy type I diabetes mellitus|| diabetic foot|| type II diabetes mellitus|| neuropathy GCST004724 diabetic foot type I diabetes mellitus|| type II diabetes mellitus|| neuropathy +Foot ulcer and neuropathy in diabetes type I diabetes mellitus|| diabetic foot|| type II diabetes mellitus|| neuropathy GCST004725 diabetic foot|| neuropathy type I diabetes mellitus|| type II diabetes mellitus +Diabetic macular edema in type 2 diabetes diabetic macular edema|| type II diabetes mellitus GCST006282 diabetic macular edema type II diabetes mellitus +Diabetic kidney disease in diabetes diabetes mellitus|| diabetic nephropathy GCST005881 diabetic nephropathy diabetes mellitus +Diabetic kidney disease in diabetes (ESRD vs. no ESRD) diabetes mellitus|| diabetic nephropathy GCST005894 diabetic nephropathy diabetes mellitus +Early diabetic kidney disease in diabetes diabetes mellitus|| diabetic nephropathy GCST005890 diabetic nephropathy diabetes mellitus +Late diabetic kidney disease in diabetes diabetes mellitus|| diabetic nephropathy GCST005888 diabetic nephropathy diabetes mellitus +Diabetic kidney disease in type 2 diabetes diabetic nephropathy|| type II diabetes mellitus GCST005895 diabetic nephropathy type II diabetes mellitus +Early diabetic kidney disease in type 2 diabetes diabetic nephropathy|| type II diabetes mellitus GCST005889 diabetic nephropathy type II diabetes mellitus +Late diabetic kidney disease in type 2 diabetes diabetic nephropathy|| type II diabetes mellitus GCST005887 diabetic nephropathy type II diabetes mellitus +Sight-threatening diabetic retinopathy in type 2 diabetes diabetic retinopathy|| type II diabetes mellitus GCST003042 diabetic retinopathy type II diabetes mellitus +Diabetic retinopathy in type 2 diabetes diabetic retinopathy|| type II diabetes mellitus GCST002684 diabetic retinopathy type II diabetes mellitus +Severe diabetic retinopathy in type 2 diabetes diabetic retinopathy|| type II diabetes mellitus GCST006424 diabetic retinopathy type II diabetes mellitus +Diarrhoea in darapladib-treated cardiovascular disease (time to event) response to darapladib|| diarrhea|| acute coronary syndrome|| coronary heart disease GCST004962 diarrhea|| response to darapladib acute coronary syndrome|| coronary heart disease +Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event) response to darapladib|| diarrhea|| acute coronary syndrome|| coronary heart disease GCST004967 diarrhea|| response to darapladib acute coronary syndrome|| coronary heart disease +Diastolic blood pressure night-to-day ratio in hypertension diastolic blood pressure change measurement|| hypertension GCST006273 diastolic blood pressure change measurement hypertension +Diastolic blood pressure response to hydrochlorothiazide in hypertension response to hydrochlorothiazide|| diastolic blood pressure change measurement|| hypertension GCST003805 diastolic blood pressure change measurement|| response to hydrochlorothiazide hypertension +Thiopurine-induced digestive symptoms in inflammatory bowel disease digestive system disease|| response to thiopurine|| inflammatory bowel disease GCST006210 digestive system disease|| response to thiopurine inflammatory bowel disease +Type 1 diabetes in high risk HLA genotype individuals (time to event) disease free survival|| type I diabetes mellitus|| carrier status GCST006196 disease free survival|| type I diabetes mellitus carrier status +Poor prognosis in Crohn's disease Crohn's disease|| disease prognosis measurement GCST004053 disease prognosis measurement Crohn's disease +Relapse in multiple sclerosis multiple sclerosis|| disease recurrence GCST004752 disease recurrence multiple sclerosis +Breast cancer-free interval (treatment with aromatase inhibitor) disease recurrence|| response to aromatase inhibitor|| breast carcinoma GCST003816 disease recurrence|| response to aromatase inhibitor breast carcinoma +Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia drug-induced agranulocytosis|| treatment refractory schizophrenia|| response to clozapine GCST003628 drug-induced agranulocytosis|| response to clozapine treatment refractory schizophrenia +Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia drug-induced agranulocytosis|| treatment refractory schizophrenia|| response to clozapine GCST003450 drug-induced agranulocytosis|| response to clozapine treatment refractory schizophrenia +Thionamide-induced agranulocytosis in Graves' disease drug-induced agranulocytosis|| response to thioamide|| Graves disease GCST003018 drug-induced agranulocytosis|| response to thioamide Graves disease +Liver injury in anti-retroviral drug treated HIV response to efavirenz|| HIV infection|| drug-induced liver injury GCST004261 drug-induced liver injury|| response to efavirenz HIV infection +Drug-induced liver injury in interferon-beta-treated multiple sclerosis multiple sclerosis|| response to interferon beta|| drug-induced liver injury GCST006270 drug-induced liver injury|| response to interferon beta multiple sclerosis +Liver injury in anti-tuberculosis drug treatment response to rifampicin|| Tuberculosis|| drug-induced liver injury GCST003792 drug-induced liver injury|| response to rifampicin Tuberculosis +Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis response to rifampicin|| Tuberculosis|| response to efavirenz|| HIV infection|| drug-induced liver injury GCST004262 drug-induced liver injury|| response to rifampicin|| response to efavirenz HIV infection|| Tuberculosis +Eating disorder in bipolar disorder eating disorder|| bipolar disorder GCST003132 eating disorder bipolar disorder +Ejection fraction in Tripanosoma cruzi seropositivity Trypanosoma cruzi seropositivity|| ejection fraction measurement GCST002281 ejection fraction measurement Trypanosoma cruzi seropositivity +Emphysema distribution in smoking smoking behavior|| emphysema pattern measurement GCST003761 emphysema pattern measurement smoking behavior +Erectile dysfunction in type 1 diabetes type I diabetes mellitus|| erectile dysfunction GCST001572 erectile dysfunction type I diabetes mellitus +Erythema nodosum in inflammatory bowel disease erythema nodosum|| inflammatory bowel disease GCST002380 erythema nodosum inflammatory bowel disease +Estrogen receptor status in breast cancer estrogen-receptor negative breast cancer|| estrogen-receptor positive breast cancer|| breast carcinoma GCST003821 estrogen-receptor negative breast cancer|| estrogen-receptor positive breast cancer breast carcinoma +Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer estrone conjugate measurement|| estrogen-receptor positive breast cancer GCST004359 estrone conjugate measurement estrogen-receptor positive breast cancer +Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer estrone conjugate measurement|| estrogen-receptor positive breast cancer|| estrone measurement GCST004360 estrone conjugate measurement|| estrone measurement estrogen-receptor positive breast cancer +Plasma estrone levels in resected estrogen-receptor positive breast cancer estrogen-receptor positive breast cancer|| estrone measurement GCST004362 estrone measurement estrogen-receptor positive breast cancer +Executive function in ADHD attention deficit hyperactivity disorder|| executive function measurement GCST006219 executive function measurement attention deficit hyperactivity disorder +Eye movement in schizophrenia (horizontal position gain) eye movement measurement|| schizophrenia GCST006448 eye movement measurement schizophrenia +Eye movement in schizophrenia (integrated eye movement score) eye movement measurement|| schizophrenia GCST006451 eye movement measurement schizophrenia +Eye movement in schizophrenia (scanpath length) eye movement measurement|| schizophrenia GCST006459 eye movement measurement schizophrenia +Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma esophageal squamous cell carcinoma|| family history of upper gastrointestinal cancer GCST004799 family history of upper gastrointestinal cancer esophageal squamous cell carcinoma +Bone mineral density (femoral neck) in inflammatory bowel disease inflammatory bowel disease|| femoral neck bone mineral density GCST005784 femoral neck bone mineral density inflammatory bowel disease +Fetal hemoglobin levels in sickle cell anemia fetal hemoglobin measurement|| Sickle cell anemia GCST002687 fetal hemoglobin measurement Sickle cell anemia +High fetal hemoglobin in sickle cell disease fetal hemoglobin measurement|| Sickle cell disease and related diseases GCST006251 fetal hemoglobin measurement Sickle cell disease and related diseases +Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1) FEV change measurement|| response to bronchodilator|| chronic obstructive pulmonary disease GCST003830 FEV change measurement|| response to bronchodilator chronic obstructive pulmonary disease +Response to inhaled glucocorticoid treatment in asthma (change in FEV1) FEV change measurement|| response to glucocorticoid|| asthma GCST002754 FEV change measurement|| response to glucocorticoid asthma +Response to montelukast in asthma (change in FEV1) FEV change measurement|| response to montelukast|| asthma GCST002979 FEV change measurement|| response to montelukast asthma +Response to zileuton treatment in asthma (FEV1 change interaction) FEV change measurement|| response to zileuton|| asthma GCST002951 FEV change measurement|| response to zileuton asthma +Post bronchodilator FEV1/FVC ratio in smoking smoking behavior|| FEV/FEC ratio GCST006310 FEV/FEC ratio smoking behavior +Pre bronchodilator FEV1/FVC ratio in never-smokers smoking status measurement|| FEV/FEC ratio GCST003826 FEV/FEC ratio smoking status measurement +Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction) allergen exposure measurement|| asthma|| FEV/FEC ratio GCST004108 FEV/FEC ratio|| allergen exposure measurement asthma +Thiopurine-induced fever in inflammatory bowel disease fever|| response to thiopurine|| inflammatory bowel disease GCST006209 fever|| response to thiopurine inflammatory bowel disease +Fibrinogen levels in ischemic stroke Ischemic stroke|| fibrinogen measurement GCST003212 fibrinogen measurement Ischemic stroke +Follicule stimulating hormone levels in polycystic ovary syndrome polycystic ovary syndrome|| follicle stimulating hormone measurement GCST005270 follicle stimulating hormone measurement polycystic ovary syndrome +Post bronchodilator percent predicted FEV1 in smoking smoking behavior|| forced expiratory volume GCST006309 forced expiratory volume smoking behavior +Lung function (FEV1) in asthma (dust mite allergen exposure interaction) forced expiratory volume|| allergen exposure measurement|| asthma GCST004107 forced expiratory volume|| allergen exposure measurement asthma +Post bronchodilator FEV1 in COPD forced expiratory volume|| response to bronchodilator|| chronic obstructive pulmonary disease GCST003263 forced expiratory volume|| response to bronchodilator chronic obstructive pulmonary disease +Electroencephalographic traits in alcoholism frontal theta oscillation measurement|| alcohol dependence GCST001503 frontal theta oscillation measurement alcohol dependence +Moderate functional decline in sporadic amyotrophic lateral sclerosis functional decline measurement|| sporadic amyotrophic lateral sclerosis GCST003333 functional decline measurement sporadic amyotrophic lateral sclerosis +Rapid functional decline in sporadic amyotrophic lateral sclerosis functional decline measurement|| sporadic amyotrophic lateral sclerosis GCST003332 functional decline measurement sporadic amyotrophic lateral sclerosis +"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia" unipolar depression|| schizophrenia|| bipolar disorder|| functional impairment measurement GCST002188 functional impairment measurement unipolar depression|| schizophrenia|| bipolar disorder +Relative hand skill in reading disability functional laterality|| dyslexia GCST002183 functional laterality dyslexia +Gallbladder carcinoma in primary sclerosing cholangitis gallbladder neoplasm|| sclerosing cholangitis GCST005857 gallbladder neoplasm sclerosing cholangitis +Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia schizophrenia|| gamma wave measurement GCST004953 gamma wave measurement schizophrenia +MGMT methylation in smokers smoking behavior|| gene methylation measurement GCST003031 gene methylation measurement smoking behavior +Glomerular filtration rate change in heart transplantation response to transplant|| GFR change measurement GCST006496 GFR change measurement|| response to transplant +Glomerular filtration rate in chronic kidney disease glomerular filtration rate|| chronic kidney disease GCST003139 glomerular filtration rate chronic kidney disease +Glomerular filtration rate in diabetes glomerular filtration rate|| diabetes mellitus GCST005891 glomerular filtration rate diabetes mellitus +Glomerular filtration rate in type 2 diabetes glomerular filtration rate|| type II diabetes mellitus GCST005892 glomerular filtration rate type II diabetes mellitus +Glomerular filtration rate in diabetics (creatinine) glomerular filtration rate|| diabetes mellitus|| serum creatinine measurement GCST003373 glomerular filtration rate|| serum creatinine measurement diabetes mellitus +Change in glucose in response to thiazide diuretic treatment in hypertension response to thiazide|| hypertension|| glucose measurement GCST005577 glucose measurement|| response to thiazide hypertension +Gout in chronic kidney disease gout|| chronic kidney disease GCST006425 gout chronic kidney disease +Thyroid-associated orbitopathy in graves' disease Graves disease|| Graves ophthalmopathy GCST003640 Graves ophthalmopathy Graves disease +Plasma haptoglobin levels in type 2 diabetes haptoglobin measurement|| type II diabetes mellitus GCST005808 haptoglobin measurement type II diabetes mellitus +Urinary haptoglobin levels in type 2 diabetes haptoglobin measurement|| type II diabetes mellitus GCST005807 haptoglobin measurement type II diabetes mellitus +Hemoglobin A2 levels in sickle cell anemia Sickle cell anemia|| hemoglobin A2 measurement GCST002536 hemoglobin A2 measurement Sickle cell anemia +Liver fibrosis severity in HIV/hepatitis C co-infection HIV-1 infection|| Hepatic fibrosis|| hepatitis C infection GCST003606 Hepatic fibrosis HIV-1 infection|| hepatitis C infection +Liver fibrosis in pediatric non-alcoholic fatty acid liver disease non-alcoholic fatty liver disease|| Hepatic fibrosis GCST004938 Hepatic fibrosis non-alcoholic fatty liver disease +Hepatic lipid content in extreme obesity hepatic lipid content measurement|| obesity GCST002632 hepatic lipid content measurement obesity +Hepatitis B surface antigen seroclearance in chronic hepatitis B infection Hepatitis B virus surface antigen seropositivity|| chronic hepatitis B infection GCST006364 Hepatitis B virus surface antigen seropositivity chronic hepatitis B infection +Familial hepatitis B virus-related hepatocellular carcinoma hepatocellular carcinoma|| hepatitis B infection GCST004736 hepatocellular carcinoma hepatitis B infection +Hepatocellular carcinoma in hepatitis B infection hepatocellular carcinoma|| hepatitis B infection GCST005746 hepatocellular carcinoma hepatitis B infection +Hepatocellular carcinoma in hepatitis B infection hepatocellular carcinoma|| hepatitis B infection GCST003189 hepatocellular carcinoma hepatitis B infection +Hepatocellular carcinoma in hepatitis C infection hepatocellular carcinoma|| hepatitis C infection GCST006037 hepatocellular carcinoma hepatitis C infection +Hepatocellular carcinoma in primary sclerosing cholangitis hepatocellular carcinoma|| sclerosing cholangitis GCST005858 hepatocellular carcinoma sclerosing cholangitis +HER2 status in breast cancer HER2 status|| breast carcinoma GCST004528 HER2 status breast carcinoma +HDL Cholesterol in HIV-infection HIV-1 infection|| high density lipoprotein cholesterol measurement GCST002744 high density lipoprotein cholesterol measurement HIV-1 infection +Hippocampal volume in schizophrenia schizophrenia|| hippocampal volume GCST002076 hippocampal volume schizophrenia +Setpoint viral load in HIV-1 infection HIV-1 infection|| HIV viral set point measurement GCST003183 HIV-1 infection HIV viral set point measurement +Hypertension risk in short sleep duration hypertension|| short sleep GCST001405 hypertension short sleep +Immunoglobulin G index levels in multiple sclerosis multiple sclerosis|| IgG index GCST002757 IgG index multiple sclerosis +Inflammatory biomarkers in Kawasaki disease mucocutaneous lymph node syndrome|| inflammatory biomarker measurement|| C-reactive protein measurement GCST002640 inflammatory biomarker measurement|| C-reactive protein measurement mucocutaneous lymph node syndrome +Initial pursuit acceleration in psychotic disorders schizophrenia|| initial pursuit acceleration|| bipolar disorder|| schizoaffective disorder GCST005026 initial pursuit acceleration schizophrenia|| bipolar disorder|| schizoaffective disorder +Interferon alpha levels in systemic lupus erythematosus interferon alpha measurement|| systemic lupus erythematosus GCST002666 interferon alpha measurement systemic lupus erythematosus +Plasma kynurenine levels in major depressive disorder unipolar depression|| kynurenine measurement GCST005342 kynurenine measurement unipolar depression +Plasma kynurenine to tryptophan ratio in major depressive disorder unipolar depression|| kynurenine:tryptophan ratio GCST005343 kynurenine:tryptophan ratio unipolar depression +Language impairment in frontotemporal lobe dementia language impairment|| Frontotemporal dementia GCST006152 language impairment Frontotemporal dementia +Laterality in neovascular age-related macular degeneration laterality measurement|| wet macular degeneration GCST004813 laterality measurement wet macular degeneration +Thiopurine-induced acute severe leukopenia in inflammatory bowel disease leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006205 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232) leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006215 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced leukopenia in inflammatory bowel disease leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006201 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced leukopenia in inflammatory bowel disease leukopenia|| response to thiopurine|| inflammatory bowel disease GCST003603 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232) leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006202 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced severe leukopenia in inflammatory bowel disease leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006204 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232) leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006200 leukopenia|| response to thiopurine inflammatory bowel disease +Lichen planus in hepatitis C lichen planus|| hepatitis C infection GCST004090 lichen planus hepatitis C infection +Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease response to darapladib|| acute coronary syndrome|| lipoprotein-associated phospholipase A(2) change measurement|| coronary heart disease GCST004966 lipoprotein-associated phospholipase A(2) change measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline) response to darapladib|| acute coronary syndrome|| lipoprotein-associated phospholipase A(2) change measurement|| coronary heart disease GCST004968 lipoprotein-associated phospholipase A(2) change measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Lipoprotein phospholipase A2 activity in cardiovascular disease lipoprotein-associated phospholipase A(2) measurement|| acute coronary syndrome|| coronary heart disease GCST004963 lipoprotein-associated phospholipase A(2) measurement acute coronary syndrome|| coronary heart disease +Liver disease severity in Alagille syndrome Alagille syndrome|| liver disease GCST003616 liver disease Alagille syndrome +Liver disease in chronic hepatitis B virus infection liver disease|| chronic hepatitis B infection GCST002204 liver disease chronic hepatitis B infection +Body mass index (change over time) in cancer cancer|| longitudinal BMI measurement GCST004106 longitudinal BMI measurement cancer +Body mass index (change over time) in cancer or chronic obstructive pulmonary disease cancer|| longitudinal BMI measurement|| chronic obstructive pulmonary disease GCST004103 longitudinal BMI measurement cancer|| chronic obstructive pulmonary disease +Body mass index (change over time) in chronic obstructive pulmonary disease longitudinal BMI measurement|| chronic obstructive pulmonary disease GCST004105 longitudinal BMI measurement chronic obstructive pulmonary disease +Body mass index (change over time) in gastrointestinal cancer longitudinal BMI measurement|| Digestive System Carcinoma GCST004101 longitudinal BMI measurement Digestive System Carcinoma +Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease longitudinal BMI measurement|| Digestive System Carcinoma|| chronic obstructive pulmonary disease GCST004100 longitudinal BMI measurement Digestive System Carcinoma|| chronic obstructive pulmonary disease +Body mass index (change over time) in lung cancer lung carcinoma|| longitudinal BMI measurement GCST004104 longitudinal BMI measurement lung carcinoma +Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease lung carcinoma|| longitudinal BMI measurement|| chronic obstructive pulmonary disease GCST004102 longitudinal BMI measurement lung carcinoma|| chronic obstructive pulmonary disease +Lipid levels in hepatitis C treatment Chronic Hepatitis C infection|| low density lipoprotein cholesterol measurement GCST001418 low density lipoprotein cholesterol measurement Chronic Hepatitis C infection +Lung cancer in ever smokers smoking status measurement|| lung carcinoma GCST006400 lung carcinoma smoking status measurement +Lung cancer in ever smokers smoking status measurement|| lung carcinoma GCST004749 lung carcinoma smoking status measurement +Lung cancer in never smokers smoking status measurement|| lung carcinoma GCST004747 lung carcinoma smoking status measurement +Lung disease severity in cystic fibrosis Cystic fibrosis|| lung disease severity measurement GCST003143 lung disease severity measurement Cystic fibrosis +Lupus nephritis in systemic lupus erythematosus systemic lupus erythematosus|| lupus nephritis GCST002479 lupus nephritis systemic lupus erythematosus +Luteinizing hormone levels in polycystic ovary syndrome luteinizing hormone measurement|| polycystic ovary syndrome GCST005269 luteinizing hormone measurement polycystic ovary syndrome +Hypersomnia during a major depressive episode in bipolar disorder major depressive episode|| bipolar disorder|| hypersomnia GCST003016 major depressive episode|| hypersomnia bipolar disorder +Depressive and manic episodes in bipolar disorder manic episode measurement|| depressive episode measurement|| bipolar disorder GCST003090 manic episode measurement|| depressive episode measurement bipolar disorder +Manic episodes in bipolar disorder manic or hypomanic episode|| bipolar disorder GCST003089 manic or hypomanic episode bipolar disorder +Mean corpuscular hemoglobin concentration in sickle cell disease Sickle cell anemia|| mean corpuscular hemoglobin concentration GCST004378 mean corpuscular hemoglobin concentration Sickle cell anemia +Total mean fractional anisotropy measurement in first episode schizophrenia schizophrenia|| mean fractional anisotropy measurement|| white matter microstructure measurement GCST004996 mean fractional anisotropy measurement|| white matter microstructure measurement schizophrenia +Medication adherence in chronic diseases diabetes mellitus|| hypertension|| medication adherence behavior GCST002637 medication adherence behavior diabetes mellitus|| hypertension +Memory dysfunction in frontotemporal lobe dementia memory impairment|| Frontotemporal dementia GCST006151 memory impairment Frontotemporal dementia +Metastasis at diagnosis in osteosarcoma metastasis measurement|| date of diagnosis|| osteosarcoma GCST002978 metastasis measurement|| date of diagnosis osteosarcoma +Methadone dose in opioid dependence opioid dependence|| methadone dose measurement GCST006856 methadone dose measurement opioid dependence +Methadone dose in opioid dependence opioid dependence|| methadone dose measurement GCST004136 methadone dose measurement opioid dependence +Migraine in bipolar disorder bipolar disorder|| migraine disorder GCST002656 migraine disorder bipolar disorder +Migraine in psychiatric disorder bipolar disorder|| migraine disorder GCST000695 migraine disorder bipolar disorder +Mood disorder in prion disease prion disease|| mood disorder GCST002864 mood disorder prion disease +Mortality in heart failure heart failure|| mortality GCST003539 mortality heart failure +Mortality in heart failure heart failure|| mortality GCST000661 mortality heart failure +Mortality in sepsis sepsis|| mortality GCST003817 mortality sepsis +Platinum-induced myelosuppression in non-small cell lung cancer myelosuppression|| response to platinum based chemotherapy|| non-small cell lung carcinoma GCST002833 myelosuppression|| response to platinum based chemotherapy non-small cell lung carcinoma +Myocardial infarction in placebo-treated cardiovascular disease (time to event) acute coronary syndrome|| coronary heart disease|| myocardial infarction|| response to placebo GCST004965 myocardial infarction|| response to placebo acute coronary syndrome|| coronary heart disease +Perioperative myocardial infarction in coronary artery bypass surgery coronary artery bypass|| myocardial infarction GCST002892 myocardial infarction coronary artery bypass +Myocardial infarction in coronary artery disease coronary heart disease|| myocardial infarction GCST000946 myocardial infarction coronary heart disease +Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction) response to darapladib|| acute coronary syndrome|| coronary heart disease|| myocardial infarction GCST004959 myocardial infarction|| response to darapladib acute coronary syndrome|| coronary heart disease +Myocardial infarction in darapladib-treated cardiovascular disease (time to event) response to darapladib|| acute coronary syndrome|| coronary heart disease|| myocardial infarction GCST004964 myocardial infarction|| response to darapladib acute coronary syndrome|| coronary heart disease +Surgical necrotising enterocolitis in extremely premature birth necrotizing enterocolitis|| premature birth GCST005800 necrotizing enterocolitis premature birth +Neuropathic pain in head and neck cancer head and neck malignant neoplasia|| neuropathic pain GCST005934 neuropathic pain head and neck malignant neoplasia +Possible neuropathic pain in post total joint replacement surgery for osteoarthritis neuropathic pain|| osteoarthritis GCST003963 neuropathic pain osteoarthritis +Neuropathic pain in type 2 diabetes neuropathic pain|| type II diabetes mellitus GCST003063 neuropathic pain type II diabetes mellitus +Neuropathic pain in type 2 diabetes neuropathic pain|| type II diabetes mellitus GCST002507 neuropathic pain type II diabetes mellitus +Neutrophil count in HIV-infection neutrophil count|| HIV-1 infection GCST002743 neutrophil count HIV-1 infection +nicotine metabolite ratio in current smokers smoking behavior|| nicotine metabolite ratio GCST003629 nicotine metabolite ratio smoking behavior +nicotine metabolite ratio in current smokers smoking behavior|| nicotine metabolite ratio GCST004976 nicotine metabolite ratio smoking behavior +Non-small cell lung cancer in heavy smokers smoking behavior|| non-small cell lung carcinoma GCST005747 non-small cell lung carcinoma smoking behavior +Obesity in adult survivors of childhood cancer not exposed to cranial radiation childhood cancer|| obesity GCST002904 obesity childhood cancer +Oligoclonal band status in multiple sclerosis multiple sclerosis|| oligoclonal band measurement GCST002758 oligoclonal band measurement multiple sclerosis +Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder attention deficit hyperactivity disorder|| oppositional defiant disorder measurement GCST003472 oppositional defiant disorder measurement attention deficit hyperactivity disorder +Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder attention deficit hyperactivity disorder|| oppositional defiant disorder measurement GCST003030 oppositional defiant disorder measurement attention deficit hyperactivity disorder +Ovarian cancer in BRCA1 mutation carriers carrier status|| ovarian carcinoma GCST004414 ovarian carcinoma carrier status +Ovarian cancer in BRCA2 mutation carriers carrier status|| ovarian carcinoma GCST004416 ovarian carcinoma carrier status +Pre-treatment pain in head and neck squamous cell carcinoma pain|| head and neck squamous cell carcinoma GCST003760 pain head and neck squamous cell carcinoma +Pallidum volume in trauma-exposed individuals pallidum volume|| response to trauma exposure GCST005242 pallidum volume|| response to trauma exposure +Thiopurine-induced pancreatitis in inflammatory bowel disease pancreatitis|| response to thiopurine|| inflammatory bowel disease GCST006208 pancreatitis|| response to thiopurine inflammatory bowel disease +Parasitemia in Tripanosoma cruzi seropositivity parasitemia measurement|| Trypanosoma cruzi seropositivity GCST002282 parasitemia measurement Trypanosoma cruzi seropositivity +Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis) parietal cortex measurement|| schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004997 parietal cortex measurement|| white matter microstructure measurement|| cingulate cortex measurement schizophrenia +Parkinsonism in frontotemporal lobe dementia Parkinson's disease|| Frontotemporal dementia GCST006153 Parkinson's disease Frontotemporal dementia +Response to anthracycline-based chemotherapy in breast cancer (pathologic complete response) pathologic complete response measurement|| breast carcinoma|| response to anthracycline-based chemotherapy GCST003224 pathologic complete response measurement|| response to anthracycline-based chemotherapy breast carcinoma +Bortezomib-induced peripheral neuropathy in multiple myeloma peripheral neuropathy|| multiple myeloma|| response to bortezomib GCST003964 peripheral neuropathy|| response to bortezomib multiple myeloma +Bortezomib-induced peripheral neuropathy in multiple myeloma peripheral neuropathy|| multiple myeloma|| response to bortezomib GCST003438 peripheral neuropathy|| response to bortezomib multiple myeloma +Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer peripheral neuropathy|| response to docetaxel|| metastatic prostate cancer GCST003672 peripheral neuropathy|| response to docetaxel metastatic prostate cancer +Neuropathy in taxane-treated breast cancer peripheral neuropathy|| response to docetaxel|| breast carcinoma|| response to paclitaxel GCST003627 peripheral neuropathy|| response to docetaxel|| response to paclitaxel breast carcinoma +Taxane-induced peripheral neuropathy in breast cancer peripheral neuropathy|| breast carcinoma|| response to taxane GCST005804 peripheral neuropathy|| response to taxane breast carcinoma +Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia peripheral neuropathy|| acute lymphoblastic leukemia|| response to vincristine GCST002792 peripheral neuropathy|| response to vincristine acute lymphoblastic leukemia +Personality traits in bipolar disorder personality trait|| bipolar disorder GCST000995 personality trait bipolar disorder +Betaine levels in individuals undergoing cardiac evaluation plasma betaine measurement|| angiographic measurement GCST003358 plasma betaine measurement angiographic measurement +Response to clopidogrel therapy in coronary heart disease platelet reactivity measurement|| response to clopidogrel|| coronary heart disease GCST003899 platelet reactivity measurement|| response to clopidogrel coronary heart disease +Pneumoconiosis in silica exposure pneumoconiosis|| response to silica exposure GCST002515 pneumoconiosis|| response to silica exposure +Post traumatic stress disorder symptom count in trauma-exposed individuals response to trauma exposure|| post-traumatic stress disorder symptom measurement GCST005550 post-traumatic stress disorder symptom measurement|| response to trauma exposure +PR interval in Tripanosoma cruzi seropositivity PR interval|| Trypanosoma cruzi seropositivity GCST002279 PR interval Trypanosoma cruzi seropositivity +Proliferative diabetic retinopathy in type 2 diabetes proliferative diabetic retinopathy|| type II diabetes mellitus GCST006283 proliferative diabetic retinopathy type II diabetes mellitus +Proteinuria in chronic kidney disease chronic kidney disease|| Proteinuria GCST003142 Proteinuria chronic kidney disease +Prothrombin fragments F1+2 levels in ischemic stroke Ischemic stroke|| prothrombin fragments F1+2 measurement GCST003235 prothrombin fragments F1+2 measurement Ischemic stroke +Psychosis in Alzheimer's disease Alzheimer's disease|| psychotic symptoms GCST001282 psychotic symptoms Alzheimer's disease +Psychotic symptoms in prion disease prion disease|| psychotic symptoms GCST002867 psychotic symptoms prion disease +Pulmonary artery enlargement in chronic obstructive pulmonary disease pulmonary artery enlargement|| chronic obstructive pulmonary disease GCST002797 pulmonary artery enlargement chronic obstructive pulmonary disease +Post-bronchodilator lung function in asthma (FEV1) pulmonary function measurement|| forced expiratory volume|| response to bronchodilator|| asthma GCST003110 pulmonary function measurement|| forced expiratory volume|| response to bronchodilator asthma +Post-bronchodilator lung function in asthma (FEV1/FVC) pulmonary function measurement|| response to bronchodilator|| asthma|| FEV/FEC ratio GCST003107 pulmonary function measurement|| response to bronchodilator|| FEV/FEC ratio asthma +Pulse pressure in young-onset hypertension pulse pressure measurement|| early onset hypertension GCST002470 pulse pressure measurement early onset hypertension +Pursuit maintenance gain in psychotic disorders schizophrenia|| pursuit maintenance gain measurement|| bipolar disorder|| schizoaffective disorder GCST005028 pursuit maintenance gain measurement schizophrenia|| bipolar disorder|| schizoaffective disorder +Putamen volume in trauma-exposed individuals response to trauma exposure|| putamen volume GCST005244 putamen volume|| response to trauma exposure +Pyoderma gangrenosum in inflammatory bowel disease pyoderma gangrenosum|| inflammatory bowel disease GCST002379 pyoderma gangrenosum inflammatory bowel disease +QRS duration in Tripanosoma cruzi seropositivity QRS duration|| Trypanosoma cruzi seropositivity GCST002284 QRS duration|| Trypanosoma cruzi seropositivity +QT interval in Tripanosoma cruzi seropositivity QT interval|| Trypanosoma cruzi seropositivity GCST002278 QT interval Trypanosoma cruzi seropositivity +Red blood cell density in sickle cell anemia Sickle cell anemia|| red blood cell density measurement GCST004379 red blood cell density measurement Sickle cell anemia +Renal elimination rate in vancomycin therapy renal elimination rate measurement|| response to vancomycin GCST002947 renal elimination rate measurement|| response to vancomycin +Serum uric acid levels in response to allopurinol in gout response to allopurinol|| gout|| uric acid measurement GCST004751 response to allopurinol|| uric acid measurement gout +Myocardial infarction in hypertension (ACE inhibitor interaction) hypertension|| response to angiotensin-converting enzyme inhibitor|| myocardial infarction GCST003187 response to angiotensin-converting enzyme inhibitor|| myocardial infarction hypertension +Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction) childhood cancer|| response to anthracycline-based chemotherapy|| cardiomyopathy GCST003300 response to anthracycline-based chemotherapy|| cardiomyopathy childhood cancer +Adverse response to antithyroid drugs in Graves disease Graves disease|| response to anti-thyroid drug GCST006278 response to anti-thyroid drug Graves disease +Remission after antidepressant treatment in major depression unipolar depression|| response to antidepressant GCST006818 response to antidepressant unipolar depression +Response to antidepressants in depression unipolar depression|| response to antidepressant GCST006817 response to antidepressant unipolar depression +Response to antipsychotic treatment in schizophrenia schizophrenia|| response to antipsychotic drug GCST006292 response to antipsychotic drug schizophrenia +Response to lurasidone in schizophrenia schizophrenia|| response to antipsychotic drug GCST006248 response to antipsychotic drug schizophrenia +Cardiovascular disease in hypertension (beta blocker interaction) hypertension|| response to beta blocker|| cardiovascular disease GCST003203 response to beta blocker|| cardiovascular disease hypertension +Myocardial infarction in hypertension (beta blocker interaction) hypertension|| response to beta blocker|| myocardial infarction GCST003201 response to beta blocker|| myocardial infarction hypertension +Response to chemotherapy in breast cancer (hypertension) (bevacizumab) response to bevacizumab|| breast carcinoma|| chemotherapy-induced hypertension GCST002567 response to bevacizumab|| chemotherapy-induced hypertension breast carcinoma +Adverse response to chemotherapy (congestive heart failure) in breast cancer response to bevacizumab|| congestive heart failure|| breast carcinoma|| response to anthracycline-based chemotherapy GCST003939 response to bevacizumab|| congestive heart failure|| response to anthracycline-based chemotherapy breast carcinoma +Asthma (bronchodilator response) response to bronchodilator|| asthma GCST002154 response to bronchodilator asthma +Asthma (bronchodilator response) response to bronchodilator|| asthma GCST001911 response to bronchodilator asthma +Asthma (bronchodilator response) response to bronchodilator|| asthma GCST001597 response to bronchodilator asthma +Bronchodilator response in asthma response to bronchodilator|| asthma GCST002796 response to bronchodilator asthma +Post bronchodilator FEV1/FVC ratio in COPD response to bronchodilator|| chronic obstructive pulmonary disease|| FEV/FEC ratio GCST003265 response to bronchodilator|| FEV/FEC ratio chronic obstructive pulmonary disease +Myocardial infarction in hypertension (calcium channel blocker interaction) hypertension|| response to calcium channel blocker|| myocardial infarction GCST003206 response to calcium channel blocker|| myocardial infarction hypertension +Carboplatin disposition in epthelial ovarian cancer Malignant epithelial tumor of ovary|| response to carboplatin GCST005351 response to carboplatin Malignant epithelial tumor of ovary +Response to cholinesterase inhibitors in Alzheimer's disease response to cholinesterase inhibitor|| Alzheimer's disease GCST001835 response to cholinesterase inhibitor Alzheimer's disease +Response to inhaled corticosteroid treatment in asthma (change in FEV1) FEV change measurement|| response to corticosteroid|| asthma GCST003567 response to corticosteroid|| FEV change measurement asthma +Response to inhaled corticosteroid treatment in asthma (change in FEV1) FEV change measurement|| response to corticosteroid|| asthma GCST002432 response to corticosteroid|| FEV change measurement asthma +Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis response to cyclophosphamide|| systemic lupus erythematosus|| lupus nephritis GCST003445 response to cyclophosphamide systemic lupus erythematosus|| lupus nephritis +Response to Dalcetrapib treatment in acute coronary syndrome response to dalcetrapib|| acute coronary syndrome|| cardiovascular event measurement GCST002747 response to dalcetrapib|| cardiovascular event measurement acute coronary syndrome +Response to dendritic cell-based immunotherapy in HIV infection response to dendritic cell-based immunotherapy|| HIV infection GCST003852 response to dendritic cell-based immunotherapy HIV infection +Myocardial infarction in hypertension (diuretic interaction) response to diruetic|| hypertension|| myocardial infarction GCST003202 response to diruetic|| myocardial infarction hypertension +Cardiovascular disease in hypertension (diuretic interaction) response to diruetic|| hypertension|| cardiovascular disease GCST003204 response to diuretic|| cardiovascular disease hypertension +Response to tocilizumab in rheumatoid arthritis rheumatoid arthritis|| response to drug GCST001476 response to drug rheumatoid arthritis +Duloxetine response in major depressive disorder (% change in symptom score) unipolar depression|| response to duloxetine GCST004738 response to duloxetine unipolar depression +Duloxetine response in major depressive disorder (remitter/non-remitter status) unipolar depression|| response to duloxetine GCST004740 response to duloxetine unipolar depression +Duloxetine response in major depressive disorder (responder/non-responder status) unipolar depression|| response to duloxetine GCST004741 response to duloxetine unipolar depression +Response to efavirenz-containing treatment in HIV 1 infection (virologic failure) HIV-1 infection|| response to efavirenz|| virologic response measurement GCST002771 response to efavirenz|| virologic response measurement HIV-1 infection +Response to gemcitabine in pancreatic cancer response to gemcitabine|| pancreatic carcinoma GCST001390 response to gemcitabine pancreatic carcinoma +Response to gemcitabine in pancreatic cancer response to gemcitabine|| pancreatic carcinoma GCST001346 response to gemcitabine pancreatic carcinoma +Response to haloperidol in psychosis psychosis|| response to haloperidol GCST002465 response to haloperidol psychosis +Response to haloperidol in schizophrenia schizophrenia|| response to haloperidol GCST006298 response to haloperidol schizophrenia +Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan) multiple myeloma|| response to high-dose melphalan|| chemotherapy-induced oral mucositis GCST002605 response to high-dose melphalan|| chemotherapy-induced oral mucositis multiple myeloma +Response to interferon beta in multiple sclerosis multiple sclerosis|| response to interferon beta GCST003193 response to interferon beta multiple sclerosis +Response to interferon beta in multiple sclerosis multiple sclerosis|| response to interferon beta GCST002910 response to interferon beta multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005708 response to interferon beta|| antibody measurement multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005709 response to interferon beta|| antibody measurement multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005707 response to interferon beta|| antibody measurement multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005706 response to interferon beta|| antibody measurement multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (time to production) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005710 response to interferon beta|| antibody measurement multiple sclerosis +Response to irinotecan in non-small-cell lung cancer response to irinotecan|| non-small cell lung carcinoma GCST001558 response to irinotecan non-small cell lung carcinoma +Response to ketogenic dietary therapies in epilepsy response to ketogenic diet|| epilepsy GCST006567 response to ketogenic diet|| epilepsy +Objective response to lithium treatment in bipolar disorder bipolar disorder|| response to lithium ion GCST003161 response to lithium ion bipolar disorder +Response to lithium treatment in bipolar disorder bipolar disorder|| response to lithium ion GCST003378 response to lithium ion bipolar disorder +Subjective response to lithium treatment in bipolar disorder bipolar disorder|| response to lithium ion GCST003160 response to lithium ion bipolar disorder +Response to mepolizumab in severe asthma response to mepolizumab|| asthma GCST005115 response to mepolizumab asthma +Response to metformin in type 2 diabetes (HbA1c reduction) A1C measurement|| type II diabetes mellitus|| response to metformin GCST004522 response to metformin|| A1C measurement type II diabetes mellitus +Methotrexate-induced interstitial lung disease in rheumatoid arthritis response to methotrexate|| rheumatoid arthritis|| interstitial lung disease GCST004358 response to methotrexate|| interstitial lung disease rheumatoid arthritis +Response to methylphenidate treatment in attention-deficit/hyperactivity disorder attention deficit hyperactivity disorder|| response to methylphenidate GCST005318 response to methylphenidate attention deficit hyperactivity disorder +Response to olanzapine in schizophrenia schizophrenia|| response to olanzapine GCST006293 response to olanzapine schizophrenia +Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio) unipolar depression|| schizophrenia|| bipolar disorder|| response to olanzapine|| concentration dose ratio GCST002885 response to olanzapine|| concentration dose ratio unipolar depression|| schizophrenia|| bipolar disorder +Paclitaxel disposition in epithelial ovarian cancer Malignant epithelial tumor of ovary|| response to paclitaxel GCST005352 response to paclitaxel Malignant epithelial tumor of ovary +Response to paliperidone in schizophrenia (CGI-S score) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004039 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to paliperidone in schizophrenia (Multivariate) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004043 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to paliperidone in schizophrenia (negative Marder score) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004041 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to paliperidone in schizophrenia (PANSS score) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004042 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to paliperidone in schizophrenia (positive Marder score) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004040 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to Pazopanib in cancer (hepatotoxicity) cancer|| response to pazopanib|| serum alanine aminotransferase measurement GCST003232 response to pazopanib|| serum alanine aminotransferase measurement cancer +Response to perphenazine in schizophrenia schizophrenia|| response to perphenazine GCST006297 response to perphenazine schizophrenia +Placebo response in major depressive disorder (% change in symptom score) unipolar depression|| response to placebo GCST004739 response to placebo unipolar depression +Placebo response in major depressive disorder (remitter/non-remitter status) unipolar depression|| response to placebo GCST004742 response to placebo unipolar depression +Placebo response in major depressive disorder (responder/non-responder status) unipolar depression|| response to placebo GCST004743 response to placebo unipolar depression +Response to platinum-based chemotherapy in non-small-cell lung cancer response to platinum based chemotherapy|| non-small cell lung carcinoma GCST001629 response to platinum based chemotherapy non-small cell lung carcinoma +Response to platinum-based chemotherapy in non-small-cell lung cancer response to platinum based chemotherapy|| non-small cell lung carcinoma GCST001035 response to platinum based chemotherapy non-small cell lung carcinoma +Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement|| response to paclitaxel GCST003443 response to platinum based chemotherapy|| cytotoxicity measurement|| response to paclitaxel ovarian carcinoma +Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement|| response to paclitaxel GCST003444 response to platinum based chemotherapy|| cytotoxicity measurement|| response to paclitaxel ovarian carcinoma +Response to carboplatin in ovarian cancer (Caspase 3/7 EC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement GCST003442 response to platinum based chemotherapy|| cytotoxicity measurement ovarian carcinoma +Response to carboplatin in ovarian cancer (MTT IC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement GCST003440 response to platinum based chemotherapy|| cytotoxicity measurement ovarian carcinoma +Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement GCST003439 response to platinum based chemotherapy|| cytotoxicity measurement ovarian carcinoma +Platinum-induced hepatotoxicity in non-small cell lung cancer response to platinum based chemotherapy|| non-small cell lung carcinoma|| drug-induced liver injury GCST002993 response to platinum based chemotherapy|| drug-induced liver injury non-small cell lung carcinoma +Response to platinum-based neoadjuvant chemotherapy in cervical cancer cervical carcinoma|| response to platinum-based neoadjuvant chemotherapy GCST004097 response to platinum-based neoadjuvant chemotherapy cervical carcinoma +Response to quetiapine in schizophrenia schizophrenia|| response to quetiapine GCST006295 response to quetiapine schizophrenia +Response to radiotherapy in prostate cancer (overall toxicity) response to radiation|| prostate carcinoma GCST003583 response to radiation prostate carcinoma +"Response to radiotherapy in prostate cancer (toxicity, decreased urine stream)" response to radiation|| prostate carcinoma GCST003581 response to radiation prostate carcinoma +"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)" response to radiation|| prostate carcinoma GCST003584 response to radiation prostate carcinoma +"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)" response to radiation|| prostate carcinoma GCST003582 response to radiation prostate carcinoma +Response to radiotherapy in prostate cancer (toxicity) response to radiation|| prostate carcinoma GCST002511 response to radiation prostate carcinoma +Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy response to radiation|| breast carcinoma|| childhood cancer GCST005112 response to radiation|| breast carcinoma childhood cancer +Obesity in adult survivors of childhood cancer exposed to cranial radiation response to radiation|| childhood cancer|| obesity GCST002900 response to radiation|| obesity childhood cancer +Response to ranibizumab in age-related macular degeneration (exudative) response to ranibizumab|| wet macular degeneration GCST006277 response to ranibizumab wet macular degeneration +Response to ranibizumab in age-related macular degeneration (dry maculae) response to ranibizumab|| age-related macular degeneration|| macula measurement GCST004802 response to ranibizumab|| macula measurement age-related macular degeneration +Response to ranibizumab in age-related macular degeneration (additional treatment requirement) response to ranibizumab|| age-related macular degeneration|| treatment outcome measurement GCST004803 response to ranibizumab|| treatment outcome measurement age-related macular degeneration +Response to rate control therapy in atrial fibrillation response to rate control therapy|| atrial fibrillation GCST002473 response to rate control therapy atrial fibrillation +Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome) response to reverse transcriptase inhibitor|| drug hypersensitivity syndrome|| HIV infection GCST004116 response to reverse transcriptase inhibitor|| drug hypersensitivity syndrome HIV infection +Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury) response to reverse transcriptase inhibitor|| HIV infection|| drug-induced liver injury GCST004114 response to reverse transcriptase inhibitor|| drug-induced liver injury HIV infection +Nevirapine-induced hypersensitivity in HIV response to reverse transcriptase inhibitor|| hypersensitivity reaction disease|| HIV infection GCST004118 response to reverse transcriptase inhibitor|| hypersensitivity reaction disease HIV infection +Nevirapine-induced hypersensitivity in HIV (rash) response to reverse transcriptase inhibitor|| maculopapular eruption|| HIV infection GCST004117 response to reverse transcriptase inhibitor|| maculopapular eruption HIV infection +Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis) response to reverse transcriptase inhibitor|| Stevens-Johnson syndrome|| toxic epidermal necrolysis|| HIV infection GCST004115 response to reverse transcriptase inhibitor|| Stevens-Johnson syndrome|| toxic epidermal necrolysis HIV infection +Response to risperidone in schizophrenia schizophrenia|| response to risperidone GCST006294 response to risperidone schizophrenia +Remission after SSRI treatment in major depression unipolar depression|| response to selective serotonin reuptake inhibitor GCST006266 response to selective serotonin reuptake inhibitor unipolar depression +Response to selective serotonin reuptake inhibitors in depression unipolar depression|| response to selective serotonin reuptake inhibitor GCST006267 response to selective serotonin reuptake inhibitor unipolar depression +Response to serotonin reuptake inhibitors in major depressive disorder unipolar depression|| response to selective serotonin reuptake inhibitor GCST002868 response to selective serotonin reuptake inhibitor unipolar depression +Response to serotonin reuptake inhibitors in non-psychotic unipolar depression unipolar depression|| response to selective serotonin reuptake inhibitor GCST003118 response to selective serotonin reuptake inhibitor unipolar depression +Response to stavudine in HIV (lipoatrophy) HIV-1 infection|| response to stavudine|| Lipoatrophy GCST002968 response to stavudine|| Lipoatrophy HIV-1 infection +Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer response to tamoxifen|| HER2 status|| estrogen-receptor positive breast cancer GCST006615 response to tamoxifen HER2 status|| estrogen-receptor positive breast cancer +Tenofovir clearance in HIV infection response to tenofovir|| HIV infection GCST006073 response to tenofovir HIV infection +Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction) response to tenofovir|| HIV infection GCST006071 response to tenofovir HIV infection +6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction) response to tenofovir|| HIV infection|| creatinine clearance measurement GCST006070 response to tenofovir|| creatinine clearance measurement HIV infection +6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction) response to tenofovir|| HIV infection|| creatinine clearance measurement GCST006072 response to tenofovir|| creatinine clearance measurement HIV infection +Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction) response to tenofovir|| HIV infection|| creatinine clearance measurement GCST006069 response to tenofovir|| creatinine clearance measurement HIV infection +Thiopurine-induced liver dysfunction in inflammatory bowel disease response to thiopurine|| inflammatory bowel disease|| liver disease GCST006212 response to thiopurine|| liver disease inflammatory bowel disease +Thiopurine-induced infection in inflammatory bowel disease response to thiopurine|| inflammatory bowel disease|| susceptibility to infectious disease measurement GCST006211 response to thiopurine|| susceptibility to infectious disease measurement inflammatory bowel disease +Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine) response to thiopurine|| thiopurine immunosuppressant-induced pancreatitis|| inflammatory bowel disease GCST002607 response to thiopurine|| thiopurine immunosuppressant-induced pancreatitis inflammatory bowel disease +Response to anti-TNF therapy in rheumatoid arthritis rheumatoid arthritis|| response to TNF antagonist GCST003329 response to TNF antagonist rheumatoid arthritis +Response to anti-TNF therapy in rheumatoid arthritis rheumatoid arthritis|| response to TNF antagonist GCST001927 response to TNF antagonist rheumatoid arthritis +"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis" rheumatoid arthritis|| response to TNF antagonist GCST002869 response to TNF antagonist rheumatoid arthritis +Response to TNF-alpha inhibitors in rheumatoid arthritis rheumatoid arthritis|| response to TNF antagonist GCST001772 response to TNF antagonist rheumatoid arthritis +Response to TNF-alpha inhibitors in rheumatoid arthritis rheumatoid arthritis|| response to TNF antagonist GCST001510 response to TNF antagonist rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score) rheumatoid arthritis|| response to TNF antagonist|| arthritis disease activity score measurement GCST006610 response to TNF antagonist|| arthritis disease activity score measurement rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate) rheumatoid arthritis|| response to TNF antagonist|| blood sedimentation GCST006607 response to TNF antagonist|| blood sedimentation rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count) rheumatoid arthritis|| response to TNF antagonist|| joint damage measurement GCST006606 response to TNF antagonist|| joint damage measurement rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count) rheumatoid arthritis|| response to TNF antagonist|| joint damage measurement GCST006609 response to TNF antagonist|| joint damage measurement rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score) rheumatoid arthritis|| self rated health|| response to TNF antagonist GCST006608 response to TNF antagonist||self rated health rheumatoid arthritis +Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia) response to trametinib|| fever|| melanoma|| response to dabrafenib GCST003456 response to trametinib|| fever|| response to dabrafenib melanoma +Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 12 weeks) response to venlafaxine|| generalized anxiety disorder GCST004272 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks) response to venlafaxine|| generalized anxiety disorder GCST004271 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks) response to venlafaxine|| generalized anxiety disorder GCST004274 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks) response to venlafaxine|| generalized anxiety disorder GCST004273 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks) response to venlafaxine|| generalized anxiety disorder GCST004270 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks) response to venlafaxine|| generalized anxiety disorder GCST004275 response to venlafaxine generalized anxiety disorder +Response to ziprazidone in schizophrenia schizophrenia|| response to ziprasidone GCST006296 response to ziprasidone schizophrenia +Risky sexual behaviors in alcohol dependence alcohol dependence|| risky sexual behaviour measurement GCST004955 risky sexual behaviour measurement alcohol dependence +Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis salivary gland lesion|| autoimmune pancreatitis type 1|| lachrymal gland lesion GCST002913 salivary gland lesion|| lachrymal gland lesion autoimmune pancreatitis type 1 +Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL) serum alanine aminotransferase measurement|| response to combination chemotherapy|| acute lymphoblastic leukemia GCST004250 serum alanine aminotransferase measurement|| response to combination chemotherapy acute lymphoblastic leukemia +Creatinine levels in ischemic stroke Ischemic stroke|| serum creatinine measurement GCST003213 serum creatinine measurement Ischemic stroke +Peak creatinine levels in vancomycin therapy response to vancomycin|| serum creatinine measurement GCST002948 serum creatinine measurement|| response to vancomycin +IgE levels in asthmatics serum IgE measurement|| asthma GCST002122 serum IgE measurement asthma +IgE levels in asthmatics (D.f. specific) serum IgE measurement|| asthma GCST002125 serum IgE measurement asthma +IgE levels in asthmatics (D.p. specific) serum IgE measurement|| asthma GCST002124 serum IgE measurement asthma +Sex hormone-binding globulin levels in polycystic ovary syndrome polycystic ovary syndrome|| sex hormone-binding globulin measurement GCST005271 sex hormone-binding globulin measurement polycystic ovary syndrome +Sexual dimorphism in anthropometric traits anthropometric measurement|| sexual dimorphism GCST002063 sexual dimorphism anthropometric measurement +Sex difference in attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| sexual dimorphism GCST005363 sexual dimorphism attention deficit hyperactivity disorder +Thiopurine-induced skin symptoms in inflammatory bowel disease skin disease|| response to thiopurine|| inflammatory bowel disease GCST006213 skin disease|| response to thiopurine inflammatory bowel disease +Skin fluorescence in type 1 diabetes skin fluorescence measurement|| type I diabetes mellitus GCST003418 skin fluorescence measurement type I diabetes mellitus +Current cigarettes per day in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking behaviour measurement GCST006042 smoking behaviour measurement chronic obstructive pulmonary disease +Current cigarettes per day in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| cigarettes per day measurement GCST005917 smoking behaviour measurement chronic obstructive pulmonary disease +Current cigarettes per day in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking behaviour measurement GCST001111 smoking behaviour measurement chronic obstructive pulmonary disease +Lifetime average cigarettes per day in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking behaviour measurement GCST001112 smoking behaviour measurement chronic obstructive pulmonary disease +Smoking cessation in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking cessation GCST005918 smoking cessation chronic obstructive pulmonary disease +Smoking cessation in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking cessation GCST001108 smoking cessation chronic obstructive pulmonary disease +Bone mineral density (lumbar spine) in inflammatory bowel disease inflammatory bowel disease|| spine bone mineral density GCST005783 spine bone mineral density inflammatory bowel disease +Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia spine bone mineral density change measurement|| response to combination chemotherapy|| acute lymphoblastic leukemia GCST005214 spine bone mineral density change measurement|| response to combination chemotherapy acute lymphoblastic leukemia +Suicidal ideation in depression or bipolar disorder unipolar depression|| suicidal ideation|| bipolar disorder GCST002505 suicidal ideation unipolar depression|| bipolar disorder +Suicide in bipolar disorder suicide behaviour measurement|| bipolar disorder|| attempted suicide GCST002699 suicide behaviour measurement|| attempted suicide bipolar disorder +Suicide ideation score in major depressive disorder suicide ideation measurement|| unipolar depression GCST002974 suicide ideation measurement unipolar depression +Systolic blood pressure in sickle cell anemia Sickle cell anemia|| systolic blood pressure GCST002187 systolic blood pressure Sickle cell anemia +Systolic blood pressure night-to-day ratio in hypertension hypertension|| systolic blood pressure change measurement GCST006274 systolic blood pressure change measurement hypertension +Systolic blood pressure response to hydrochlorothiazide in hypertension response to hydrochlorothiazide|| hypertension|| systolic blood pressure change measurement GCST003807 response to hydrochlorothiazide|| systolic blood pressure change measurement hypertension +Blood pressure response to hydrochlorothiazide in hypertension response to hydrochlorothiazide|| diastolic blood pressure change measurement|| hypertension|| systolic blood pressure change measurement GCST002784 systolic blood pressure change measurement|| response to hydrochlorothiazide|| diastolic blood pressure change measurement hypertension +Testosterone levels in polycystic ovary syndrome polycystic ovary syndrome|| testosterone measurement GCST005272 testosterone measurement polycystic ovary syndrome +Thalamus volume in trauma-exposed individuals response to trauma exposure|| thalamus volume GCST005245 thalamus volume|| response to trauma exposure +Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines thiopurine methyltransferase activity measurement|| response to mercaptopurine|| acute lymphoblastic leukemia GCST003609 response to mercaptopurine|| thiopurine methyltransferase activity measurement acute lymphoblastic leukemia +Thrombin-antithrombin complex levels in ischemic stroke Ischemic stroke|| thrombin-antithrombin complex measurement GCST003233 thrombin-antithrombin complex measurement Ischemic stroke +Thrombocytopenia in coronary artery bypass surgery coronary artery bypass|| thrombocytopenia GCST006435 thrombocytopenia coronary artery bypass +Thrombomodulin levels in ischemic stroke Ischemic stroke|| thrombomodulin measurement GCST003234 thrombomodulin measurement Ischemic stroke +Thyroid peroxidase autoantibody levels in type 1 diabetes type I diabetes mellitus|| thyroid peroxidase antibody measurement GCST004383 thyroid peroxidase antibody measurement type I diabetes mellitus +Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor ticagrelor measurement|| acute coronary syndrome GCST002882 ticagrelor measurement acute coronary syndrome +Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes response to simvastatin|| type II diabetes mellitus|| total cholesterol change measurement|| response to fenofibrate GCST004765 response to simvastatin|| total cholesterol change measurement|| response to fenofibrate type II diabetes mellitus +Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes triglyceride change measurement|| response to simvastatin|| type II diabetes mellitus|| response to fenofibrate GCST004766 response to simvastatin|| triglyceride change measurement|| response to fenofibrate type II diabetes mellitus +Triglyceride levels in chylomicrons and largest VLDL chylomicron measurement|| triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005512 triglyceride measurement chylomicron measurement|| very low density lipoprotein cholesterol measurement +Triglyceride levels in small HDL triglyceride measurement|| high density lipoprotein cholesterol measurement GCST005509 triglyceride measurement high density lipoprotein cholesterol measurement +Triglyceride levels in very large HDL triglyceride measurement|| high density lipoprotein cholesterol measurement GCST005498 triglyceride measurement high density lipoprotein cholesterol measurement +Triglyceride levels in IDL triglyceride measurement|| intermediate density lipoprotein measurement GCST005480 triglyceride measurement intermediate density lipoprotein measurement +Triglyceride levels in large VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005460 triglyceride measurement very low density lipoprotein cholesterol measurement +Triglyceride levels in medium VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005467 triglyceride measurement very low density lipoprotein cholesterol measurement +Triglyceride levels in small VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005472 triglyceride measurement very low density lipoprotein cholesterol measurement +Triglyceride levels in very large VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005452 triglyceride measurement very low density lipoprotein cholesterol measurement +Triglyceride levels in very small VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005475 triglyceride measurement very low density lipoprotein cholesterol measurement +CSF tryptophan concentration in tuberculous meningitis tryptophan measurement|| meningeal tuberculosis GCST005331 tryptophan measurement meningeal tuberculosis +Depression in smokers smoking behavior|| unipolar depression GCST006427 unipolar depression smoking behavior +Serum urate levels in chronic kidney disease urate measurement|| chronic kidney disease GCST006426 urate measurement chronic kidney disease +Urate levels in obese individuals obese body mass index status|| urate measurement GCST002828 urate measurement obese body mass index status +Urate levels in overweight individuals urate measurement|| overweight body mass index status GCST002829 urate measurement overweight body mass index status +Urate levels in lean individuals urate measurement|| underweight body mass index status GCST002830 urate measurement underweight body mass index status +Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension response to hydrochlorothiazide|| hypertension|| uric acid measurement GCST005646 uric acid measurement|| response to hydrochlorothiazide hypertension +"Urinary 1,3-butadiene metabolite levels in smokers" "smoking status measurement|| urinary 1,3-butadiene measurement" GCST004254 "urinary 1,3-butadiene measurement" smoking status measurement +Urinary albumin-to-creatinine ratio in diabetes diabetes mellitus|| urinary albumin to creatinine ratio GCST003250 urinary albumin to creatinine ratio diabetes mellitus +Fractional excretion of metabolites in chronic kidney disease chronic kidney disease|| urinary metabolite measurement GCST005666 urinary metabolite measurement chronic kidney disease +Urinary metabolite concentrations in chronic kidney disease chronic kidney disease|| urinary metabolite measurement GCST005651 urinary metabolite measurement chronic kidney disease +Urinary metabolite ratios in chronic kidney disease chronic kidney disease|| urinary metabolite measurement GCST005649 urinary metabolite measurement chronic kidney disease +S-phenylmercapturic acid levels in smokers smoking behavior|| urinary S-phenylmercapturic acid measurement GCST003483 urinary S-phenylmercapturic acid measurement smoking behavior +Uveitis in juvenile idiopathic arthritis chronic childhood arthritis|| uveitis GCST006126 uveitis chronic childhood arthritis +Vancomycin trough in vancomycin therapy vancomycin trough measurement|| response to vancomycin GCST002946 vancomycin trough measurement|| response to vancomycin +Vaso-occlusive pain in sickle-cell anemia Sickle cell anemia|| vaso-occlusive pain measurement GCST004644 vaso-occlusive pain measurement Sickle cell anemia +Vein graft stenosis in coronary artery bypass grafting coronary artery bypass|| vein graft stenosis GCST002793 vein graft stenosis coronary artery bypass +Response to abacavir-containing treatment in HIV-1 infection (virologic failure) HIV-1 infection|| virologic response measurement|| response to abacavir GCST002769 virologic response measurement|| response to abacavir HIV-1 infection +Vision loss in proton beam irradiation treatment of choroidal melanoma response to radiation|| choroidal melanoma|| visual acuity measurement GCST005589 visual acuity measurement|| response to radiation choroidal melanoma +Response to ranibizumab in age-related macular degeneration (visual acuity) visual acuity measurement|| response to ranibizumab|| age-related macular degeneration GCST004801 visual acuity measurement|| response to ranibizumab age-related macular degeneration +Vitamin B levels in ischemic stroke stroke|| vitamin B measurement GCST002559 vitamin B measurement stroke +vWF levels in ischaemic stroke and hyperhomocysteinaemia Ischemic stroke|| von Willebrand factor measurement|| homocysteine measurement GCST004598 von Willebrand factor measurement Ischemic stroke|| homocysteine measurement +White matter hyperintensities in ischemic stroke Ischemic stroke|| white matter hyperintensity measurement GCST003245 white matter hyperintensity measurement Ischemic stroke +White matter microstructure in first episode schizophrenia (left anterior cingulate cortex) schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004994 white matter microstructure measurement|| cingulate cortex measurement schizophrenia +White matter microstructure in first episode schizophrenia (left posterior cingulate cortex) schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004995 white matter microstructure measurement|| cingulate cortex measurement schizophrenia +White matter microstructure in first episode schizophrenia (right anterior cingulate cortex) schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004993 white matter microstructure measurement|| cingulate cortex measurement schizophrenia +White matter microstructure in first episode schizophrenia (right posterior cingulate cortex) schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004992 white matter microstructure measurement|| cingulate cortex measurement schizophrenia +White matter microstructure in first episode schizophrenia (left inferior parietal cortex) parietal cortex measurement|| schizophrenia|| white matter microstructure measurement GCST004991 white matter microstructure measurement|| parietal cortex measurement schizophrenia +Yu-Zhi constitution type in type 2 diabetes Yu-Zhi constitution type|| type II diabetes mellitus GCST003026 Yu-Zhi constitution type type II diabetes mellitus +Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation response to allogeneic hematopoietic stem cell transplant|| acute graft vs. host disease GCST002958 response to allogeneic hematopoietic stem cell transplant|| acute graft vs. host disease +Acute graft versus host disease in bone marrow transplantation (donor effect) acute graft vs. host disease|| donor genotype effect measurement GCST003942 acute graft vs. host disease|| donor genotype effect measurement +Subjective response to lithium treatment bipolar disorder|| response to lithium ion GCST003158 bipolar disorder|| response to lithium ion +Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic) blood pressure|| response to thiazide|| response to beta blocker GCST005039 blood pressure|| response to thiazide|| response to beta blocker +Odor events in darapladib-treated cardiovascular disease (time to event) response to darapladib|| body odor measurement|| acute coronary syndrome|| coronary heart disease GCST004960 body odor measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Bronchopulmonary dysplasia in preterm infants infant|| Bronchopulmonary dysplasia GCST004783 Bronchopulmonary dysplasia infant +Major coronary event in darapladib-treated cardiovascular disease (time to event) response to darapladib|| acute coronary syndrome|| coronary heart disease|| cardiovascular event measurement GCST004957 cardiovascular event measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Cerebrospinal fluid clusterin levels in APOEe4- carriers Alzheimer's disease|| cerebrospinal fluid clusterin measurement GCST003137 cerebrospinal fluid clusterin measurement Alzheimer's disease +Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) chemotherapy-induced alopecia|| response to antimicrotubule agent GCST002177 chemotherapy-induced alopecia|| response to antimicrotubule agent +Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) chemotherapy-induced alopecia|| response to docetaxel GCST002180 chemotherapy-induced alopecia|| response to docetaxel +Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) chemotherapy-induced alopecia|| response to paclitaxel GCST002179 chemotherapy-induced alopecia|| response to paclitaxel +Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction) childhood trauma measurement|| response to antipsychotic drug|| treatment refractory schizophrenia GCST004374 childhood trauma measurement|| response to antipsychotic drug treatment refractory schizophrenia +Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD) chronic kidney disease|| diabetic nephropathy GCST005893 chronic kidney disease|| diabetic nephropathy +Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003867 chronic kidney disease|| type 1 diabetes nephropathy +Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003863 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (early and late stages) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003864 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (early stage) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003865 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003862 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003861 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (late stage) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003866 chronic kidney disease|| type 1 diabetes nephropathy +Phospholipid levels in chylomicrons and largest VLDL chylomicron measurement|| very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005511 chylomicron measurement|| very low density lipoprotein cholesterol measurement|| phospholipid measurement +Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma childhood onset asthma|| cortisol measurement|| response to corticosteroid|| response to synacthen GCST005926 cortisol measurement|| response to corticosteroid|| response to synacthen childhood onset asthma +Cough in response to angiotensin-converting enzyme inhibitor drugs response to angiotensin-converting enzyme inhibitor|| Cough GCST004049 Cough|| response to angiotensin-converting enzyme inhibitor +Cough in response to angiotensin-converting enzyme inhibitor drugs response to angiotensin-converting enzyme inhibitor|| Cough GCST003027 Cough|| response to angiotensin-converting enzyme inhibitor +Diabetic nephropathy in type 1 diabetes type I diabetes mellitus|| diabetic retinopathy GCST002716 diabetic nephropathy type I diabetes mellitus +Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic) diastolic blood pressure|| response to thiazide|| response to beta blocker GCST005041 diastolic blood pressure|| response to thiazide|| response to beta blocker +Disease-free survival in breast cancer disease free survival|| breast carcinoma GCST002847 disease free survival|| breast carcinoma +Survival in colon cancer disease free survival|| colonic neoplasm|| overall survival GCST002822 disease free survival|| colonic neoplasm|| overall survival +Survival in microsatellite instability low/stable colorectal cancer disease free survival|| colorectal cancer|| microsatellite instability measurement|| overall survival GCST002820 disease free survival|| colorectal cancer|| microsatellite instability measurement|| overall survival +Survival in rectal cancer disease free survival|| rectum cancer|| overall survival GCST002821 disease free survival|| rectum cancer|| overall survival +Disease progression in age-related macular degeneration age-related macular degeneration|| disease progression measurement GCST005359 age-related macular degeneration|| disease progression measurement +Disease progression to geographic atrophy form in age-related macular degeneration atrophic macular degeneration|| disease progression measurement GCST005360 atrophic macular degeneration|| disease progression measurement +Age at loss of ambulation in Duchenne muscular dystrophy Duchenne muscular dystrophy|| disease progression measurement GCST006286 Duchenne muscular dystrophy|| disease progression measurement +Huntington's disease progression Huntington disease|| disease progression measurement GCST004691 Huntington disease|| disease progression measurement +Disease progression to choroidal neovascularization form in age-related macular degeneration disease progression measurement|| wet macular degeneration GCST005358 disease progression measurement|| wet macular degeneration +Depression (age of onset) mental or behavioural disorder|| age at onset GCST001643 age at onset mental or behavioural disorder +Schizophrenia (age at onset) (sex interaction) schizophrenia|| age at onset GCST001114 +Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction) schizophrenia|| dorsolateral prefrontal cortex functional measurement GCST000271 dorsolateral prefrontal cortex functional measurement|| schizophrenia +Cholesterol ester levels in medium HDL esterified cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005506 esterified cholesterol measurement|| high density lipoprotein cholesterol measurement +Cholesterol ester levels in very large HDL esterified cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005501 esterified cholesterol measurement|| high density lipoprotein cholesterol measurement +Cholesterol ester levels in very large HDL esterified cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005495 esterified cholesterol measurement|| high density lipoprotein cholesterol measurement +Cholesterol ester levels in large LDL esterified cholesterol measurement|| low density lipoprotein cholesterol measurement GCST005484 esterified cholesterol measurement|| low density lipoprotein cholesterol measurement +Cholesterol ester levels in medium LDL esterified cholesterol measurement|| low density lipoprotein cholesterol measurement GCST005489 esterified cholesterol measurement|| low density lipoprotein cholesterol measurement +Estrogen receptor status in HER2 positive breast cancer estrogen-receptor negative breast cancer|| HER2 status|| estrogen-receptor positive breast cancer|| breast carcinoma GCST003822 estrogen receptor status HER2 status|| breast carcinoma +F-cell distribution in sickle cell anaemia fetal hemoglobin measurement|| Sickle cell anemia GCST000982 fetal hemoglobin measurement Sickle cell anemia +Pulmonary function in asthmatics pulmonary function measurement|| asthma GCST002608 pulmonary function measurement asthma +Gestational age at birth in labor-initiated deliveries (child effect) gestational age|| birth measurement GCST003687 gestational age birth measurement +Gestational age at birth in labor-initiated deliveries (maternal effect) gestational age|| birth measurement GCST003684 gestational age birth measurement +Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect) gestational age|| birth measurement GCST003689 gestational age birth measurement +Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect) gestational age|| birth measurement GCST003685 gestational age birth measurement +Glomerular filtration rate in non diabetics (creatinine) glomerular filtration rate|| serum creatinine measurement GCST003401 glomerular filtration rate|| serum creatinine measurement +Decline in glucose metabolism in posterior cingulate cortex glucose metabolism decline measurement|| cingulate cortex measurement GCST006632 glucose metabolism decline measurement|| cingulate cortex measurement +HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes HDL cholesterol change measurement|| response to simvastatin|| type II diabetes mellitus|| response to fenofibrate GCST004763 HDL cholesterol change measurement|| response to fenofibrate|| response to simvastatin type II diabetes mellitus +Antipsychotic drug-induced QTc interval change in schizophrenia heart rate variability measurement|| response to antipsychotic drug GCST004987 heart rate variability measurement|| response to antipsychotic drug schizophrenia +Estrogen receptor status in HER2 negative breast cancer estrogen-receptor negative breast cancer|| HER2 status|| estrogen-receptor positive breast cancer|| breast carcinoma GCST003823 estrogen receptor status breast carcinoma|| HER2 status +Hippocampal volume in trauma-exposed individuals response to trauma exposure|| hippocampal volume GCST005243 hippocampal volume||response to trauma exposure +HIV-1 viral setpoint HIV-1 infection|| HIV viral set point measurement GCST002976 HIV viral set point measurement HIV-1 infection +Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide) response to triamcinolone acetonide|| intraocular pressure change measurement GCST002837 intraocular pressure change measurement|| response to triamcinolone acetonide +Joint damage progression in ACPA-positive rheumatoid arthritis ACPA-positive rheumatoid arthritis|| joint damage measurement GCST002139 joint damage measurement ACPA-positive rheumatoid arthritis +Joint damage progression in ACPA-negative rheumatoid arthritis ACPA-negative rheumatoid arthritis|| joint damage measurement GCST003256 joint damage measurement ACPA-negative rheumatoid arthritis +LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes LDL cholesterol change measurement|| response to simvastatin|| type II diabetes mellitus|| response to fenofibrate GCST004764 LDL cholesterol change measurement|| response to fenofibrate|| response to simvastatin type II diabetes mellitus +Change in LVEF in response to paclitaxel in HER2+ breast cancer left ventricular diastolic function measurement|| response to paclitaxel GCST004789 left ventricular diastolic function measurement|| response to paclitaxel +Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer response to trastuzumab|| left ventricular diastolic function measurement|| response to paclitaxel GCST004788 left ventricular diastolic function measurement|| response to trastuzumab|| response to paclitaxel +Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer response to trastuzumab|| left ventricular diastolic function measurement|| response to paclitaxel GCST004790 left ventricular diastolic function measurement|| response to trastuzumab|| response to paclitaxel +Phospholipid levels in large LDL low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005482 low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in medium LDL low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005487 low density lipoprotein cholesterol measurement|| phospholipid measurement +Brain activation in response to working memory task memory performance|| functional brain measurement|| short-term memory GCST003698 memory performance|| functional brain measurement|| short-term memory +Remission after SSRI treatment in MDD or neuroticism unipolar depression|| neuroticism measurement|| response to selective serotonin reuptake inhibitor GCST005835 neuroticism measurement|| response to selective serotonin reuptake inhibitor unipolar depression +Cisplatin-induced hearing loss in brain tumor patients ototoxicity|| hearing loss|| response to cisplatin GCST002780 ototoxicity|| hearing loss|| response to cisplatin +Phospholipid levels in large HDL phospholipid measurement|| high density lipoprotein cholesterol measurement GCST005499 phospholipid measurement|| high density lipoprotein cholesterol measurement +Phospholipid levels in medium HDL phospholipid measurement|| high density lipoprotein cholesterol measurement GCST005504 phospholipid measurement|| high density lipoprotein cholesterol measurement +Phospholipid levels in very large HDL phospholipid measurement|| high density lipoprotein cholesterol measurement GCST005493 phospholipid measurement|| high density lipoprotein cholesterol measurement +Phospholipid levels in IDL phospholipid measurement|| intermediate density lipoprotein measurement GCST005477 phospholipid measurement|| intermediate density lipoprotein measurement +Acute graft rejection in renal transplantation (donor effect) renal transplant outcome measurement|| donor genotype effect measurement GCST005432 renal transplant outcome measurement|| donor genotype effect measurement +Acute graft rejection in renal transplantation (donor-recipient interaction) renal transplant outcome measurement|| donor genotype effect measurement GCST005433 renal transplant outcome measurement|| donor genotype effect measurement +Angioedema in response to angiotensin-converting enzyme inhibitor response to angiotensin-converting enzyme inhibitor|| angioedema GCST002091 response to angiotensin-converting enzyme inhibitor|| angioedema +Response to antidepressants in depression unipolar depression|| mood disorder|| response to antidepressant GCST003803 response to antidepressant unipolar depression|| mood disorder +Response to aripiprazole in schizophrenia schizophrenia|| response to aripiprazole|| response to antipsychotic drug GCST006285 response to aripiprazole|| response to antipsychotic drug schizophrenia +Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) response to bronchodilator|| asthma GCST002291 response to bronchodilator|| response to corticosteroid asthma +Response to bupropion in depression unipolar depression|| response to bupropion|| mood disorder GCST003800 response to bupropion unipolar depression|| mood disorder +Response to angiotensin II receptor blocker therapy response to candesartan|| hypertension GCST001520 response to candesartan hypertension +Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) response to candesartan|| hypertension GCST001518 response to candesartan hypertension +Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) response to cyclophosphamide|| chemotherapy-induced alopecia|| response to 5' fluorouracil|| response to doxorubicin GCST002178 response to cyclophosphamide|| chemotherapy-induced alopecia|| response to 5' fluorouracil|| response to doxorubicin +Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) response to epirubicin|| response to cyclophosphamide|| chemotherapy-induced alopecia|| response to 5' fluorouracil GCST002176 response to epirubicin|| response to cyclophosphamide|| chemotherapy-induced alopecia|| response to 5' fluorouracil +Response to citalopram or escitalopram in depression unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder GCST003802 response to escitalopram|| response to citalopram unipolar depression|| mood disorder +Thiazide-induced adverse metabolic effects in hypertensive patients response to hydrochlorothiazide|| triglyceride measurement|| fasting blood glucose measurement GCST001859 response to hydrochlorothiazide|| triglyceride measurement|| fasting blood glucose measurement +Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy response to interferon|| hepatocellular carcinoma|| virologic response measurement GCST004160 response to interferon|| hepatocellular carcinoma virologic response measurement +Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer response to irinotecan|| non-small cell lung carcinoma GCST001901 response to irinotecan non-small cell lung carcinoma +Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels) triglyceride change measurement|| response to long-chain n-3 PUFA dietary supplementation GCST006055 response to long-chain n-3 PUFA dietary supplementation|| triglyceride change measurement +Urinary symptoms in response to radiotherapy in prostate cancer response to radiation|| prostate carcinoma|| lower urinary tract symptom GCST001847 response to radiation|| lower urinary tract symptom prostate carcinoma +Response to SSRI in MDD or conscientiouness conscientiousness measurement|| unipolar depression|| response to selective serotonin reuptake inhibitor GCST005836 conscientiousness measurement|| response to selective serotonin reuptake inhibitor unipolar depression +Response to selective serotonin reuptake inhibitors in depression unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder GCST003801 response to selective serotonin reuptake inhibitor unipolar depression|| mood disorder +Response to SSRI in MDD or openness unipolar depression|| response to selective serotonin reuptake inhibitor|| openness measurement GCST005834 response to selective serotonin reuptake inhibitor|| openness measurement unipolar depression +Remission after SSRI treatment in MDD or openness unipolar depression|| response to selective serotonin reuptake inhibitor|| openness measurement GCST005833 response to selective serotonin reuptake inhibitor|| openness measurement unipolar depression +Nucleus accumbens volume in trauma-exposed individuals response to trauma exposure|| nucleus accumbens volume GCST005241 response to trauma exposure|| nucleus accumbens volume +Rheumatoid factor seropositivity in rheumatoid arthritis rheumatoid arthritis|| rheumatoid factor seropositivity measurement|| rheumatoid factor measurement GCST003330 rheumatoid factor seropositivity measurement|| rheumatoid factor measurement rheumatoid arthritis +Age at smoking initiation in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking initiation GCST001113 smoking initiation chronic obstructive pulmonary disease +Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels) systolic blood pressure|| blood pressure|| response to losartan GCST002583 systolic blood pressure|| blood pressure|| response to losartan +Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic) systolic blood pressure|| response to thiazide|| response to beta blocker GCST005040 systolic blood pressure|| response to thiazide|| response to beta blocker +Tacrolimus trough concentration in kidney transplant patients tacrolimus measurement|| renal transplant outcome measurement GCST005144 tacrolimus measurement renal transplant outcome measurement +Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous) tuberculin skin test reactivity measurement|| decreased susceptibility to bacterial infection GCST004689 tuberculin skin test reactivity measurement|| decreased susceptibility to bacterial infection +Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous) tuberculin skin test reactivity measurement|| decreased susceptibility to bacterial infection GCST004690 tuberculin skin test reactivity measurement|| decreased susceptibility to bacterial infection +Cholesterol ester levels in large VLDL very low density lipoprotein cholesterol measurement|| esterified cholesterol measurement GCST005461 very low density lipoprotein cholesterol measurement|| esterified cholesterol measurement +Cholesterol ester levels in medium VLDL very low density lipoprotein cholesterol measurement|| esterified cholesterol measurement GCST005465 very low density lipoprotein cholesterol measurement|| esterified cholesterol measurement +Phospholipid levels in large VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005454 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in medium VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005463 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in small VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005469 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in very large VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005451 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in very small VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005474 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity) visual acuity measurement|| wet macular degeneration|| response to anti-vascular endothelial growth factor drug GCST006808 visual acuity measurement|| response to anti-vascular endothelial growth factor drug wet macular degeneration +Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction) cognitive impairment|| Alzheimer's disease|| cognitive decline measurement GCST004253 cognitive impairment|| Alzheimer's disease|| cognitive decline measurement +ACPA-negative rheumatoid arthritis (smoking interaction) rheumatoid arthritis|| smoking status measurement|| ACPA-negative rheumatoid arthritis GCST006807 rheumatoid arthritis|| smoking status measurement|| ACPA-negative rheumatoid arthritis +ACPA-positive rheumatoid arthritis (smoking interaction) rheumatoid arthritis|| smoking status measurement|| ACPA-positive rheumatoid arthritis GCST006410 rheumatoid arthritis|| smoking status measurement|| ACPA-positive rheumatoid arthritis +Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) urticaria|| response to non-steroidal anti-inflammatory|| angioedema GCST002263 urticaria|| response to non-steroidal anti-inflammatory|| angioedema +Acylcarnitine levels acylcarnitine measurement|| blood metabolite measurement GCST002961 acylcarnitine measurement|| blood metabolite measurement +Adult onset asthma (smoking interaction) smoking behavior|| adult onset asthma GCST004220 smoking behavior|| adult onset asthma +Advanced age-related macular degeneration atrophic macular degeneration|| age-related macular degeneration|| wet macular degeneration GCST003219 atrophic macular degeneration|| age-related macular degeneration|| wet macular degeneration +Advanced glycation end-product levels advanced glycation end-product measurement|| type II diabetes mellitus GCST003457 advanced glycation end-product measurement|| type II diabetes mellitus +Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) response to 5' fluorouracil|| response to antineoplastic agent GCST001997 response to 5' fluorouracil|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) response to antineoplastic agent|| response to anthracycline-based chemotherapy GCST002008 response to antineoplastic agent|| response to anthracycline-based chemotherapy +Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) response to antineoplastic agent|| response to antimetabolite GCST002005 response to antineoplastic agent|| response to antimetabolite +Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) response to antineoplastic agent|| response to antimicrotubule agent GCST002001 response to antineoplastic agent|| response to antimicrotubule agent +Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) response to platinum based chemotherapy|| response to antineoplastic agent GCST001998 response to platinum based chemotherapy|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) response to topoisomerase inhibitor|| response to antineoplastic agent GCST001994 response to topoisomerase inhibitor|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) response to camptothecin|| response to antineoplastic agent GCST001993 response to camptothecin|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) response to carboplatin|| response to antineoplastic agent GCST002004 response to carboplatin|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) response to cisplatin|| response to antineoplastic agent GCST002007 response to cisplatin|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) response to cyclophosphamide|| response to antineoplastic agent GCST002002 response to cyclophosphamide|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) response to docetaxel|| response to antineoplastic agent GCST001995 response to docetaxel|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) response to antineoplastic agent|| response to doxorubicin GCST002009 response to antineoplastic agent|| response to doxorubicin +Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) response to epirubicin|| response to antineoplastic agent GCST001996 response to epirubicin|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) response to etoposide|| response to antineoplastic agent GCST002000 response to etoposide|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) response to gemcitabine|| response to antineoplastic agent GCST002003 response to gemcitabine|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) response to carboplatin|| response to paclitaxel|| response to antineoplastic agent GCST002006 response to carboplatin|| response to paclitaxel|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) response to paclitaxel|| response to antineoplastic agent GCST001999 response to paclitaxel|| response to antineoplastic agent +Affective disorder and suicide attempts attempted suicide|| mood disorder GCST006420 attempted suicide|| mood disorder +Age of smoking initiation age at onset|| smoking initiation GCST002394 age at onset|| smoking initiation +Age-related disease endophenotypes total cholesterol measurement|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| hematocrit|| ventricular rate measurement|| glucose measurement|| body mass index|| high density lipoprotein cholesterol measurement GCST004046 total cholesterol measurement|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| hematocrit|| ventricular rate measurement|| glucose measurement|| body mass index|| high density lipoprotein cholesterol measurement +Age-related diseases and mortality cancer|| heart failure|| diabetes mellitus|| stroke|| coronary heart disease|| atrial fibrillation|| mortality GCST004044 cancer|| heart failure|| diabetes mellitus|| stroke|| coronary heart disease|| atrial fibrillation|| mortality +"Age-related diseases, mortality and associated endophenotypes" total cholesterol measurement|| hematocrit|| stroke|| ventricular rate measurement|| coronary heart disease|| body mass index|| atrial fibrillation|| high density lipoprotein cholesterol measurement|| cancer|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| heart failure|| diabetes mellitus|| glucose measurement|| mortality GCST004045 total cholesterol measurement|| hematocrit|| stroke|| ventricular rate measurement|| coronary heart disease|| body mass index|| atrial fibrillation|| high density lipoprotein cholesterol measurement|| cancer|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| heart failure|| diabetes mellitus|| glucose measurement|| mortality +Age-related macular degeneration glaucoma|| age-related macular degeneration GCST001899 glaucoma|| age-related macular degeneration +Age-related macular degeneration (CNV vs. GA) atrophic macular degeneration|| wet macular degeneration GCST001577 atrophic macular degeneration|| wet macular degeneration +Age-related macular degeneration (smoking status interaction) smoking status measurement|| age-related macular degeneration GCST001990 smoking status measurement|| age-related macular degeneration +Aggressive periodontitis (sex interaction) sex interaction measurement|| aggressive periodontitis GCST002635 sex interaction measurement|| aggressive periodontitis +Aggressive prostate cancer cancer aggressiveness measurement|| prostate carcinoma GCST003585 cancer aggressiveness measurement|| prostate carcinoma +Aging (time to death) longevity|| aging GCST001167 longevity|| aging +Aging traits age at menopause|| aging|| exercise test|| age at death GCST000096 age at menopause|| aging|| exercise test|| age at death +Alcohol consumption (drinkers vs non-drinkers) alcohol consumption measurement|| alcohol drinking GCST004404 alcohol consumption measurement|| alcohol drinking +Alcohol consumption (drinks per week) alcohol consumption measurement|| alcohol drinking GCST004405 alcohol consumption measurement|| alcohol drinking +Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis alcoholic liver cirrhosis|| alcohol dependence|| alcoholic pancreatitis GCST004757 alcoholic liver cirrhosis|| alcohol dependence|| alcoholic pancreatitis +Alcohol misuse (trauma interaction) stressful life event measurement|| alcohol dependence measurement GCST004225 stressful life event measurement|| alcohol dependence measurement +Alzheimer's disease (APOE e4 interaction) Alzheimer's disease|| APOE carrier status GCST002814 Alzheimer's disease|| APOE carrier status +Alzheimer's disease or family history of Alzheimer's disease Alzheimer's disease|| family history of Alzheimer’s disease GCST005922 Alzheimer's disease|| family history of Alzheimer’s disease +Alzheimer's disease or small vessel stroke Alzheimer's disease|| small vessel stroke GCST003423 Alzheimer's disease|| small vessel stroke +Alzheimer's disease or type 2 diabetes (pleiotropy) Alzheimer's disease|| type II diabetes mellitus GCST004880 Alzheimer's disease|| type II diabetes mellitus +Amino acid levels blood metabolite measurement|| amino acid measurement GCST002966 blood metabolite measurement|| amino acid measurement +Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy) rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| amyotrophic lateral sclerosis|| celiac disease|| ulcerative colitis|| Crohn's disease GCST005321 rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| amyotrophic lateral sclerosis|| celiac disease|| ulcerative colitis|| Crohn's disease +Amyotrophic lateral sclerosis or frontotemporal dementia amyotrophic lateral sclerosis|| Frontotemporal dementia GCST002510 amyotrophic lateral sclerosis|| Frontotemporal dementia +Amyotrophic lateral sclerosis or schizophrenia (pleiotropy) schizophrenia|| amyotrophic lateral sclerosis GCST004252 schizophrenia|| amyotrophic lateral sclerosis +Androgen levels dihydrotestosterone measurement|| testosterone measurement GCST001653 dihydrotestosterone measurement|| testosterone measurement +Anorexia nervosa or obsessive-compulsive disorder anorexia nervosa|| obsessive-compulsive disorder GCST006576 anorexia nervosa|| obsessive-compulsive disorder +Anti-thyroid drug induced agranulocytosis drug-induced agranulocytosis|| response to anti-thyroid drug GCST003527 drug-induced agranulocytosis|| response to anti-thyroid drug +Antiepileptic drug-induced maculopapular exanthema maculopapular eruption|| response to anticonvulsant GCST005197 maculopapular eruption|| response to anticonvulsant +Antipsychotic drug-induced weight gain (time interaction) longitudinal BMI measurement|| antipsychotic drug related weight gain GCST003108 longitudinal BMI measurement|| antipsychotic drug related weight gain +Antithyroid drug-induced agranulocytosis drug-induced agranulocytosis|| response to thioamide GCST003580 drug-induced agranulocytosis|| response to thioamide +Anxiety and major depressive disorder unipolar depression|| anxiety GCST002200 unipolar depression|| anxiety +Asthma (sex interaction) sex interaction measurement|| asthma GCST002445 sex interaction measurement|| asthma +Asthma and hay fever seasonal allergic rhinitis|| asthma GCST002322 seasonal allergic rhinitis|| asthma +Asthma or atopy (farm exposure interaction) farm exposure measurement|| asthma GCST000934 farm exposure measurement|| asthma +Asthma or chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| asthma GCST002519 chronic obstructive pulmonary disease|| asthma +Asymmetrical dimethylarginine levels asymmetrical dimethylarginine measurement|| serum dimethylarginine measurement GCST002241 asymmetrical dimethylarginine measurement|| serum dimethylarginine measurement +Atopic march childhood onset asthma|| atopic eczema|| atopic march GCST003180 childhood onset asthma|| atopic eczema|| atopic march +Attention deficit hyperactivity disorder (sex interaction) attention deficit hyperactivity disorder|| sex interaction measurement GCST005361 attention deficit hyperactivity disorder|| sex interaction measurement +Attention deficit hyperactivity disorder and conduct disorder attention deficit hyperactivity disorder|| conduct disorder GCST000253 attention deficit hyperactivity disorder|| conduct disorder +Attention deficit hyperactivity disorder and obsessive compulsive disorder obsessive-compulsive disorder|| attention deficit hyperactivity disorder GCST004223 obsessive-compulsive disorder|| attention deficit hyperactivity disorder +Attention deficit hyperactivity disorder or educational attainment (years of education) (pleiotropy) attention deficit hyperactivity disorder|| self reported educational attainment GCST006216 attention deficit hyperactivity disorder|| self reported educational attainment +Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction) attention deficit hyperactivity disorder|| parental emotion expression measurmement GCST000247 attention deficit hyperactivity disorder|| parental emotion expression measurmement +Autism spectrum disorder or schizophrenia schizophrenia|| autism spectrum disorder GCST004521 schizophrenia|| autism spectrum disorder +Autism spectrum disorder-related traits autism spectrum disorder|| autism|| autism spectrum disorder symptom GCST002639 autism spectrum disorder|| autism|| autism spectrum disorder symptom +"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)" attention deficit hyperactivity disorder|| unipolar depression|| schizophrenia|| autism spectrum disorder|| bipolar disorder GCST001877 attention deficit hyperactivity disorder|| unipolar depression|| schizophrenia|| autism spectrum disorder|| bipolar disorder +Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis) autoimmune thyroid disease|| Hashimoto's thyroiditis|| Graves disease GCST005524 autoimmune thyroid disease|| Hashimoto's thyroiditis|| Graves disease +Axial length or spherical error (univariate decomposition analysis) axial length measurement|| refractive error measurement GCST006864 axial length measurement|| refractive error measurement +"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)" Hodgkins lymphoma|| multiple myeloma|| chronic lymphocytic leukemia GCST004099 Hodgkins lymphoma|| multiple myeloma|| chronic lymphocytic leukemia +Barrett's esophagus or Esophageal adenocarcinoma esophageal adenocarcinoma|| Barrett's esophagus GCST003740 esophageal adenocarcinoma|| Barrett's esophagus +Barrett's esophagus x BMI interaction Barrett's esophagus|| body mass index GCST006529 Barrett's esophagus|| body mass index +Barrett's esophagus x gastroesophageal reflux disease interaction Barrett's esophagus|| gastroesophageal reflux disease GCST006526 Barrett's esophagus|| gastroesophageal reflux disease +Barrett's esophagus x pack-years of smoking exposure interaction pack-years measurement|| Barrett's esophagus GCST006528 pack-years measurement|| Barrett's esophagus +Barrett's esophagus x smoking interaction smoking status measurement|| Barrett's esophagus GCST006527 smoking status measurement|| Barrett's esophagus +Behavioral disturbance or psychiatric symptoms and prion disease behavioral abnormality|| prion disease GCST002866 behavioral abnormality|| prion disease +Behavioural disinhibition (generation interaction) nicotine use|| generational effect measurement|| illegal drug consumption|| non-substance related disinhibited behaviour|| alcohol drinking|| alcohol dependence GCST002131 nicotine use|| generational effect measurement|| illegal drug consumption|| non-substance related disinhibited behaviour|| alcohol drinking|| alcohol dependence +Benign prostatic hyperplasia and/or lower urinary tract symptoms lower urinary tract symptom|| benign prostatic hyperplasia GCST004638 lower urinary tract symptom|| benign prostatic hyperplasia +Binge eating behaviour and bipolar disorder binge eating|| bipolar disorder GCST005386 binge eating|| bipolar disorder +Binge eating behaviour and bipolar disorder binge eating|| bipolar disorder GCST002419 binge eating|| bipolar disorder +Biochemical measures serum albumin measurement|| total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| fibrinogen measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement GCST000328 serum albumin measurement|| total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| fibrinogen measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement +Biomedical quantitative traits diastolic blood pressure|| systolic blood pressure|| bone density|| heart rate|| waist-hip ratio|| body mass index GCST000381 diastolic blood pressure|| systolic blood pressure|| bone density|| heart rate|| waist-hip ratio|| body mass index +Bipolar disorder (body mass index interaction) bipolar disorder|| body mass index GCST002306 bipolar disorder|| body mass index +Bipolar disorder (inflammation and infection response interaction) HSV1 seropositivity|| bipolar disorder|| cytomegalovirus seropositivity GCST002815 HSV1 seropositivity|| bipolar disorder|| cytomegalovirus seropositivity +Bipolar disorder and eating disorder eating disorder|| bipolar disorder GCST003135 eating disorder|| bipolar disorder +Bipolar disorder and schizophrenia schizophrenia|| bipolar disorder GCST001567 schizophrenia|| bipolar disorder +Bipolar disorder lithium response (categorical) or schizophrenia schizophrenia|| bipolar disorder|| response to lithium ion GCST005082 schizophrenia|| bipolar disorder|| response to lithium ion +Bipolar disorder lithium response (continuous) or schizophrenia schizophrenia|| bipolar disorder|| response to lithium ion GCST005081 schizophrenia|| bipolar disorder|| response to lithium ion +Bipolar disorder or attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| bipolar disorder GCST004001 attention deficit hyperactivity disorder|| bipolar disorder +Bipolar disorder or major depressive disorder unipolar depression|| bipolar disorder GCST000641 unipolar depression|| bipolar disorder +Blood metabolite levels urate measurement|| mannose measurement|| blood metabolite measurement|| X12063 measurement GCST002872 urate measurement|| mannose measurement|| blood metabolite measurement|| X12063 measurement +Blood pressure diastolic blood pressure|| systolic blood pressure GCST004705 diastolic blood pressure|| systolic blood pressure +Blood pressure (age interaction) blood pressure|| age at assessment GCST002495 blood pressure|| age at assessment +Blood pressure (anthropometric measures interaction) anthropometric measurement|| diastolic blood pressure|| systolic blood pressure GCST002471 anthropometric measurement|| diastolic blood pressure|| systolic blood pressure +Blood pressure (response to antihypertensive medication) blood pressure|| response to antihypertensive drug GCST002262 blood pressure|| response to antihypertensive drug +Blood pressure (smoking interaction) pack-years measurement|| smoking behavior|| smoking status measurement|| diastolic blood pressure|| systolic blood pressure|| blood pressure|| smoking behaviour measurement|| cigarettes per day measurement GCST002587 pack-years measurement|| smoking behavior|| smoking status measurement|| diastolic blood pressure|| systolic blood pressure|| blood pressure|| smoking behaviour measurement|| cigarettes per day measurement +Blood pressure measurement (cold pressor test) blood pressure|| response to cold pressor test GCST002247 blood pressure|| response to cold pressor test +Blood pressure measurement (high sodium and potassium intervention) blood pressure|| response to high sodium diet|| response to dietary potassium supplementation GCST002252 blood pressure|| response to high sodium diet|| response to dietary potassium supplementation +Blood pressure measurement (high sodium intervention) blood pressure|| response to high sodium diet GCST002249 blood pressure|| response to high sodium diet +Blood pressure measurement (low sodium intervention) blood pressure|| response to low sodium diet GCST002250 blood pressure|| response to low sodium diet +Blood pressure traits (multi-trait analysis) pulse pressure measurement|| diastolic blood pressure|| systolic blood pressure|| hypertension GCST004388 pulse pressure measurement|| diastolic blood pressure|| systolic blood pressure|| hypertension +BMI (adjusted for smoking behaviour) smoking behavior|| body mass index GCST004495 smoking behavior|| body mass index +BMI (smoking interaction) smoking behavior|| body mass index GCST004496 smoking behavior|| body mass index +BMI x dairy intake interaction (1df interaction test) energy intake|| body mass index GCST006173 energy intake|| body mass index +Body mass index physical activity measurement|| body mass index GCST004557 physical activity measurement|| body mass index +Body mass index (smoking years interaction) smoking behaviour measurement|| body mass index GCST004581 smoking behaviour measurement|| body mass index +Body mass index (alcohol intake interaction) alcohol consumption measurement|| body mass index GCST001753 alcohol consumption measurement|| body mass index +Body mass index (dietary energy interaction) diet measurement|| body mass index GCST004587 diet measurement|| body mass index +Body mass index (ever vs never smoking interaction) smoking behaviour measurement|| body mass index GCST004586 smoking behaviour measurement|| body mass index +Body mass index (joint analysis main effects and physical activity interaction) physical activity measurement|| body mass index GCST004558 physical activity measurement|| body mass index +Body mass index (joint analysis main effects and smoking interaction) smoking behavior|| body mass index GCST004497 smoking behavior|| body mass index +Body mass index (physical activity interaction) physical activity measurement|| body mass index GCST004568 physical activity measurement|| body mass index +Body mass index (recreational physical activity interaction) physical activity measurement|| body mass index GCST004580 physical activity measurement|| body mass index +Body mass index (sex interaction) sex interaction measurement|| body mass index GCST000930 sex interaction measurement|| body mass index +Body mass index and cholesterol (psychopharmacological treatment) total cholesterol measurement|| response to drug|| body mass index GCST001440 total cholesterol measurement|| response to drug|| body mass index +Body mass index and fat mass adipose tissue measurement|| body mass index GCST000443 adipose tissue measurement|| body mass index +Body mass index and waist-hip ratio (pleiotropy) waist-hip ratio|| body mass index GCST006430 waist-hip ratio|| body mass index +Body mass index x age interaction body mass index|| age at assessment GCST005954 body mass index|| age at assessment +Body mass index x sex interaction sex interaction measurement|| body mass index GCST005949 sex interaction measurement|| body mass index +Body mass index x sex x age interaction sex interaction measurement|| body mass index|| age at assessment GCST005955 sex interaction measurement|| body mass index|| age at assessment +Body mass index x sex x age interaction (4df test) sex interaction measurement|| body mass index|| age at assessment GCST005950 sex interaction measurement|| body mass index|| age at assessment +Bone mineral density (hip) and age at menarche hip bone mineral density|| age at menarche GCST003102 hip bone mineral density|| age at menarche +Bone mineral density (sex interaction) sex interaction measurement|| bone density GCST001566 sex interaction measurement|| bone density +Bone mineral density (spine) and age at menarche age at menarche|| spine bone mineral density GCST003101 age at menarche|| spine bone mineral density +Brain structure (hippocampal volume) brain measurement|| hippocampal volume GCST000615 brain measurement|| hippocampal volume +Breast cancer (menopausal hormone therapy interaction) breast carcinoma|| hormone replacement therapy GCST002265 breast carcinoma|| hormone replacement therapy +Breast cancer (menopausal hormone therapy interaction) breast carcinoma|| hormone replacement therapy GCST001869 breast carcinoma|| hormone replacement therapy +Breast cancer and/or colorectal cancer colorectal cancer|| breast carcinoma GCST006035 colorectal cancer|| breast carcinoma +Breast milk fatty acid composition (infant genotype effect) fatty acid measurement|| fetal genotype effect measurement|| breast milk measurement GCST005587 fatty acid measurement|| fetal genotype effect measurement|| breast milk measurement +Breast milk fatty acid composition (maternal genotype effect) fatty acid measurement|| breast milk measurement|| parental genotype effect measurement GCST005586 fatty acid measurement|| breast milk measurement|| parental genotype effect measurement +Burning and freckling freckles|| sunburn GCST000196 freckles|| sunburn +C-reactive protein (red blood cell fatty acid level interaction) fatty acid measurement|| C-reactive protein measurement GCST004815 fatty acid measurement|| C-reactive protein measurement +C-reactive protein and white blood cell count leukocyte count|| C-reactive protein measurement GCST001605 leukocyte count|| C-reactive protein measurement +C-reactive protein levels or HDL-cholesterol levels (pleiotropy) C-reactive protein measurement|| high density lipoprotein cholesterol measurement GCST003680 C-reactive protein measurement|| high density lipoprotein cholesterol measurement +C-reactive protein levels or LDL-cholesterol levels (pleiotropy) low density lipoprotein cholesterol measurement|| C-reactive protein measurement GCST003679 low density lipoprotein cholesterol measurement|| C-reactive protein measurement +C-reactive protein levels or total cholesterol levels (pleiotropy) total cholesterol measurement|| C-reactive protein measurement GCST003678 total cholesterol measurement|| C-reactive protein measurement +C-reactive protein levels or triglyceride levels (pleiotropy) triglyceride measurement|| C-reactive protein measurement GCST003681 triglyceride measurement|| C-reactive protein measurement +Calcific aortic valve stenosis aortic stenosis|| aortic valve calcification GCST005785 aortic stenosis|| aortic valve calcification +Cancer cancer|| lung carcinoma|| estrogen-receptor negative breast cancer|| colorectal cancer|| ovarian endometrioid carcinoma|| prostate carcinoma|| ovarian serous carcinoma|| breast carcinoma|| ovarian carcinoma|| lung adenocarcinoma|| squamous cell lung carcinoma GCST003587 cancer|| lung carcinoma|| estrogen-receptor negative breast cancer|| colorectal cancer|| ovarian endometrioid carcinoma|| prostate carcinoma|| ovarian serous carcinoma|| breast carcinoma|| ovarian carcinoma|| lung adenocarcinoma|| squamous cell lung carcinoma +Cancer (pleiotropy) cancer|| lung carcinoma|| estrogen-receptor negative breast cancer|| colorectal cancer|| ovarian endometrioid carcinoma|| prostate carcinoma|| ovarian serous carcinoma|| breast carcinoma|| ovarian carcinoma|| lung adenocarcinoma|| squamous cell lung carcinoma GCST003588 cancer|| lung carcinoma|| estrogen-receptor negative breast cancer|| colorectal cancer|| ovarian endometrioid carcinoma|| prostate carcinoma|| ovarian serous carcinoma|| breast carcinoma|| ovarian carcinoma|| lung adenocarcinoma|| squamous cell lung carcinoma +Carbamazepine-induced maculopapular exanthema maculopapular eruption|| response to carbamazepine GCST005198 maculopapular eruption|| response to carbamazepine +Cardiac muscle measurement cardiovascular measurement|| left ventricular hypertrophy GCST000936 cardiovascular measurement|| left ventricular hypertrophy +Cardiovascular disease risk factors aspartate aminotransferase measurement|| butyrylcholinesterase measurement|| triglyceride measurement|| ferritin measurement|| serum gamma-glutamyl transferase measurement|| low density lipoprotein cholesterol measurement|| C-reactive protein measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement GCST001247 aspartate aminotransferase measurement|| butyrylcholinesterase measurement|| triglyceride measurement|| ferritin measurement|| serum gamma-glutamyl transferase measurement|| low density lipoprotein cholesterol measurement|| C-reactive protein measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement +Cardiovascular risk factors waist circumference|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| cardiovascular disease|| high density lipoprotein cholesterol measurement GCST004704 waist circumference|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| cardiovascular disease|| high density lipoprotein cholesterol measurement +Cardiovascular risk factors (age interaction) waist circumference|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| cardiovascular disease|| high density lipoprotein cholesterol measurement|| age at assessment GCST000789 waist circumference|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| cardiovascular disease|| high density lipoprotein cholesterol measurement|| age at assessment +Carotenoid and tocopherol levels carotenoid measurement|| tocopherol measurement GCST000324 carotenoid measurement|| tocopherol measurement +Carotid artery intima media thickness (sex interaction) sex interaction measurement|| carotid artery intima media thickness GCST002856 sex interaction measurement|| carotid artery intima media thickness +Carotid plaque burden (smoking interaction) smoking behaviour measurement|| carotid plaque build GCST002482 smoking behaviour measurement|| carotid plaque build +Caudate activity during disappointment caudate nucleus measurement|| response to disappointment|| functional brain measurement GCST004969 caudate nucleus measurement|| response to disappointment|| functional brain measurement +Caudate activity during reward caudate nucleus measurement|| functional brain measurement|| response to reward GCST004970 caudate nucleus measurement|| functional brain measurement|| response to reward +Cellular adhesion molecule (red blood cell fatty acid level interaction) fatty acid measurement|| cellular adhesion molecule measurement GCST004820 fatty acid measurement|| cellular adhesion molecule measurement +Cerebrospinal fluid AB1-42 levels beta-amyloid 1-42 measurement|| cerebrospinal fluid biomarker measurement GCST003072 beta-amyloid 1-42 measurement|| cerebrospinal fluid biomarker measurement +Cerebrospinal fluid levels of Alzheimer's disease-related proteins matrix metalloproteinase measurement|| angiotensin-converting enzyme measurement|| Alzheimer's disease|| CCL4 measurement|| interleukin-6 measurement|| Alzheimer's disease biomarker measurement|| CCL2 measurement GCST002665 matrix metalloproteinase measurement|| angiotensin-converting enzyme measurement|| Alzheimer's disease|| CCL4 measurement|| interleukin-6 measurement|| Alzheimer's disease biomarker measurement|| CCL2 measurement +Cerebrospinal fluid α-synuclein levels cerebrospinal fluid biomarker measurement|| alpha synuclein measurement GCST006279 cerebrospinal fluid biomarker measurement|| alpha synuclein measurement +Cerebrospinal P-tau181p levels p-tau measurement|| cerebrospinal fluid biomarker measurement GCST003071 p-tau measurement|| cerebrospinal fluid biomarker measurement +Cerebrospinal T-tau levels cerebrospinal fluid biomarker measurement|| t-tau measurement GCST003070 cerebrospinal fluid biomarker measurement|| t-tau measurement +Cerivastatin-induced rhabdomyolysis response to statin|| rhabdomyolysis GCST001002 response to statin|| rhabdomyolysis +Childhood onset asthma (traffic air pollution exposure interaction) childhood onset asthma|| traffic air pollution measurement GCST003975 childhood onset asthma|| traffic air pollution measurement +Childhood onset systemic lupus erythematosus age at onset|| systemic lupus erythematosus GCST006260 age at onset|| systemic lupus erythematosus +Cholesterol and Triglycerides triglyceride measurement|| high density lipoprotein cholesterol measurement GCST001704 triglyceride measurement|| high density lipoprotein cholesterol measurement +Chronic alcoholic pancreatitis or alcohol-related cirrhosis alcoholic liver cirrhosis|| alcoholic pancreatitis GCST004755 alcoholic liver cirrhosis|| alcoholic pancreatitis +Chronic bronchitis and chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| chronic bronchitis GCST002625 chronic obstructive pulmonary disease|| chronic bronchitis +"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)" ankylosing spondylitis|| psoriasis|| ulcerative colitis|| Crohn's disease|| sclerosing cholangitis GCST005537 ankylosing spondylitis|| psoriasis|| ulcerative colitis|| Crohn's disease|| sclerosing cholangitis +Chronic kidney disease cystatin C measurement|| chronic kidney disease|| serum creatinine measurement GCST000649 cystatin C measurement|| chronic kidney disease|| serum creatinine measurement +Chronic kidney disease and serum creatinine levels chronic kidney disease|| serum creatinine measurement GCST000742 chronic kidney disease|| serum creatinine measurement +Chronic obstructive pulmonary disease-related biomarkers tumor necrosis factor-alpha measurement|| interleukin-6 measurement|| chronic obstructive pulmonary disease|| interleukin-8 measurement|| fibrinogen measurement|| C-reactive protein measurement|| CC16 measurement|| surfactant protein D measurement GCST001737 tumor necrosis factor-alpha measurement|| interleukin-6 measurement|| chronic obstructive pulmonary disease|| interleukin-8 measurement|| fibrinogen measurement|| C-reactive protein measurement|| CC16 measurement|| surfactant protein D measurement +Chronic venous disease chronic venous insufficiency|| Varicose veins GCST004343 chronic venous insufficiency|| Varicose veins +Chylomicron and largest VLDL particle concentration chylomicron measurement|| very low density lipoprotein cholesterol measurement GCST005510 chylomicron measurement|| very low density lipoprotein cholesterol measurement +Cingulate cortical amyloid beta load amyloid-beta measurement|| cingulate cortex measurement GCST003113 amyloid-beta measurement|| cingulate cortex measurement +Circulating chromogranin peptide levels CHGB cleavage product measurement|| CHGA cleavage product measurement GCST004038 CHGB cleavage product measurement|| CHGA cleavage product measurement +Cisplatin-induced ototoxicity ototoxicity|| response to cisplatin GCST003898 ototoxicity|| response to cisplatin +Cleft lip with or without cleft palate cleft palate|| cleft lip GCST004050 cleft palate|| cleft lip +Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction) cleft lip|| alcohol exposure measurement GCST005653 cleft lip|| alcohol exposure measurement +Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction) tobacco smoke exposure measurement|| cleft lip GCST005654 tobacco smoke exposure measurement|| cleft lip +Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction) vitamin supplement exposure measurement|| cleft lip GCST005652 vitamin supplement exposure measurement|| cleft lip +Cleft plate (environmental tobacco smoke interaction) cleft palate|| environmental tobacco smoke exposure measurement GCST002348 cleft palate|| environmental tobacco smoke exposure measurement +Clinical laboratory measurements alkaline phosphatase measurement|| calcium measurement|| hemoglobin measurement|| clinical laboratory measurement|| mean corpuscular hemoglobin|| glucose measurement|| erythrocyte measurement|| bilirubin measurement GCST003540 alkaline phosphatase measurement|| calcium measurement|| hemoglobin measurement|| clinical laboratory measurement|| mean corpuscular hemoglobin|| glucose measurement|| erythrocyte measurement|| bilirubin measurement +Clozapine-induced agranulocytosis drug-induced agranulocytosis|| response to clozapine GCST002595 drug-induced agranulocytosis|| response to clozapine +Clozapine-induced cytotoxicity cytotoxicity measurement|| response to clozapine GCST002777 cytotoxicity measurement|| response to clozapine +Cluster headache smoking status measurement|| cluster headache GCST003900 smoking status measurement|| cluster headache +Coffee consumption coffee consumption|| cups of coffee per day measurement GCST003621 coffee consumption|| cups of coffee per day measurement +Coffee consumption (cups per day) coffee consumption|| cups of coffee per day measurement GCST002650 coffee consumption|| cups of coffee per day measurement +Cognitive ability (MTAG) intelligence|| self reported educational attainment GCST005141 intelligence|| self reported educational attainment +Cognitive impairment (brain beta-amyloid deposition interaction) cognitive impairment|| cerebral amyloid deposition measurement GCST003399 cognitive impairment|| cerebral amyloid deposition measurement +Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement Stevens-Johnson syndrome|| toxic epidermal necrolysis|| response to cold medicine GCST002779 Stevens-Johnson syndrome|| toxic epidermal necrolysis|| response to cold medicine +Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications Stevens-Johnson syndrome|| toxic epidermal necrolysis|| response to cold medicine GCST004072 Stevens-Johnson syndrome|| toxic epidermal necrolysis|| response to cold medicine +Colorectal cancer (alcohol consumption interaction) colorectal cancer|| alcohol consumption measurement GCST003873 colorectal cancer|| alcohol consumption measurement +Colorectal cancer (aspirin and/or NSAID use interaction) drug use measurement|| aspirin use measurement|| NSAID use measurement|| colorectal cancer GCST002816 drug use measurement|| aspirin use measurement|| NSAID use measurement|| colorectal cancer +Colorectal cancer (calcium intake interaction) calcium intake measurement|| colorectal cancer GCST002596 calcium intake measurement|| colorectal cancer +Colorectal cancer (diet interaction) colorectal cancer|| diet measurement GCST002415 colorectal cancer|| diet measurement +Colorectal cancer (environment interaction) smoking status measurement|| colorectal cancer|| alcohol consumption measurement|| overweight body mass index status GCST001731 smoking status measurement|| colorectal cancer|| alcohol consumption measurement|| overweight body mass index status +Colorectal cancer (menopausal hormone therapy interaction) colorectal cancer|| hormone replacement therapy GCST003385 colorectal cancer|| hormone replacement therapy +Colorectal cancer (oestrogen hormone therapy interaction) colorectal cancer|| hormone replacement therapy GCST003387 colorectal cancer|| hormone replacement therapy +Colorectal cancer (oestrogen-progestogen hormone therapy interaction) colorectal cancer|| hormone replacement therapy GCST003386 colorectal cancer|| hormone replacement therapy +Colorectal cancer (smoking interaction) smoking status measurement|| colorectal cancer GCST003874 smoking status measurement|| colorectal cancer +Colorectal or endometrial cancer colorectal cancer|| endometrial neoplasm GCST003209 colorectal cancer|| endometrial neoplasm +Colorectal or endometrial cancer colorectal cancer|| endometrial neoplasm GCST003208 colorectal cancer|| endometrial neoplasm +Common traits (Other) sensory perception of taste|| functional laterality|| hair morphology|| circadian rhythm|| personality|| braces|| sensory perception of smell|| Attached earlobe|| Astigmatism|| Sneeze GCST000706 sensory perception of taste|| functional laterality|| hair morphology|| circadian rhythm|| personality|| braces|| sensory perception of smell|| Attached earlobe|| Astigmatism|| Sneeze +Complement C3 and C4 levels complement C4 measurement|| complement C3 measurement GCST001679 complement C4 measurement|| complement C3 measurement +Comprehensive strength and appendicular lean mass comprehensive strength index|| muscle measurement GCST001656 comprehensive strength index|| muscle measurement +Conduct disorder (maternal expressed emotions interaction) parental emotion expression measurmement|| conduct disorder GCST000245 parental emotion expression measurmement|| conduct disorder +Congenital left-sided heart lesions (maternal effect) congenital left-sided heart lesions|| parental genotype effect measurement GCST002574 congenital left-sided heart lesions|| parental genotype effect measurement +Coronary artery calcification (smoking interaction) smoking status measurement|| coronary artery calcification GCST002213 smoking status measurement|| coronary artery calcification +Coronary artery disease and/or body mass index (pleiotropy) body mass index|| coronary artery disease GCST004838 body mass index|| coronary artery disease +Coronary artery disease or ischemic stroke stroke|| coronary heart disease GCST002287 stroke|| coronary heart disease +Coronary artery disease or large artery stroke large artery stroke|| coronary heart disease GCST002290 large artery stroke|| coronary heart disease +Coronary artery disease-related phenotypes coronary heart disease|| angiographic measurement GCST002659 coronary heart disease|| angiographic measurement +Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction) coronary atheroscleroris measurement|| traffic air pollution measurement GCST004224 coronary atheroscleroris measurement|| traffic air pollution measurement +Coronary heart disease event reduction (statin therapy interaction) response to statin|| coronary heart disease GCST001545 response to statin|| coronary heart disease +Coronary heart disease events during statin therapy response to statin|| cardiovascular event measurement GCST006217 response to statin|| cardiovascular event measurement +Corrected insulin response adjusted for insulin sensitivity index insulin sensitivity measurement|| insulin response measurement GCST005216 insulin sensitivity measurement|| insulin response measurement +Corticobasal degeneration and immune-mediated diseases (pleiotropy) Corticobasal degeneration|| rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease GCST005322 Corticobasal degeneration|| rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease +Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L) adrenal suppression measurement|| response to corticosteroid GCST005927 adrenal suppression measurement|| response to corticosteroid +Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L) adrenal suppression measurement|| response to corticosteroid GCST005924 adrenal suppression measurement|| response to corticosteroid +Crohn's disease and celiac disease celiac disease|| Crohn's disease GCST000955 celiac disease|| Crohn's disease +Crohn's disease and psoriasis psoriasis|| Crohn's disease GCST001473 psoriasis|| Crohn's disease +Crohn's disease and sarcoidosis (combined) Sarcoidosis|| Crohn's disease GCST000212 Sarcoidosis|| Crohn's disease +Crohn's disease-related phenotypes stricture|| ileocolitis|| erythema nodosum|| perianal Crohn's disease|| Crohn's disease|| mild disease course|| complicated disease course GCST002729 stricture|| ileocolitis|| erythema nodosum|| perianal Crohn's disease|| Crohn's disease|| mild disease course|| complicated disease course +Cutaneous psoriasis cutaneous psoriasis measurement|| psoriasis GCST003269 cutaneous psoriasis measurement|| psoriasis +Cystic fibrosis-related diabetes Cystic fibrosis|| type II diabetes mellitus GCST002025 Cystic fibrosis|| type II diabetes mellitus +Cytokine and corticosteroid-stimulated IL-6 production interleukin-6 measurement|| response to corticosteroid|| response to cytokine GCST002858 interleukin-6 measurement|| response to corticosteroid|| response to cytokine +Cytokine-stimulated IL-6 production interleukin-6 measurement|| response to cytokine GCST002859 interleukin-6 measurement|| response to cytokine +Delta-5 desaturase activity response to n3-polyunsaturated fat supplement delta-5 desaturase measurement|| response to polyunsaturated fatty acid supplementation GCST005668 delta-5 desaturase measurement|| response to polyunsaturated fatty acid supplementation +Delta-6 desaturase activity response to n3-polyunsaturated fat supplement delta-6 desaturase measurement|| response to polyunsaturated fatty acid supplementation GCST005669 delta-6 desaturase measurement|| response to polyunsaturated fatty acid supplementation +Dementia and core Alzheimer's disease neuropathologic changes dementia|| Alzheimer's disease neuropathologic change GCST002593 dementia|| Alzheimer's disease neuropathologic change +Depressed affect unipolar depression|| mood disorder GCST006475 unipolar depression|| mood disorder +Depression unipolar depression|| depressive symptom measurement GCST003769 unipolar depression|| depressive symptom measurement +Depressive symptom measurement or major depressive disorder unipolar depression|| depressive symptom measurement GCST004024 unipolar depression|| depressive symptom measurement +Depressive symptoms (SSRI exposure interaction) drug use measurement|| depressive symptom measurement|| SSRI use measurement GCST002755 drug use measurement|| depressive symptom measurement|| SSRI use measurement +Depressive symptoms (stressful life events interaction) depressive symptom measurement|| stressful life event measurement GCST003835 depressive symptom measurement|| stressful life event measurement +Dermatomyositis or juvenile dermatomyositis dermatomyositis|| juvenile dermatomyositis GCST006053 dermatomyositis|| juvenile dermatomyositis +Developmental language disorder (linguistic errors) linguistic error measurement|| specific language impairment GCST003397 linguistic error measurement|| specific language impairment +Developmental language disorder (syntactic complexity) syntactic complexity measurement|| specific language impairment GCST003398 syntactic complexity measurement|| specific language impairment +Diabetes related insulin traits insulin sensitivity measurement|| A1C measurement|| insulin resistance|| fasting blood insulin measurement GCST000077 insulin sensitivity measurement|| A1C measurement|| insulin resistance|| fasting blood insulin measurement +Diastolic blood pressure (alcohol consumption interaction) diastolic blood pressure|| alcohol drinking GCST002309 diastolic blood pressure|| alcohol drinking +Diastolic blood pressure (cigarette smoking interaction) smoking status measurement|| diastolic blood pressure GCST006187 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure (cigarette smoking interaction) diastolic blood pressure|| smoking behaviour measurement GCST003366 diastolic blood pressure|| smoking behaviour measurement +Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) diastolic blood pressure|| alcohol consumption measurement GCST006169 diastolic blood pressure|| alcohol consumption measurement +Diastolic blood pressure x alcohol consumption interaction (2df test) diastolic blood pressure|| alcohol drinking GCST006166 diastolic blood pressure|| alcohol drinking +Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test) smoking status measurement|| diastolic blood pressure GCST006194 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test) smoking status measurement|| diastolic blood pressure GCST006193 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure x smoking status (ever vs never) interaction (1df test) smoking status measurement|| diastolic blood pressure GCST006191 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure x smoking status (ever vs never) interaction (2df test) smoking status measurement|| diastolic blood pressure GCST006190 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure x sodium interaction (1df test) sodium measurement|| diastolic blood pressure GCST006112 sodium measurement|| diastolic blood pressure +Diastolic blood pressure x sodium interaction (2df test) sodium measurement|| diastolic blood pressure GCST006111 sodium measurement|| diastolic blood pressure +Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) esophageal adenocarcinoma|| digestive system disease|| Barrett's esophagus GCST002231 esophageal adenocarcinoma|| digestive system disease|| Barrett's esophagus +Diisocyanate-induced asthma response to diisocyanate|| asthma GCST002875 response to diisocyanate|| asthma +Drug-induced liver injury response to flupirtine|| drug-induced liver injury GCST003426 response to flupirtine|| drug-induced liver injury +Drug-induced liver injury (anti-tuberculosis drugs) response to anti-tuberculosis drug|| drug-induced liver injury GCST004084 response to anti-tuberculosis drug|| drug-induced liver injury +Drug-induced liver injury (diclofenac) response to diclofenac|| drug-induced liver injury GCST004083 response to diclofenac|| drug-induced liver injury +Drug-induced liver injury (fluoroquinolones) response to fluoroquinolones|| drug-induced liver injury GCST004085 response to fluoroquinolones|| drug-induced liver injury +Drug-induced liver injury (nitrofurantoin) response to nitrofurantoin|| drug-induced liver injury GCST004082 response to nitrofurantoin|| drug-induced liver injury +Drug-induced liver injury (nonsteroidal anti-inflammatory drugs) response to non-steroidal anti-inflammatory|| drug-induced liver injury GCST004087 response to non-steroidal anti-inflammatory|| drug-induced liver injury +Drug-induced liver injury (statins) response to statin|| drug-induced liver injury GCST004080 response to statin|| drug-induced liver injury +Drug-induced liver injury (terbinafine) drug-induced liver injury|| response to terbinafine GCST004078 drug-induced liver injury|| response to terbinafine +Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) Stevens-Johnson syndrome|| toxic epidermal necrolysis GCST001181 Stevens-Johnson syndrome|| toxic epidermal necrolysis +Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) Stevens-Johnson syndrome|| toxic epidermal necrolysis GCST000942 Stevens-Johnson syndrome|| toxic epidermal necrolysis +Drug-induced torsades de pointes torsades de pointes|| response to drug GCST002269 torsades de pointes|| response to drug +Early gestational weight gain (fetal effect) early gestational weight gain|| fetal genotype effect measurement GCST005032 early gestational weight gain|| fetal genotype effect measurement +Echocardiographic traits cardiovascular measurement|| left ventricular function|| left atrial function GCST000110 cardiovascular measurement|| left ventricular function|| left atrial function +Egg allergy (maternal genetic effects) egg allergy measurement|| parental genotype effect measurement GCST005728 egg allergy measurement|| parental genotype effect measurement +Egg allergy (parent-of-origin effect) egg allergy measurement|| parental genotype effect measurement GCST005725 egg allergy measurement|| parental genotype effect measurement +Electrocardiographic traits QRS complex|| QRS duration|| electrocardiography|| PR interval|| heart rate|| QT interval GCST000561 QRS complex|| QRS duration|| electrocardiography|| PR interval|| heart rate|| QT interval +Electrodermal activity skin conductance level|| skin conductance response frequency|| electrodermal activity measurement|| skin conductance response amplitude GCST002706 skin conductance level|| skin conductance response frequency|| electrodermal activity measurement|| skin conductance response amplitude +Electroencephalogram traits theta wave measurement|| delta wave measurement|| alpha peak frequency measurement|| alpha wave measurement|| electroencephalogram measurement|| beta wave measurement GCST002709 theta wave measurement|| delta wave measurement|| alpha peak frequency measurement|| alpha wave measurement|| electroencephalogram measurement|| beta wave measurement +End stage renal disease x APOL1 genotype interaction chronic kidney disease|| APOL1 risk genotype carrier status GCST006813 chronic kidney disease|| APOL1 risk genotype carrier status +End-stage coagulation factor VIII measurement|| von Willebrand factor measurement|| coagulation factor measurement GCST001798 factor VIII measurement|| von Willebrand factor measurement|| coagulation factor measurement +Endometriosis or endometrial cancer (pleiotropy) endometrial carcinoma|| endometriosis GCST005906 endometrial carcinoma|| endometriosis +Endothelial growth factor levels endothelial growth factor measurement|| angiopoietin-2 receptor measurement|| angiopoietin-2 measurement|| hepatocyte growth factor measurement GCST002731 endothelial growth factor measurement|| angiopoietin-2 receptor measurement|| angiopoietin-2 measurement|| hepatocyte growth factor measurement +Entorhinal cortical thickness (Alzheimer's disease interaction) Alzheimer's disease|| cortical thickness GCST000889 Alzheimer's disease|| cortical thickness +Entorhinal cortical volume (Alzheimer's disease interaction) Alzheimer's disease|| entorhinal cortical volume GCST000893 Alzheimer's disease|| entorhinal cortical volume +Epilepsy (remission after treatment) response to drug|| epilepsy GCST002141 response to drug|| epilepsy +Epilepsy and lamotrigine-induced maculopapular eruptions response to lamotrigine|| maculopapular eruption|| epilepsy GCST002949 response to lamotrigine|| maculopapular eruption|| epilepsy +Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis multiple sclerosis|| Epstein Barr virus nuclear antigen 1 IgG measurement GCST003340 multiple sclerosis|| Epstein Barr virus nuclear antigen 1 IgG measurement +Epstein-Barr virus immune response (EBNA-1) antibody measurement|| Epstein-Barr virus infection GCST001812 antibody measurement|| Epstein-Barr virus infection +Erectile dysfunction and prostate cancer treatment response to radiation|| prostate carcinoma|| erectile dysfunction GCST001700 response to radiation|| prostate carcinoma|| erectile dysfunction +Erectile dysfunction and prostate cancer treatment response to radiation|| prostate carcinoma|| erectile dysfunction GCST000824 response to radiation|| prostate carcinoma|| erectile dysfunction +Esophageal adenocarcinoma x BMI interaction esophageal adenocarcinoma|| body mass index GCST006525 esophageal adenocarcinoma|| body mass index +Esophageal adenocarcinoma x gastroesophageal reflux disease interaction esophageal adenocarcinoma|| gastroesophageal reflux disease GCST006531 esophageal adenocarcinoma|| gastroesophageal reflux disease +Esophageal adenocarcinoma x pack-years of smoking exposure interaction esophageal adenocarcinoma|| pack-years measurement GCST006532 esophageal adenocarcinoma|| pack-years measurement +Esophageal adenocarcinoma x smoking interaction esophageal adenocarcinoma|| smoking status measurement GCST006530 esophageal adenocarcinoma|| smoking status measurement +Esophageal cancer (squamous cell) squamous cell carcinoma|| esophageal carcinoma GCST001674 squamous cell carcinoma|| esophageal carcinoma +Esophageal cancer and gastric cancer esophageal carcinoma|| gastric carcinoma GCST000777 esophageal carcinoma|| gastric carcinoma +Exhaled carbon monoxide levels smoking behavior|| carbon monoxide exhalation measurement GCST002584 smoking behavior|| carbon monoxide exhalation measurement +"Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)" nose morphology measurement|| mouth morphology measurement GCST004317 nose morphology measurement|| mouth morphology measurement +Familial lung adenocarcinoma lung adenocarcinoma|| family history of lung cancer GCST006087 lung adenocarcinoma|| family history of lung cancer +Familial lung cancer lung carcinoma|| family history of lung cancer GCST006086 lung carcinoma|| family history of lung cancer +Familial squamous cell lung carcinoma squamous cell lung carcinoma|| family history of lung cancer GCST006088 squamous cell lung carcinoma|| family history of lung cancer +Fast beta electroencephalogram alcohol dependence measurement|| electroencephalogram measurement GCST003902 alcohol dependence measurement|| electroencephalogram measurement +Fasting blood glucose (BMI interaction) body mass index|| fasting blood glucose measurement GCST001527 body mass index|| fasting blood glucose measurement +Fasting blood insulin (BMI interaction) body mass index|| fasting blood insulin measurement GCST001526 body mass index|| fasting blood insulin measurement +Fasting insulin (dietary factor interaction) diet measurement|| fasting blood insulin measurement GCST002248 diet measurement|| fasting blood insulin measurement +Femoral neck bone mineral density or breast cancer (pleiotropy) breast carcinoma|| femoral neck bone mineral density GCST004836 breast carcinoma|| femoral neck bone mineral density +Femoral neck bone mineral density or plasma lipids (pleiotropy) lipid measurement|| femoral neck bone mineral density GCST005317 lipid measurement|| femoral neck bone mineral density +Femoral neck bone mineral density or type 2 diabetes (pleiotropy) type II diabetes mellitus|| femoral neck bone mineral density GCST006861 type II diabetes mellitus|| femoral neck bone mineral density +"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)" smoking status measurement|| alcohol drinking|| fibrinogen measurement|| body mass index GCST002734 smoking status measurement|| alcohol drinking|| fibrinogen measurement|| body mass index +Folate pathway vitamin levels vitamin B measurement|| vitamin B12 measurement|| vitamin B6 measurement GCST000358 vitamin B measurement|| vitamin B12 measurement|| vitamin B6 measurement +Food addiction eating behaviour|| food addiction measurement GCST003489 eating behaviour|| food addiction measurement +Food allergy (maternal genetic effects) food allergy measurement|| parental genotype effect measurement GCST005724 food allergy measurement|| parental genotype effect measurement +Food allergy (parent-of-origin effect) food allergy measurement|| parental genotype effect measurement GCST005721 food allergy measurement|| parental genotype effect measurement +Food antigen IgG levels serum IgG measurement|| response to dietary antigen GCST002518 serum IgG measurement|| response to dietary antigen +Forced expiratory volume in 1 second (environmental tobacco smoke interaction) forced expiratory volume|| environmental tobacco smoke exposure measurement GCST004800 forced expiratory volume|| environmental tobacco smoke exposure measurement +Forced expiratory volume in 1 second (occupational environmental exposures interaction) response to biological dust exposure|| response to gases and fumes exposure|| forced expiratory volume|| response to mineral dust exposure GCST002955 response to biological dust exposure|| response to gases and fumes exposure|| forced expiratory volume|| response to mineral dust exposure +Free cholesterol levels in IDL free cholesterol measurement|| intermediate density lipoprotein measurement GCST005479 free cholesterol measurement|| intermediate density lipoprotein measurement +Free cholesterol levels in large HDL free cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005502 free cholesterol measurement|| high density lipoprotein cholesterol measurement +Free cholesterol levels in large LDL free cholesterol measurement|| low density lipoprotein cholesterol measurement GCST005485 free cholesterol measurement|| low density lipoprotein cholesterol measurement +Free cholesterol levels in large VLDL free cholesterol measurement|| very low density lipoprotein cholesterol measurement GCST005459 free cholesterol measurement|| very low density lipoprotein cholesterol measurement +Free cholesterol levels in medium VLDL free cholesterol measurement|| very low density lipoprotein cholesterol measurement GCST005466 free cholesterol measurement|| very low density lipoprotein cholesterol measurement +Free cholesterol levels in small VLDL free cholesterol measurement|| very low density lipoprotein cholesterol measurement GCST005471 free cholesterol measurement|| very low density lipoprotein cholesterol measurement +Free cholesterol levels in very large HDL free cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005496 free cholesterol measurement|| high density lipoprotein cholesterol measurement +Frontotemporal dementia and immune-mediated diseases (pleiotropy) rheumatoid arthritis|| psoriasis|| celiac disease|| Frontotemporal dementia|| ulcerative colitis|| Crohn's disease GCST005319 rheumatoid arthritis|| psoriasis|| celiac disease|| Frontotemporal dementia|| ulcerative colitis|| Crohn's disease +Gestational age at birth (child effect) gestational age|| birth measurement GCST003686 gestational age|| birth measurement +Gestational age at birth (maternal effect) gestational age|| birth measurement GCST003688 gestational age|| birth measurement +Gestational age at birth (maternal effect) gestational age|| parental genotype effect measurement GCST004899 gestational age|| parental genotype effect measurement +Gestational age at birth (maternal effect) gestational age|| parental genotype effect measurement GCST004844 gestational age|| parental genotype effect measurement +Gestational weight gain (fetal effect) fetal genotype effect measurement|| gestational weight gain measurement GCST005031 fetal genotype effect measurement|| gestational weight gain measurement +GIP levels in response to oral glucose tolerance test (120 minutes) glucose-dependent insulinotropic peptide measurement|| glucose tolerance test GCST005166 glucose-dependent insulinotropic peptide measurement|| glucose tolerance test +GIP levels in response to oral glucose tolerance test (fasting) glucose-dependent insulinotropic peptide measurement|| glucose tolerance test GCST005167 glucose-dependent insulinotropic peptide measurement|| glucose tolerance test +Glioblastoma central nervous system cancer|| glioblastoma multiforme GCST004349 central nervous system cancer|| glioblastoma multiforme +Glioblastoma (age-stratified) age at onset|| glioblastoma multiforme GCST006480 age at onset|| glioblastoma multiforme +Glioma central nervous system cancer|| glioma GCST004347 central nervous system cancer|| glioma +Glomerular filtration rate (creatinine) glomerular filtration rate|| serum creatinine measurement GCST003371 glomerular filtration rate|| serum creatinine measurement +Glomerular filtration rate (creatinine) glomerular filtration rate|| serum creatinine measurement GCST003372 glomerular filtration rate|| serum creatinine measurement +Glomerular filtration rate (creatinine) glomerular filtration rate|| serum creatinine measurement GCST004292 glomerular filtration rate|| serum creatinine measurement +Glomerular filtration rate (cystatin C) glomerular filtration rate|| cystatin C measurement GCST003375 glomerular filtration rate|| cystatin C measurement +Glomerular filtration rate (cystatin C) glomerular filtration rate|| cystatin C measurement GCST004293 glomerular filtration rate|| cystatin C measurement +GLP-1 levels in response to oral glucose tolerance test (120 minutes) glucagon-like peptide-1 measurement|| glucose tolerance test GCST005165 glucagon-like peptide-1 measurement|| glucose tolerance test +GLP-1 levels in response to oral glucose tolerance test (fasting) glucagon-like peptide-1 measurement|| glucose tolerance test GCST005164 glucagon-like peptide-1 measurement|| glucose tolerance test +Glucagon levels in response to oral glucose tolerance test (120 minutes) glucagon measurement|| glucose tolerance test GCST005163 glucagon measurement|| glucose tolerance test +Glucagon levels in response to oral glucose tolerance test (fasting) glucagon measurement|| glucose tolerance test GCST005162 glucagon measurement|| glucose tolerance test +Glucocorticoid-induced osteonecrosis response to glucocorticoid|| osteonecrosis GCST003084 response to glucocorticoid|| osteonecrosis +Glucocorticoid-induced osteonecrosis (age 10 years and older) response to glucocorticoid|| osteonecrosis GCST003081 response to glucocorticoid|| osteonecrosis +Glucocorticoid-induced osteonecrosis (time dependent analysis) response to glucocorticoid|| osteonecrosis GCST003083 response to glucocorticoid|| osteonecrosis +Glucocorticoid-induced osteonecrosis (time independent analysis) response to glucocorticoid|| osteonecrosis GCST003080 response to glucocorticoid|| osteonecrosis +Glucose homeostasis traits insulin metabolic clearance rate measurement|| disposition index measurement|| insulin sensitivity measurement|| glucose homeostasis measurement|| glucose effectiveness measurement|| acute insulin response measurement GCST002726 insulin metabolic clearance rate measurement|| disposition index measurement|| insulin sensitivity measurement|| glucose homeostasis measurement|| glucose effectiveness measurement|| acute insulin response measurement +Glycemic traits (multi-trait analysis) fasting blood glucose measurement|| glucose tolerance test|| fasting blood insulin measurement GCST006404 fasting blood glucose measurement|| glucose tolerance test|| fasting blood insulin measurement +Glycemic traits (pregnancy) C-peptide measurement|| fasting blood glucose measurement|| glucose tolerance test GCST002110 C-peptide measurement|| fasting blood glucose measurement|| glucose tolerance test +Glycerophospholipid levels glycerophospholipid measurement|| blood metabolite measurement GCST002965 glycerophospholipid measurement|| blood metabolite measurement +Gout vs. Hyperuricemia gout|| hyperuricemia GCST005801 gout|| hyperuricemia +Graft survival time in renal transplantation (donor effect) renal transplant outcome measurement|| donor genotype effect measurement GCST005429 renal transplant outcome measurement|| donor genotype effect measurement +Graft survival time in renal transplantation (donor-recipient interaction) renal transplant outcome measurement|| donor genotype effect measurement GCST005430 renal transplant outcome measurement|| donor genotype effect measurement +Gray matter volume (schizophrenia interaction) schizophrenia|| grey matter volume measurement GCST002203 schizophrenia|| grey matter volume measurement +Gut microbiota (bacterial taxa) gut microbiome measurement|| taxonomic microbiome measurement GCST003875 gut microbiome measurement|| taxonomic microbiome measurement +Hashimoto thyroiditis versus Graves' disease autoimmune thyroid disease|| Hashimoto's thyroiditis|| Graves disease GCST002705 autoimmune thyroid disease|| Hashimoto's thyroiditis|| Graves disease +HDL Cholesterol - Triglycerides (HDLC-TG) triglyceride measurement|| high density lipoprotein cholesterol measurement GCST001005 triglyceride measurement|| high density lipoprotein cholesterol measurement +HDL cholesterol and triglyceride levels triglyceride measurement|| high density lipoprotein cholesterol measurement GCST006682 triglyceride measurement|| high density lipoprotein cholesterol measurement +HDL cholesterol and triglyceride levels (pleiotropy) triglyceride measurement|| high density lipoprotein cholesterol measurement GCST006669 triglyceride measurement|| high density lipoprotein cholesterol measurement +Hearing function (0.25 kHz) hearing threshold measurement|| hearing measurement GCST003039 hearing threshold measurement|| hearing measurement +Hearing function (0.5 kHz) hearing threshold measurement|| hearing measurement GCST003037 hearing threshold measurement|| hearing measurement +Hearing function (1 kHz) hearing threshold measurement|| hearing measurement GCST003041 hearing threshold measurement|| hearing measurement +Hearing function (2 kHz) hearing threshold measurement|| hearing measurement GCST003032 hearing threshold measurement|| hearing measurement +Hearing function (4 kHz) hearing threshold measurement|| hearing measurement GCST003035 hearing threshold measurement|| hearing measurement +Hearing function (8 kHz) hearing threshold measurement|| hearing measurement GCST003034 hearing threshold measurement|| hearing measurement +Hearing function (high tone) pure tone hearing measurement|| hearing measurement GCST003040 pure tone hearing measurement|| hearing measurement +Hearing function (low tone) pure tone hearing measurement|| hearing measurement GCST003036 pure tone hearing measurement|| hearing measurement +Hearing function (medium tone) pure tone hearing measurement|| hearing measurement GCST003033 pure tone hearing measurement|| hearing measurement +Heart rate response to beta blockers response to beta blocker|| heart rate GCST005519 response to beta blocker|| heart rate +Heart rate response to beta blockers (atenolol add-on therapy) response to beta blocker|| heart rate GCST005520 response to beta blocker|| heart rate +Heart rate response to beta blockers (atenolol monotherapy) response to beta blocker|| heart rate GCST005521 response to beta blocker|| heart rate +Heavy vaginal discharge quality of life during menstruation measurement|| vaginal discharge GCST006639 quality of life during menstruation measurement|| vaginal discharge +Hematological and biochemical traits serum albumin measurement|| aspartate aminotransferase measurement|| alkaline phosphatase measurement|| hemoglobin measurement|| serum alanine aminotransferase measurement|| serum gamma-glutamyl transferase measurement|| hematocrit|| creatine kinase measurement|| protein measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement|| serum creatinine measurement GCST000583 serum albumin measurement|| aspartate aminotransferase measurement|| alkaline phosphatase measurement|| hemoglobin measurement|| serum alanine aminotransferase measurement|| serum gamma-glutamyl transferase measurement|| hematocrit|| creatine kinase measurement|| protein measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement|| serum creatinine measurement +Hematological parameters leukocyte count|| erythrocyte count|| mean corpuscular volume|| mean corpuscular hemoglobin|| platelet count GCST000498 leukocyte count|| erythrocyte count|| mean corpuscular volume|| mean corpuscular hemoglobin|| platelet count +Hematology traits hemoglobin measurement|| leukocyte count|| erythrocyte count|| hematocrit GCST001779 hemoglobin measurement|| leukocyte count|| erythrocyte count|| hematocrit +Hematology traits mean corpuscular volume|| mean corpuscular hemoglobin|| platelet count GCST000510 mean corpuscular volume|| mean corpuscular hemoglobin|| platelet count +Hemostatic factors and hematological phenotypes platelet aggregation|| hemoglobin measurement|| erythrocyte count|| mean corpuscular hemoglobin|| blood viscosity|| tissue plasminogen activator measurement|| plasminogen activator inhibitor 1 measurement GCST000080 platelet aggregation|| hemoglobin measurement|| erythrocyte count|| mean corpuscular hemoglobin|| blood viscosity|| tissue plasminogen activator measurement|| plasminogen activator inhibitor 1 measurement +Heparin-induced thrombocytopenia response to heparin|| thrombocytopenia GCST006144 response to heparin|| thrombocytopenia +Heparin-induced thrombocytopenia response to heparin|| thrombocytopenia GCST002722 response to heparin|| thrombocytopenia +Hepatitis B (viral clearance) seroconversion|| hepatitis B infection GCST003718 seroconversion|| hepatitis B infection +Hepatitis B virus-related hepatocellular carcinoma hepatocellular carcinoma|| hepatitis B infection GCST005570 hepatocellular carcinoma|| hepatitis B infection +Hepatitis C induced liver fibrosis hepatitis C infection|| cirrhosis of liver GCST001623 hepatitis C infection|| cirrhosis of liver +Hereditary hemochromatosis-related traits (HFE mutation homozygotes) hereditary hemochromatosis type 1|| transferrin measurement|| serum iron measurement GCST002660 hereditary hemochromatosis type 1|| transferrin measurement|| serum iron measurement +Hexose levels blood metabolite measurement|| hexose measurement GCST002959 blood metabolite measurement|| hexose measurement +Hip bone mineral density and alcohol drinking hip bone mineral density|| alcohol consumption measurement GCST003920 hip bone mineral density|| alcohol consumption measurement +Hip circumference (psychosocial stress interaction) hip circumference|| psychosocial stress measurement GCST002641 hip circumference|| psychosocial stress measurement +Hip circumference adjusted for BMI hip circumference|| body mass index GCST004067 hip circumference|| body mass index +Hip osteoarthritis or femoral neck bone mineral density osteoarthritis|| hip|| femoral neck bone mineral density GCST005229 osteoarthritis|| hip|| femoral neck bone mineral density +Hip osteoarthritis or lumbar spine bone mineral density osteoarthritis|| hip|| spine bone mineral density GCST005226 osteoarthritis|| hip|| spine bone mineral density +Hippocampal volume (Alzheimer's disease interaction) Alzheimer's disease|| hippocampal volume GCST000897 Alzheimer's disease|| hippocampal volume +HIV-1 susceptibility HIV-1 infection|| Susceptibility to viral and mycobacterial infections GCST002818 HIV-1 infection|| Susceptibility to viral and mycobacterial infections +HIV-1 susceptibility HIV-1 infection|| Susceptibility to viral and mycobacterial infections GCST001353 HIV-1 infection|| Susceptibility to viral and mycobacterial infections +HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment) HIV-associated neurocognitive disorder|| asymptomatic neurocognitive impairment GCST004410 HIV-associated neurocognitive disorder|| asymptomatic neurocognitive impairment +HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment) HIV-associated neurocognitive disorder|| mild neurocognitive disorder|| asymptomatic neurocognitive impairment GCST004411 HIV-associated neurocognitive disorder|| mild neurocognitive disorder|| asymptomatic neurocognitive impairment +HIV-associated neurocognitive disorder (mild neurocognitive disorder) HIV-associated neurocognitive disorder|| mild neurocognitive disorder GCST004408 HIV-associated neurocognitive disorder|| mild neurocognitive disorder +Homeostasis model assessment of beta-cell function (dietary factor interaction) diet measurement|| HOMA-B GCST002251 diet measurement|| HOMA-B +Homeostasis model assessment of insulin resistance (dietary factor interaction) diet measurement|| HOMA-IR GCST002253 diet measurement|| HOMA-IR +Hormone measurements estradiol measurement|| sex hormone-binding globulin measurement|| testosterone measurement GCST002195 estradiol measurement|| sex hormone-binding globulin measurement|| testosterone measurement +Immune reponse to smallpox (secreted IFN-alpha) response to vaccine|| cytokine measurement GCST001538 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted IL-10) response to vaccine|| cytokine measurement GCST001534 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted IL-12p40) response to vaccine|| cytokine measurement GCST001537 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted IL-1beta) response to vaccine|| cytokine measurement GCST001533 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted IL-2) response to vaccine|| cytokine measurement GCST001535 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted TNF-alpha) response to vaccine|| cytokine measurement GCST001536 response to vaccine|| cytokine measurement +Immune response to smallpox vaccine (IL-6) response to vaccine|| cytokine measurement GCST001532 response to vaccine|| cytokine measurement +Immunoglobulin light (AL) amyloidosis (serum Ig kappa profile) AL amyloidosis|| IgG isotype profile measurement GCST004810 AL amyloidosis|| IgG isotype profile measurement +Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement) heart amyloid deposition measurement|| AL amyloidosis|| kidney amyloid deposition measurement GCST004806 heart amyloid deposition measurement|| AL amyloidosis|| kidney amyloid deposition measurement +Immunoglobulin light chain (AL) amyloidosis (heart involvement) heart amyloid deposition measurement|| AL amyloidosis GCST004805 heart amyloid deposition measurement|| AL amyloidosis +Immunoglobulin light chain (AL) amyloidosis (kidney involvement) AL amyloidosis|| kidney amyloid deposition measurement GCST004812 AL amyloidosis|| kidney amyloid deposition measurement +Immunoglobulin light chain (AL) amyloidosis (liver involvement) AL amyloidosis|| liver amyloid deposition measurement GCST004807 AL amyloidosis|| liver amyloid deposition measurement +Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile) AL amyloidosis|| IgG isotype profile measurement GCST004809 AL amyloidosis|| IgG isotype profile measurement +Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile) AL amyloidosis|| IgG isotype profile measurement GCST004804 AL amyloidosis|| IgG isotype profile measurement +Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile) AL amyloidosis|| IgG isotype profile measurement GCST004811 AL amyloidosis|| IgG isotype profile measurement +Immunoglobulin light chain (AL) amyloidosis (serum IgG profile) AL amyloidosis|| IgG isotype profile measurement GCST004808 AL amyloidosis|| IgG isotype profile measurement +Inflammatory biomarkers interleukin-1 beta measurement|| interleukin 1 receptor antagonist measurement GCST002255 interleukin-1 beta measurement|| interleukin 1 receptor antagonist measurement +Inflammatory biomarkers blood sedimentation|| interleukin-6 measurement|| C-reactive protein measurement|| CCL2 measurement GCST001385 blood sedimentation|| interleukin-6 measurement|| C-reactive protein measurement|| CCL2 measurement +Inflammatory bowel disease ulcerative colitis|| Crohn's disease|| inflammatory bowel disease GCST005837 ulcerative colitis|| Crohn's disease|| inflammatory bowel disease +Insulin levels in response to oral glucose tolerance test (120 minutes) insulin measurement|| glucose tolerance test GCST005161 insulin measurement|| glucose tolerance test +Insulin levels in response to oral glucose tolerance test (30 minutes) insulin measurement|| glucose tolerance test GCST005160 insulin measurement|| glucose tolerance test +Insulin levels in response to oral glucose tolerance test (fasting) insulin measurement|| glucose tolerance test GCST005159 insulin measurement|| glucose tolerance test +Intercellular adhesion molecule 1 (red blood cell fatty acid level interaction) fatty acid measurement|| ICAM-1 measurement GCST004818 fatty acid measurement|| ICAM-1 measurement +Interleukin-6 (red blood cell fatty acid level interaction) fatty acid measurement|| interleukin-6 measurement GCST004814 fatty acid measurement|| interleukin-6 measurement +"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)" thoracic aortic aneurysm|| Abdominal Aortic Aneurysm|| brain aneurysm GCST003683 thoracic aortic aneurysm|| Abdominal Aortic Aneurysm|| brain aneurysm +Iron status biomarkers (ferritin levels) iron biomarker measurement|| ferritin measurement GCST002677 iron biomarker measurement|| ferritin measurement +Iron status biomarkers (iron levels) iron biomarker measurement|| serum iron measurement GCST002679 iron biomarker measurement|| serum iron measurement +Iron status biomarkers (transferrin levels) iron biomarker measurement|| transferrin measurement GCST002678 iron biomarker measurement|| transferrin measurement +Iron status biomarkers (transferrin saturation) iron biomarker measurement|| transferrin saturation measurement GCST002680 iron biomarker measurement|| transferrin saturation measurement +Ischemic stroke (cardioembolic) Ischemic stroke|| cardiac embolism GCST003490 Ischemic stroke|| cardiac embolism +Ischemic stroke (cardioembolic) Ischemic stroke|| cardiac embolism GCST003323 Ischemic stroke|| cardiac embolism +Ischemic stroke (cardioembolic) Ischemic stroke|| cardiac embolism GCST003257 Ischemic stroke|| cardiac embolism +Ischemic stroke (large artery atherosclerosis) Ischemic stroke|| large artery stroke GCST003322 Ischemic stroke|| large artery stroke +Ischemic stroke (large artery atherosclerosis) Ischemic stroke|| large artery stroke GCST003259 Ischemic stroke|| large artery stroke +Ischemic stroke (small artery occlusion) Ischemic stroke|| small artery occlusion GCST003260 Ischemic stroke|| small artery occlusion +Itch intensity from mosquito bite adjusted by bite size mosquito bite reaction itch intensity measurement|| mosquito bite reaction size measurement GCST004865 mosquito bite reaction itch intensity measurement|| mosquito bite reaction size measurement +Itch intensity from mosquito bite adjusted by bite size mosquito bite reaction itch intensity measurement|| mosquito bite reaction size measurement GCST004862 mosquito bite reaction itch intensity measurement|| mosquito bite reaction size measurement +Joint destruction and growth retardation Kashin-Beck disease|| joint damage measurement|| height growth measurement GCST003727 Kashin-Beck disease|| joint damage measurement|| height growth measurement +JT interval (sulfonylurea treatment interaction) JT interval|| response to sulfonylurea GCST004032 JT interval|| response to sulfonylurea +Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular) "systemic juvenile idiopathic arthritis|| polyarticular juvenile idiopathic arthritis, rheumatoid factor negative|| oligoarticular juvenile idiopathic arthritis" GCST005528 "systemic juvenile idiopathic arthritis|| polyarticular juvenile idiopathic arthritis, rheumatoid factor negative|| oligoarticular juvenile idiopathic arthritis" +Kidney function decline traits chronic kidney disease|| rapid kidney function decline|| GFR change measurement GCST002720 chronic kidney disease|| rapid kidney function decline|| GFR change measurement +Knee osteoarthritis osteoarthritis|| knee GCST003820 osteoarthritis|| knee +Knee osteoarthritis osteoarthritis|| knee GCST004881 osteoarthritis|| knee +Knee osteoarthritis osteoarthritis|| knee GCST000629 osteoarthritis|| knee +Knee osteoarthritis osteoarthritis|| knee GCST000186 osteoarthritis|| knee +Knee osteoarthritis or femoral neck bone mineral density osteoarthritis|| knee|| femoral neck bone mineral density GCST005224 osteoarthritis|| knee|| femoral neck bone mineral density +Knee osteoarthritis or lumbar spine bone mineral density osteoarthritis|| knee|| spine bone mineral density GCST005227 osteoarthritis|| knee|| spine bone mineral density +Lamotrigine-induced maculopapular exanthema response to lamotrigine|| maculopapular eruption GCST005199 response to lamotrigine|| maculopapular eruption +Language performance in older adults (adjusted for episodic memory) cognitive decline measurement|| memory performance|| language measurement GCST004372 cognitive decline measurement|| memory performance|| language measurement +Lapatinib-induced hepatotoxicity response to lapatinib|| drug-induced liver injury GCST002918 response to lapatinib|| drug-induced liver injury +Late gestational weight gain (fetal effect) fetal genotype effect measurement|| late gestational weight gain GCST005030 fetal genotype effect measurement|| late gestational weight gain +Lateral ventricle volume in trauma-exposed individuals lateral ventricle volume measurement|| response to trauma exposure GCST005286 lateral ventricle volume measurement|| response to trauma exposure +LDL peak particle diameter (total fat intake interaction) LDL peak particle diameter measurement|| total fat intake measurement GCST002989 LDL peak particle diameter measurement|| total fat intake measurement +Lean body mass and age at menarche (combined) body fat distribution|| age at menarche GCST001584 body fat distribution|| age at menarche +Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction) cerebrospinal fluid biomarker measurement|| left inferior lateral ventricle volume measurement GCST002554 cerebrospinal fluid biomarker measurement|| left inferior lateral ventricle volume measurement +Left superior temporal gyrus thickness (schizophrenia interaction) schizophrenia|| left superior temporal gyrus thickness measurement GCST003069 schizophrenia|| left superior temporal gyrus thickness measurement +Left ventricular function change in anthracycline treatment left ventricular function|| response to anthracycline-based chemotherapy GCST004353 left ventricular function|| response to anthracycline-based chemotherapy +Left ventricular QRS voltage QRS amplitude|| S wave amplitude|| R wave amplitude GCST003630 QRS amplitude|| S wave amplitude|| R wave amplitude +Lewy body disease Lewy body dementia|| Lewy body dementia measurement GCST002591 Lewy body dementia|| Lewy body dementia measurement +Lipid traits total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST002321 total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipid traits total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST002174 total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipid traits triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST002173 triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipid traits (pleiotropy) (HIPO component 1) total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST006666 total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipid traits (pleiotropy) (HIPO component 2) total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST006667 total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipoprotein-associated phospholipase A2 (red blood cell fatty acid level interaction) fatty acid measurement|| lipoprotein-associated phospholipase A(2) measurement GCST004816 fatty acid measurement|| lipoprotein-associated phospholipase A(2) measurement +Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms lipoprotein A measurement|| apolipoprotein A 1 measurement GCST004399 lipoprotein A measurement|| apolipoprotein A 1 measurement +Lobular breast cancer (menopausal hormone therapy interaction) invasive lobular carcinoma|| hormone replacement therapy GCST002266 invasive lobular carcinoma|| hormone replacement therapy +lower facial morphology traits (ordinal measurement) lip morphology measurement|| chin morphology measurement GCST003634 lip morphology measurement|| chin morphology measurement +lower facial morphology traits (quantitative measurement) lip morphology measurement|| chin morphology measurement GCST003636 lip morphology measurement|| chin morphology measurement +Lumbar spine bone mineral density or breast cancer (pleiotropy) breast carcinoma|| spine bone mineral density GCST004837 breast carcinoma|| spine bone mineral density +Lumbar spine bone mineral density or coronary artery disease (pleiotropy) spine bone mineral density|| coronary artery disease GCST004717 spine bone mineral density|| coronary artery disease +Lung cancer lung carcinoma|| squamous cell carcinoma|| lung adenocarcinoma GCST002466 lung carcinoma|| squamous cell carcinoma|| lung adenocarcinoma +Lung cancer (asbestos exposure interaction) lung carcinoma|| asbestos exposure measurement GCST003049 lung carcinoma|| asbestos exposure measurement +Lung cancer (asbestos exposure interaction) lung carcinoma|| asbestos exposure measurement GCST001543 lung carcinoma|| asbestos exposure measurement +Lung cancer (household air pollution interaction) lung carcinoma|| household air pollution measurement GCST002739 lung carcinoma|| household air pollution measurement +Lung cancer (smoking interaction) smoking status measurement|| lung carcinoma GCST002392 smoking status measurement|| lung carcinoma +Lung cancer and family history of lung cancer lung carcinoma|| family history of lung cancer GCST002753 lung carcinoma|| family history of lung cancer +Lung cancer x radon exposure interaction (1df) lung carcinoma|| radon exposure measurement GCST006413 lung carcinoma|| radon exposure measurement +Lung function (maximal voluntary ventilation) maximal voluntary ventilation|| pulmonary function measurement GCST005127 maximal voluntary ventilation|| pulmonary function measurement +Major depression and alcohol dependence unipolar depression|| alcohol dependence GCST005022 unipolar depression|| alcohol dependence +Major depressive disorder (stressful life events interaction) unipolar depression|| self rated health|| stressful life event measurement GCST003319 unipolar depression|| self rated health|| stressful life event measurement +Male fertility birth rate|| male fertility|| family size GCST001540 birth rate|| male fertility|| family size +Mammographic density (dense area) dense area measurement|| mammographic density measurement GCST002667 dense area measurement|| mammographic density measurement +Mammographic density (non-dense area) non-dense area measurement|| mammographic density measurement GCST002668 non-dense area measurement|| mammographic density measurement +Maternal genotype effects in autism spectrum disorder families autism spectrum disorder|| genetic variation GCST002368 autism spectrum disorder|| genetic variation +Mean arterial pressure (alcohol consumption interaction) diastolic blood pressure|| alcohol drinking GCST002308 diastolic blood pressure|| alcohol drinking +Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test) mean arterial pressure|| alcohol consumption measurement GCST006172 mean arterial pressure|| alcohol consumption measurement +Mean arterial pressure x alcohol consumption interaction (2df test) mean arterial pressure|| alcohol drinking GCST006167 mean arterial pressure|| alcohol drinking +Mean arterial pressure x sodium interaction (1df test) sodium measurement|| mean arterial pressure GCST006116 sodium measurement|| mean arterial pressure +Mean arterial pressure x sodium interaction (2df test) sodium measurement|| mean arterial pressure GCST006114 sodium measurement|| mean arterial pressure +Mean corpuscular hemoglobin hemoglobin measurement|| mean corpuscular hemoglobin GCST000587 hemoglobin measurement|| mean corpuscular hemoglobin +Mean corpuscular hemoglobin concentration hemoglobin measurement|| mean corpuscular hemoglobin concentration GCST000582 hemoglobin measurement|| mean corpuscular hemoglobin concentration +Menarche and menopause (age at onset) age at menarche|| age at menopause GCST001336 age at menarche|| age at menopause +Menarche and menopause (age at onset) age at menarche|| age at menopause GCST000403 age at menarche|| age at menopause +Menstruation quality of life impact (acne) quality of life during menstruation measurement|| acne GCST006640 quality of life during menstruation measurement|| acne +Menstruation quality of life impact (aggressiveness) quality of life during menstruation measurement|| aggressive behavior GCST006641 quality of life during menstruation measurement|| aggressive behavior +Menstruation quality of life impact (bowel movement) quality of life during menstruation measurement|| abnormal peristalsis GCST006643 quality of life during menstruation measurement|| abnormal peristalsis +Menstruation quality of life impact (depression) quality of life during menstruation measurement|| unipolar depression GCST006644 quality of life during menstruation measurement|| unipolar depression +Menstruation quality of life impact (dysmenorrhea) quality of life during menstruation measurement|| dysmenorrheic pain measurement GCST006636 quality of life during menstruation measurement|| dysmenorrheic pain measurement +Menstruation quality of life impact (edema) quality of life during menstruation measurement|| edema GCST006645 quality of life during menstruation measurement|| edema +Menstruation quality of life impact (fever) quality of life during menstruation measurement|| fever GCST006638 quality of life during menstruation measurement|| fever +Menstruation quality of life impact (headache) quality of life during menstruation measurement|| Headache GCST006646 quality of life during menstruation measurement|| Headache +Menstruation quality of life impact (increased appetite) quality of life during menstruation measurement|| eating behaviour GCST006642 quality of life during menstruation measurement|| eating behaviour +Menstruation quality of life impact (joint pain) quality of life during menstruation measurement|| arthralgia GCST006647 quality of life during menstruation measurement|| arthralgia +Menstruation quality of life impact (loss of concentration) quality of life during menstruation measurement|| decreased attention GCST006648 quality of life during menstruation measurement|| decreased attention +Menstruation quality of life impact (nervousness) nervousness|| quality of life during menstruation measurement GCST006649 nervousness|| quality of life during menstruation measurement +Menstruation quality of life impact (pressure in breast) quality of life during menstruation measurement|| breast pressure measurement GCST006650 quality of life during menstruation measurement|| breast pressure measurement +Menstruation quality of life impact (sleepiness) quality of life during menstruation measurement|| sleepiness GCST006651 quality of life during menstruation measurement|| sleepiness +Menstruation quality of life impact (stiff neck) quality of life during menstruation measurement|| Stiff neck GCST006652 quality of life during menstruation measurement|| Stiff neck +Mental development (prenatal lead exposure interaction) blood lead measurement|| mental development measurement GCST004769 blood lead measurement|| mental development measurement +Metabolic traits inflammatory response|| triglyceride measurement|| insulin measurement|| glucose measurement GCST000292 inflammatory response|| triglyceride measurement|| insulin measurement|| glucose measurement +Metabolite levels serum albumin measurement|| metabolite measurement|| serum alanine aminotransferase measurement|| low density lipoprotein cholesterol measurement|| fasting blood glucose measurement|| uric acid measurement GCST001233 serum albumin measurement|| metabolite measurement|| serum alanine aminotransferase measurement|| low density lipoprotein cholesterol measurement|| fasting blood glucose measurement|| uric acid measurement +Metabolite levels phenylalanine measurement|| acylcarnitine measurement|| carbohydrate measurement|| tyrosine measurement|| sphingolipid measurement|| lysine measurement|| lipid measurement|| phospholipid measurement|| serotonin measurement GCST000274 phenylalanine measurement|| acylcarnitine measurement|| carbohydrate measurement|| tyrosine measurement|| sphingolipid measurement|| lysine measurement|| lipid measurement|| phospholipid measurement|| serotonin measurement +Metabolite levels (5-HIAA/ MHPG Ratio) MHPG measurement|| 5-HIAA measurement GCST001821 MHPG measurement|| 5-HIAA measurement +Metabolite levels (HVA-5-HIAA Factor score) HVA measurement|| 5-HIAA measurement GCST001817 HVA measurement|| 5-HIAA measurement +Metabolite levels (HVA/5-HIAA ratio) HVA measurement|| 5-HIAA measurement GCST001818 HVA measurement|| 5-HIAA measurement +Metabolite levels (HVA/MHPG ratio) HVA measurement|| MHPG measurement GCST001823 HVA measurement|| MHPG measurement +Metabolite levels (lipid measures) lipid measurement|| blood metabolite measurement GCST003664 lipid measurement|| blood metabolite measurement +Metabolite levels (lipoprotein measures) lipoprotein measurement|| blood metabolite measurement GCST003665 lipoprotein measurement|| blood metabolite measurement +Metabolite levels (small molecules and protein measures) blood metabolite measurement|| protein measurement|| amino acid measurement GCST003666 blood metabolite measurement|| protein measurement|| amino acid measurement +middle facial morphology traits (ordinal measurement) nose morphology measurement|| cheekbone morphology measurement GCST003633 nose morphology measurement|| cheekbone morphology measurement +Midgestational circulating levels of organochlorine pesticides gestational serum measurement|| organochlorine pesticide measurement GCST004281 gestational serum measurement|| organochlorine pesticide measurement +Midgestational circulating levels of organochlorine pesticides (fetal genetic effect) gestational serum measurement|| fetal genotype effect measurement|| organochlorine pesticide measurement GCST004282 gestational serum measurement|| fetal genotype effect measurement|| organochlorine pesticide measurement +Midgestational circulating levels of PBDEs polybrominated biphenyl measurement|| gestational serum measurement|| polybrominated diphenyl ether measurement GCST004285 polybrominated biphenyl measurement|| gestational serum measurement|| polybrominated diphenyl ether measurement +Midgestational circulating levels of PBDEs (fetal genetic effect) polybrominated biphenyl measurement|| gestational serum measurement|| fetal genotype effect measurement|| polybrominated diphenyl ether measurement GCST004286 polybrominated biphenyl measurement|| gestational serum measurement|| fetal genotype effect measurement|| polybrominated diphenyl ether measurement +Midgestational circulating levels of PCBs polychlorinated biphenyls measurement|| gestational serum measurement GCST004283 polychlorinated biphenyls measurement|| gestational serum measurement +Midgestational circulating levels of PCBs (fetal genetic effect) polychlorinated biphenyls measurement|| gestational serum measurement|| fetal genotype effect measurement GCST004284 polychlorinated biphenyls measurement|| gestational serum measurement|| fetal genotype effect measurement +Midgestational cytokine/chemokine levels (fetal genetic effect) gestational serum measurement|| fetal genotype effect measurement|| protein measurement GCST006623 gestational serum measurement|| fetal genotype effect measurement|| protein measurement +Midgestational cytokine/chemokine levels (maternal genetic effect) gestational serum measurement|| protein measurement|| parental genotype effect measurement GCST006621 gestational serum measurement|| protein measurement|| parental genotype effect measurement +Migraine or coronary artery disease migraine disorder|| coronary artery disease GCST004944 migraine disorder|| coronary artery disease +Milk allergy (maternal genetic effects) milk allergy measurement|| parental genotype effect measurement GCST005722 milk allergy measurement|| parental genotype effect measurement +Milk allergy (parent-of-origin effect) milk allergy measurement|| parental genotype effect measurement GCST005726 milk allergy measurement|| parental genotype effect measurement +Modified Stumvoll Insulin Sensitivity Index (BMI interaction) insulin sensitivity measurement|| body mass index GCST003659 insulin sensitivity measurement|| body mass index +Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) insulin sensitivity measurement|| body mass index GCST003658 insulin sensitivity measurement|| body mass index +Monocyte chemoattractant protein-1 (red blood cell fatty acid level interaction) fatty acid measurement|| CCL2 measurement GCST004821 fatty acid measurement|| CCL2 measurement +Mood disorder and prion disease prion disease|| mood disorder GCST002862 prion disease|| mood disorder +Motor development (prenatal lead exposure interaction) motor development measurement|| blood lead measurement GCST004768 motor development measurement|| blood lead measurement +"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)" lung carcinoma|| squamous cell carcinoma|| gastric carcinoma GCST001718 lung carcinoma|| squamous cell carcinoma|| gastric carcinoma +Multiple keratinocyte cancers squamous cell carcinoma|| mulitple keratinocyte carcinoma susceptibility measurement|| basal cell carcinoma GCST004134 squamous cell carcinoma|| mulitple keratinocyte carcinoma susceptibility measurement|| basal cell carcinoma +Multiple myeloma and monoclonal gammopathy multiple myeloma|| monoclonal gammopathy GCST002922 multiple myeloma|| monoclonal gammopathy +Multiple sclerosis (OCB status) multiple sclerosis|| oligoclonal band measurement GCST001892 multiple sclerosis|| oligoclonal band measurement +Multiple sclerosis or amyotrophic lateral sclerosis multiple sclerosis|| amyotrophic lateral sclerosis GCST002274 multiple sclerosis|| amyotrophic lateral sclerosis +Neonatal cytokine/chemokine levels (fetal genetic effect) fetal genotype effect measurement|| protein measurement GCST006622 fetal genotype effect measurement|| protein measurement +Neonatal cytokine/chemokine levels (maternal genetic effect) protein measurement|| parental genotype effect measurement GCST006625 protein measurement|| parental genotype effect measurement +Neovascular age-related macular degeneration age-related macular degeneration|| wet macular degeneration GCST004737 age-related macular degeneration|| wet macular degeneration +Neuranatomic and neurocognitive phenotypes neuroimaging measurement|| South Texas Assessment of Neurocognition GCST001037 neuroimaging measurement|| South Texas Assessment of Neurocognition +Neuritic plaques or cerebral amyloid angiopathy (pleiotropy) neuritic plaque measurement|| cerebral amyloid angiopathy GCST005515 neuritic plaque measurement|| cerebral amyloid angiopathy +Neuritic plaques or neurofibrillary tangles (pleiotropy) neuritic plaque measurement|| neurofibrillary tangles measurement GCST005516 neuritic plaque measurement|| neurofibrillary tangles measurement +Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy) neuritic plaque measurement|| cerebral amyloid angiopathy|| neurofibrillary tangles measurement GCST005514 neuritic plaque measurement|| cerebral amyloid angiopathy|| neurofibrillary tangles measurement +Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy) cerebral amyloid angiopathy|| neurofibrillary tangles measurement GCST005517 cerebral amyloid angiopathy|| neurofibrillary tangles measurement +Neuroticism (age interaction) neurotic disorder|| age at assessment GCST000724 neurotic disorder|| age at assessment +Nicotine dependence and major depression (severity of comorbidity) nicotine dependence symptom count|| depressive symptom measurement GCST006631 nicotine dependence symptom count|| depressive symptom measurement +Night sleep phenotypes sleep duration|| nighttime rest measurement|| sleep quality|| sleep latency GCST003542 sleep duration|| nighttime rest measurement|| sleep quality|| sleep latency +Non-alcoholic fatty liver disease histology (AST) non-alcoholic fatty liver disease|| cirrhosis of liver GCST000767 non-alcoholic fatty liver disease|| cirrhosis of liver +Non-alcoholic fatty liver disease histology (lobular) non-alcoholic fatty liver disease|| cirrhosis of liver GCST000766 non-alcoholic fatty liver disease|| cirrhosis of liver +Non-alcoholic fatty liver disease histology (other) serum alanine aminotransferase measurement|| non-alcoholic fatty liver disease|| cirrhosis of liver GCST000765 serum alanine aminotransferase measurement|| non-alcoholic fatty liver disease|| cirrhosis of liver +Non-chemotherapy drug induced agranulocytosis drug-induced agranulocytosis|| response to drug GCST003526 drug-induced agranulocytosis|| response to drug +Non-glioblastoma glioma central nervous system cancer|| glioma GCST004348 central nervous system cancer|| glioma +Non-response to antidepressants and depression unipolar depression|| mood disorder|| response to antidepressant GCST003812 unipolar depression|| mood disorder|| response to antidepressant +Non-response to bupropion and depression unipolar depression|| response to bupropion|| mood disorder GCST003804 unipolar depression|| response to bupropion|| mood disorder +Non-response to citalopram or escitalopram and depression unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder GCST003810 unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder +Non-response to selective serotonin reuptake inhibitors and depression unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder GCST003808 unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder +Nonalcoholic steatohepatitis-derived hepatocellular carcinoma hepatocellular carcinoma|| non-alcoholic steatohepatitis GCST005309 hepatocellular carcinoma|| non-alcoholic steatohepatitis +Nonsyndromic cleft lip with cleft palate cleft palate|| cleft lip GCST004166 cleft palate|| cleft lip +Nonsyndromic cleft lip with or without cleft palate cleft palate|| cleft lip GCST006415 cleft palate|| cleft lip +Nonsyndromic cleft lip with or without cleft palate cleft palate|| cleft lip GCST004088 cleft palate|| cleft lip +Nonsyndromic cleft lip with or without cleft palate cleft palate|| cleft lip GCST002811 cleft palate|| cleft lip +Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test) cleft palate|| sex interaction measurement|| cleft lip GCST006680 cleft palate|| sex interaction measurement|| cleft lip +Number of children female fertility|| fertility measurement GCST002801 female fertility|| fertility measurement +Number of children (6+ vs. 0 or 1) female fertility|| fertility measurement GCST002800 female fertility|| fertility measurement +Number of pregnancies female fertility|| fertility measurement GCST002799 female fertility|| fertility measurement +Obesity and osteoporosis obesity|| osteoporosis GCST000469 obesity|| osteoporosis +Obesity-related traits cortisol secretion measurement|| hormone measurement|| antioxidant measurement|| CCL2 measurement|| body mass index|| IGFBP-3 measurement|| fatty acid measurement|| tumor necrosis factor-alpha measurement|| gestational age|| energy expenditure|| sleep measurement|| metabolic rate measurement|| urinary metabolite measurement|| blood urea nitrogen measurement|| vitamin B12 measurement|| energy intake|| ICAM-1 measurement|| body height|| hip circumference|| arm span|| physical activity|| heart rate|| protein measurement|| estradiol measurement|| thyroid stimulating hormone measurement|| waist circumference|| total cholesterol measurement|| interleukin-6 measurement|| body composition measurement|| birth weight|| amino acid measurement|| C-reactive protein measurement|| HOMA-IR|| head circumference|| adiponectin measurement|| high density lipoprotein cholesterol measurement|| aspartate aminotransferase measurement|| leptin measurement|| transforming growth factor beta measurement|| systolic blood pressure|| IGFBP-1 measurement|| bone density|| body weight|| fasting blood glucose measurement|| homocysteine measurement|| folic acid measurement|| serum alanine aminotransferase measurement|| CCL5 measurement|| IGF-1 measurement|| testosterone measurement|| insulin sensitivity measurement|| diastolic blood pressure|| maximal oxygen uptake measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| lean body mass|| fasting blood insulin measurement GCST001762 cortisol secretion measurement|| hormone measurement|| antioxidant measurement|| CCL2 measurement|| body mass index|| IGFBP-3 measurement|| fatty acid measurement|| tumor necrosis factor-alpha measurement|| gestational age|| energy expenditure|| sleep measurement|| metabolic rate measurement|| urinary metabolite measurement|| blood urea nitrogen measurement|| vitamin B12 measurement|| energy intake|| ICAM-1 measurement|| body height|| hip circumference|| arm span|| physical activity|| heart rate|| protein measurement|| estradiol measurement|| thyroid stimulating hormone measurement|| waist circumference|| total cholesterol measurement|| interleukin-6 measurement|| body composition measurement|| birth weight|| amino acid measurement|| C-reactive protein measurement|| HOMA-IR|| head circumference|| adiponectin measurement|| high density lipoprotein cholesterol measurement|| aspartate aminotransferase measurement|| leptin measurement|| transforming growth factor beta measurement|| systolic blood pressure|| IGFBP-1 measurement|| bone density|| body weight|| fasting blood glucose measurement|| homocysteine measurement|| folic acid measurement|| serum alanine aminotransferase measurement|| CCL5 measurement|| IGF-1 measurement|| testosterone measurement|| insulin sensitivity measurement|| diastolic blood pressure|| maximal oxygen uptake measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| lean body mass|| fasting blood insulin measurement +Obesity-related traits fat body mass|| body mass index|| obesity GCST001288 fat body mass|| body mass index|| obesity +Obesity-related traits body weight|| waist-hip ratio|| body mass index GCST000060 body weight|| waist-hip ratio|| body mass index +Objective response to lithium treatment bipolar disorder|| response to lithium ion GCST003159 bipolar disorder|| response to lithium ion +Obsessive-compulsive disorder or autism spectrum disorder obsessive-compulsive disorder|| autism spectrum disorder GCST004703 obsessive-compulsive disorder|| autism spectrum disorder +Obstructive sleep apnea (average oxygen saturation during sleep) sleep apnea measurement|| obstructive sleep apnea GCST003673 sleep apnea measurement|| obstructive sleep apnea +Obstructive sleep apnea trait (apnea hypopnea index) sleep apnea measurement|| obstructive sleep apnea GCST003674 sleep apnea measurement|| obstructive sleep apnea +Obstructive sleep apnea trait (average respiratory event duration) sleep apnea measurement|| obstructive sleep apnea GCST003675 sleep apnea measurement|| obstructive sleep apnea +Occipital cortical area (total cortical area interaction) total cortical area measurement|| visual cortical surface area measurement GCST001411 total cortical area measurement|| visual cortical surface area measurement +Offspring birth weight birth weight|| parental genotype effect measurement GCST005314 birth weight|| parental genotype effect measurement +Open-angle glaucoma and intra-ocular pressure open-angle glaucoma|| intraocular pressure measurement GCST005408 open-angle glaucoma|| intraocular pressure measurement +Open-angle glaucoma and optic cup area optic cup area measurement|| open-angle glaucoma GCST005406 optic cup area measurement|| open-angle glaucoma +Open-angle glaucoma and optic disc area open-angle glaucoma|| optic disc area measurement GCST005410 open-angle glaucoma|| optic disc area measurement +Open-angle glaucoma and vertical cup-disc ratio cup-to-disc ratio measurement|| open-angle glaucoma GCST005409 cup-to-disc ratio measurement|| open-angle glaucoma +Opioid requirements during laparoscopic-assisted colectomy response to opioid|| analgesia requirement measurement GCST005364 response to opioid|| analgesia requirement measurement +Oral cancers (chewing tobacco related) matrix metalloproteinase measurement|| mouth neoplasm GCST001480 matrix metalloproteinase measurement|| mouth neoplasm +Oral cavity and pharyngeal cancer pharynx cancer|| oral cavity cancer GCST003857 pharynx cancer|| oral cavity cancer +Orofacial clefts (cleft lip vs. cleft lip and palate) cleft palate|| Orofacial clefting syndrome|| cleft lip GCST005079 cleft palate|| Orofacial clefting syndrome|| cleft lip +Orofacial clefts (maternal alcohol consumption interaction) alcohol consumption measurement|| Orofacial clefting syndrome|| cleft lip GCST001082 alcohol consumption measurement|| Orofacial clefting syndrome|| cleft lip +Osteoarthritis (with total hip replacement) hip osteoarthritis symptom severity measurement|| osteoarthritis GCST004199 hip osteoarthritis symptom severity measurement|| osteoarthritis +Osteoarthritis of the hip (hospital diagnosed) osteoarthritis|| hip GCST005810 osteoarthritis|| hip +Osteoarthritis of the hip (with total joint replacement) osteoarthritis|| hip GCST005572 osteoarthritis|| hip +Osteoarthritis of the hip or knee osteoarthritis|| hip|| osteoarthritis|| knee GCST005573 osteoarthritis|| hip|| osteoarthritis|| knee +Osteoarthritis of the hip or knee (hospital diagnosed) osteoarthritis|| hip|| osteoarthritis|| knee GCST005812 osteoarthritis|| hip|| osteoarthritis|| knee +Osteoarthritis of the hip or knee (with total joint replacement) osteoarthritis|| hip|| osteoarthritis|| knee GCST005571 osteoarthritis|| hip|| osteoarthritis|| knee +Osteoarthritis of the knee (hospital diagnosed) osteoarthritis|| knee GCST005813 osteoarthritis|| knee +Osteoarthritis of the knee (with total joint replacement) osteoarthritis|| knee GCST005574 osteoarthritis|| knee +Osteoarthritis or femoral neck bone mineral density osteoarthritis|| femoral neck bone mineral density GCST005228 osteoarthritis|| femoral neck bone mineral density +Osteoarthritis or lumbar spine bone mineral density osteoarthritis|| spine bone mineral density GCST005225 osteoarthritis|| spine bone mineral density +Osteoporosis or obesity (pleiotropy) obesity|| osteoporosis GCST005114 obesity|| osteoporosis +Osteoprotegerin (red blood cell fatty acid level interaction) fatty acid measurement|| osteoprotegerin measurement GCST004819 fatty acid measurement|| osteoprotegerin measurement +Other erythrocyte phenotypes erythrocyte count|| mean corpuscular hemoglobin concentration GCST000500 erythrocyte count|| mean corpuscular hemoglobin concentration +P-Selectin (red blood cell fatty acid level interaction) fatty acid measurement|| P-Selectin measurement GCST004822 fatty acid measurement|| P-Selectin measurement +Paclitaxel-induced cytotoxicity cytotoxicity measurement|| response to paclitaxel GCST002924 cytotoxicity measurement|| response to paclitaxel +Paclitaxel-induced neuropathy peripheral neuropathy|| response to paclitaxel GCST002923 peripheral neuropathy|| response to paclitaxel +Paclitaxel-induced neuropathy brain serotonin transporter measurement|| response to paclitaxel GCST002074 brain serotonin transporter measurement|| response to paclitaxel +Paclitaxel-induced neuropathy response to paclitaxel|| neuropathy GCST001755 response to paclitaxel|| neuropathy +Paclitaxel-induced neuropathy response to paclitaxel|| neuropathy GCST001624 response to paclitaxel|| neuropathy +Pain medicine use during menstruation drug use measurement|| quality of life during menstruation measurement GCST006637 drug use measurement|| quality of life during menstruation measurement +Parkinson disease and lewy body pathology Parkinson's disease|| Lewy body measurement GCST002778 Parkinson's disease|| Lewy body measurement +Parkinson's disease (coffee consumption interaction) Parkinson's disease|| coffee consumption GCST001205 Parkinson's disease|| coffee consumption +Parkinson's disease (pesticide exposure interaction) Parkinson's disease|| pesticide exposure measurement GCST003600 Parkinson's disease|| pesticide exposure measurement +Peanut allergy (maternal genetic effects) peanut allergy measurement|| parental genotype effect measurement GCST005723 peanut allergy measurement|| parental genotype effect measurement +Peanut allergy (parent-of-origin effect) peanut allergy measurement|| parental genotype effect measurement GCST005727 peanut allergy measurement|| parental genotype effect measurement +Pediatric autoimmune diseases autoimmune thyroid disease|| type I diabetes mellitus|| Common variable immunodeficiency|| chronic childhood arthritis|| ankylosing spondylitis|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease|| autoimmune disease|| systemic lupus erythematosus GCST003097 autoimmune thyroid disease|| type I diabetes mellitus|| Common variable immunodeficiency|| chronic childhood arthritis|| ankylosing spondylitis|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease|| autoimmune disease|| systemic lupus erythematosus +Pediatric non-alcoholic fatty liver disease activity score non-alcoholic fatty liver disease|| cirrhosis of liver GCST001928 non-alcoholic fatty liver disease|| cirrhosis of liver +Percent mammographic density mammographic density percentage|| mammographic density measurement GCST002669 mammographic density percentage|| mammographic density measurement +Pericardial adipose tissue adjusted for height and weight pericardial adipose tissue measurement|| body weight|| body height GCST006544 pericardial adipose tissue measurement|| body weight|| body height +Pericardial adipose tissue adjusted for height and weight pericardial adipose tissue measurement|| body weight|| body height GCST006543 pericardial adipose tissue measurement|| body weight|| body height +Pericardial adipose tissue adjusted for height and weight pericardial adipose tissue measurement|| body weight|| body height GCST003968 pericardial adipose tissue measurement|| body weight|| body height +Periodontal disease-related phenotypes periodontitis|| periodontal measurement GCST003484 periodontitis|| periodontal measurement +Peripheral arterial disease (traffic-related air pollution interaction) peripheral arterial disease|| traffic air pollution measurement GCST004482 peripheral arterial disease|| traffic air pollution measurement +Phenytoin-induced maculopapular exanthema maculopapular eruption|| response to phenytoin GCST005200 maculopapular eruption|| response to phenytoin +Phenytoin-induced severe cutaneous adverse reactions severe cutaneous adverse reaction|| response to phenytoin GCST002558 severe cutaneous adverse reaction|| response to phenytoin +Plantar fascial disorders Plantar Fasciitis|| Plantar Fibromatosis GCST005558 Plantar Fasciitis|| Plantar Fibromatosis +Platelet thrombus formation platelet reactivity measurement|| thrombus formation measurement GCST001501 platelet reactivity measurement|| thrombus formation measurement +Post bronchodilator FEV1 forced expiratory volume|| response to bronchodilator GCST003262 forced expiratory volume|| response to bronchodilator +Post bronchodilator FEV1/FVC ratio response to bronchodilator|| FEV/FEC ratio GCST003264 response to bronchodilator|| FEV/FEC ratio +Posterior cortical atrophy and Alzheimer's disease Alzheimer's disease|| Posterior cortical atrophy GCST003452 Alzheimer's disease|| Posterior cortical atrophy +Postprandial triglyceride response to high fat diet meal response to high fat food intake|| triglyceride change measurement GCST003014 response to high fat food intake|| triglyceride change measurement +Preterm birth (maternal effect) premature birth|| parental genotype effect measurement GCST004898 premature birth|| parental genotype effect measurement +Preterm birth (maternal effect) premature birth|| parental genotype effect measurement GCST004841 premature birth|| parental genotype effect measurement +Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction) body mass index|| premature birth|| parental genotype effect measurement GCST004842 body mass index|| premature birth|| parental genotype effect measurement +Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction) body mass index|| premature birth|| parental genotype effect measurement GCST004843 body mass index|| premature birth|| parental genotype effect measurement +"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)" rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| Sarcoidosis|| celiac disease|| ulcerative colitis|| Crohn's disease|| sclerosing cholangitis GCST005563 rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| Sarcoidosis|| celiac disease|| ulcerative colitis|| Crohn's disease|| sclerosing cholangitis +Progressive supranuclear palsy and immune-mediated diseases (pleiotropy) rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease|| Progressive supranuclear palsy GCST005320 rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease|| Progressive supranuclear palsy +Prostate cancer (SNP x SNP interaction) genetic variation|| prostate carcinoma GCST001370 genetic variation|| prostate carcinoma +Prostate cancer aggressiveness cancer aggressiveness measurement|| Gleason score measurement|| prostate carcinoma GCST002886 cancer aggressiveness measurement|| Gleason score measurement|| prostate carcinoma +Prostate cancer mortality survival time|| metastatic prostate cancer GCST000844 survival time|| metastatic prostate cancer +Proteinuria and chronic kidney disease chronic kidney disease|| Proteinuria GCST003141 chronic kidney disease|| Proteinuria +Psoriatic arthritis vs Cutaneous psoriasis cutaneous psoriasis measurement|| psoriatic arthritis|| psoriasis GCST003271 cutaneous psoriasis measurement|| psoriatic arthritis|| psoriasis +Psychiatric diseases (pleiotropy) (HIPO component 1) attention deficit hyperactivity disorder|| unipolar depression|| schizophrenia|| autism spectrum disorder|| bipolar disorder GCST006668 attention deficit hyperactivity disorder|| unipolar depression|| schizophrenia|| autism spectrum disorder|| bipolar disorder +Psychosis and Alzheimer's disease Alzheimer's disease|| psychotic symptoms GCST001285 Alzheimer's disease|| psychotic symptoms +Psychotic symptoms and prion disease prion disease|| psychotic symptoms GCST002871 prion disease|| psychotic symptoms +Pubertal anthropometrics puberty|| height growth measurement GCST001876 puberty|| height growth measurement +Pulmonary artery enlargement and chronic obstructive pulmonary disease pulmonary artery enlargement|| chronic obstructive pulmonary disease GCST002798 pulmonary artery enlargement|| chronic obstructive pulmonary disease +Pulmonary function pulmonary function measurement|| forced expiratory volume|| FEV/FEC ratio|| vital capacity GCST002113 pulmonary function measurement|| forced expiratory volume|| FEV/FEC ratio|| vital capacity +Pulmonary function (smoking interaction) pulmonary function measurement|| smoking behaviour measurement GCST001784 pulmonary function measurement|| smoking behaviour measurement +Pulmonary function decline forced expiratory volume|| FEV/FEC ratio GCST001444 forced expiratory volume|| FEV/FEC ratio +Pulse pressure (alcohol consumption interaction) pulse pressure measurement|| alcohol drinking GCST002310 pulse pressure measurement|| alcohol drinking +Pulse pressure (dietary potassium intake interaction) pulse pressure measurement|| dietary potassium intake measurement GCST005201 pulse pressure measurement|| dietary potassium intake measurement +Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test) pulse pressure measurement|| alcohol consumption measurement GCST006171 pulse pressure measurement|| alcohol consumption measurement +Pulse pressure x alcohol consumption interaction (2df test) pulse pressure measurement|| alcohol drinking GCST006168 pulse pressure measurement|| alcohol drinking +Pulse pressure x sodium interaction (1df test) pulse pressure measurement|| sodium measurement GCST006117 pulse pressure measurement|| sodium measurement +Pulse pressure x sodium interaction (2df test) pulse pressure measurement|| sodium measurement GCST006118 pulse pressure measurement|| sodium measurement +Putamen activity during reward functional brain measurement|| putamen measurement|| response to reward GCST004971 functional brain measurement|| putamen measurement|| response to reward +Putamen actvity during disappointment response to disappointment|| functional brain measurement|| putamen measurement GCST004972 response to disappointment|| functional brain measurement|| putamen measurement +QRS complex (12-leadsum) QRS amplitude|| QRS complex GCST003872 QRS amplitude|| QRS complex +QRS complex (Cornell) QRS amplitude|| QRS complex GCST003871 QRS amplitude|| QRS complex +QRS complex (Sokolow-Lyon) QRS amplitude|| QRS complex GCST003870 QRS amplitude|| QRS complex +QRS duration QRS complex|| QRS duration GCST003844 QRS complex|| QRS duration +QRS interval (sulfonylurea treatment interaction) QRS duration|| response to sulfonylurea GCST004033 QRS duration|| response to sulfonylurea +QT interval (ambient particulate matter interaction) QT interval|| particulate matter air pollution measurement GCST004642 QT interval|| particulate matter air pollution measurement +QT interval (sulfonylurea treatment interaction) response to sulfonylurea|| QT interval GCST004031 response to sulfonylurea|| QT interval +QT interval (tricyclic/tetracyclic antidepressant use interaction) response to tetracyclic antidepressant|| QT interval|| response to tricyclic antidepressant GCST004010 response to tetracyclic antidepressant|| QT interval|| response to tricyclic antidepressant +Quantitative traits waist circumference|| total cholesterol measurement|| body fat distribution|| C-reactive protein measurement|| body mass index|| high density lipoprotein cholesterol measurement|| body height|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| low density lipoprotein cholesterol measurement|| body weight|| thyroid stimulating hormone measurement GCST000337 waist circumference|| total cholesterol measurement|| body fat distribution|| C-reactive protein measurement|| body mass index|| high density lipoprotein cholesterol measurement|| body height|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| low density lipoprotein cholesterol measurement|| body weight|| thyroid stimulating hormone measurement +Rate of change of FEV1 (time interaction) FEV change measurement|| forced expiratory volume GCST002517 FEV change measurement|| forced expiratory volume +Ratio of apolipoprotein A1 to apolipoprotein B apolipoprotein A 1 measurement|| apolipoprotein B measurement GCST005443 apolipoprotein A 1 measurement|| apolipoprotein B measurement +Reading disability and language impairment language impairment|| dyslexia GCST002175 language impairment|| dyslexia +Reading disability or specific language impairment (pleiotropy) specific language impairment|| dyslexia GCST004401 specific language impairment|| dyslexia +Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy) intelligence|| specific language impairment|| dyslexia GCST004402 intelligence|| specific language impairment|| dyslexia +Reading or mathematical ability reading|| mathematical ability GCST002522 reading|| mathematical ability +Red blood cell fatty acid levels arachidonic acid measurement|| fatty acid measurement|| linolenic acid measurement|| oleic acid measurement|| docosapentaenoic acid measurement|| linoleic acid measurement GCST002712 arachidonic acid measurement|| fatty acid measurement|| linolenic acid measurement|| oleic acid measurement|| docosapentaenoic acid measurement|| linoleic acid measurement +Red blood cell traits mean corpuscular volume|| mean corpuscular hemoglobin GCST002109 mean corpuscular volume|| mean corpuscular hemoglobin +Red blood cell traits hemoglobin measurement|| erythrocyte count|| mean corpuscular hemoglobin concentration|| mean corpuscular volume|| hematocrit|| mean corpuscular hemoglobin|| red blood cell distribution width GCST001873 hemoglobin measurement|| erythrocyte count|| mean corpuscular hemoglobin concentration|| mean corpuscular volume|| hematocrit|| mean corpuscular hemoglobin|| red blood cell distribution width +Red blood cell traits erythrocyte count|| mean corpuscular hemoglobin concentration|| mean corpuscular volume|| mean corpuscular hemoglobin GCST000814 erythrocyte count|| mean corpuscular hemoglobin concentration|| mean corpuscular volume|| mean corpuscular hemoglobin +Renal function and chronic kidney disease renal system measurement|| chronic kidney disease GCST000397 renal system measurement|| chronic kidney disease +Renal function-related traits (BUN) renal system measurement|| blood urea nitrogen measurement GCST001610 renal system measurement|| blood urea nitrogen measurement +Renal function-related traits (urea) renal system measurement|| uric acid measurement GCST001608 renal system measurement|| uric acid measurement +Reporting of stressful life event self rated health|| stressful life event measurement GCST001774 self rated health|| stressful life event measurement +Residual cognition cognition|| aging GCST004291 cognition|| aging +Response to antidepressants and depression unipolar depression|| mood disorder|| response to antidepressant GCST003813 unipolar depression|| mood disorder|| response to antidepressant +Response to bleomycin (chromatid breaks) response to bleomycin|| chromatid break measurement|| response to antibiotic GCST000882 response to bleomycin|| chromatid break measurement|| response to antibiotic +Response to bupropion and depression unipolar depression|| response to bupropion|| mood disorder GCST003806 unipolar depression|| response to bupropion|| mood disorder +Response to citalopram or escitalopram and depression unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder GCST003811 unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder +Response to clopidogrel therapy platelet reactivity measurement|| response to clopidogrel GCST004266 platelet reactivity measurement|| response to clopidogrel +Response to exercise (triglyceride level interaction) triglyceride change measurement|| response to exercise GCST003207 triglyceride change measurement|| response to exercise +Response to fenofibrate (HDL cholesterol levels) HDL cholesterol change measurement|| response to fenofibrate GCST003485 HDL cholesterol change measurement|| response to fenofibrate +Response to fenofibrate (LDL cholesterol levels) LDL cholesterol change measurement|| response to fenofibrate GCST003486 LDL cholesterol change measurement|| response to fenofibrate +Response to fenofibrate (total cholesterol levels) total cholesterol change measurement|| response to fenofibrate GCST003487 total cholesterol change measurement|| response to fenofibrate +Response to fenofibrate (triglyceride levels) triglyceride change measurement|| response to fenofibrate GCST003488 triglyceride change measurement|| response to fenofibrate +Response to Homoharringtonine (cytotoxicity) response to homoharringtonine|| cytotoxicity measurement GCST002749 response to homoharringtonine|| cytotoxicity measurement +Response to metformin (IC50) cytotoxicity measurement|| response to metformin GCST003791 cytotoxicity measurement|| response to metformin +Response to selective serotonin reuptake inhibitors and depression unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder GCST003809 unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder +Response to simvastatin treatment (PCSK9 protein level change) response to simvastatin|| PCSK9 protein measurement GCST002642 response to simvastatin|| PCSK9 protein measurement +Response to statin therapy (LDL cholesterol subfractions) response to statin|| low density lipoprotein cholesterol measurement GCST002865 response to statin|| low density lipoprotein cholesterol measurement +Response to statins (HDL cholesterol change) HDL cholesterol change measurement|| response to statin GCST003617 HDL cholesterol change measurement|| response to statin +Response to statins (LDL cholesterol change) response to statin|| low density lipoprotein cholesterol measurement GCST002675 response to statin|| low density lipoprotein cholesterol measurement +Response to statins (LDL cholesterol change) response to statin|| LDL cholesterol change measurement GCST001408 response to statin|| LDL cholesterol change measurement +Response to thiazide diuretic treatment (hypokalemia) response to hydrochlorothiazide|| hypokalemia GCST002600 response to hydrochlorothiazide|| hypokalemia +Response to treatment for acute lymphoblastic leukemia acute lymphoblastic leukemia|| response to antineoplastic agent GCST000323 acute lymphoblastic leukemia|| response to antineoplastic agent +Response to ximelagatran treatment (increased serum alanine aminotransferase levels) serum alanine aminotransferase measurement|| response to ximelagatran GCST000034 serum alanine aminotransferase measurement|| response to ximelagatran +Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) rheumatoid arthritis|| anti-citrullinated protein antibody seropositivity|| rheumatoid factor seropositivity measurement GCST004174 rheumatoid arthritis|| anti-citrullinated protein antibody seropositivity|| rheumatoid factor seropositivity measurement +Ribavirin-induced anemia anemia|| response to ribavirin GCST000729 anemia|| response to ribavirin +Risky sexual behaviors (alcohol dependence interaction) behavioural disinhibition measurement|| alcohol dependence|| risky sexual behaviour measurement GCST003860 behavioural disinhibition measurement|| alcohol dependence|| risky sexual behaviour measurement +Risky sexual behaviors (alcohol dependence interaction) alcohol dependence|| risky sexual behaviour measurement GCST004956 alcohol dependence|| risky sexual behaviour measurement +RR interval (tricyclic/tetracyclic antidepressant use interaction) RR interval|| response to tetracyclic antidepressant|| response to tricyclic antidepressant GCST004011 RR interval|| response to tetracyclic antidepressant|| response to tricyclic antidepressant +Rubella-specific interferon-gamma secretion interferon gamma measurement|| response to vaccine GCST005177 interferon gamma measurement|| response to vaccine +Rubella-specific interleukin-6 secretion interleukin-6 measurement|| response to vaccine GCST005176 interleukin-6 measurement|| response to vaccine +Sasang constitutional medicine type (So-Eum) So-Eum|| Sasang constitutional medicine type GCST002854 So-Eum|| Sasang constitutional medicine type +Sasang constitutional medicine type (So-Yang) So-Yang|| Sasang constitutional medicine type GCST002852 So-Yang|| Sasang constitutional medicine type +Sasang constitutional medicine type (Tae-Eum) Tae-Eum|| Sasang constitutional medicine type GCST002853 Tae-Eum|| Sasang constitutional medicine type +Sasang constitutional medicine type (Tae-Yang) Tae-Yang|| Sasang constitutional medicine type GCST002851 Tae-Yang|| Sasang constitutional medicine type +Schizophrenia (cytomegalovirus infection interaction) schizophrenia|| cytomegalovirus infection GCST001833 schizophrenia|| cytomegalovirus infection +Schizophrenia (inflammation and infection response interaction) schizophrenia|| HSV1 seropositivity|| Toxoplasma gondii seropositivity|| cytomegalovirus seropositivity GCST002812 schizophrenia|| HSV1 seropositivity|| Toxoplasma gondii seropositivity|| cytomegalovirus seropositivity +Schizophrenia or bipolar disorder schizophrenia|| bipolar disorder GCST002295 schizophrenia|| bipolar disorder +Schizophrenia or cigarettes per day (pleiotropy) schizophrenia|| cigarettes per day measurement GCST005266 schizophrenia|| cigarettes per day measurement +Schizophrenia or general cognitive function (pleiotropy) schizophrenia|| cognitive function measurement GCST004975 schizophrenia|| cognitive function measurement +Schizophrenia or lung cancer (pleiotropy) lung carcinoma|| schizophrenia GCST005267 lung carcinoma|| schizophrenia +Schizophrenia or reaction time (pleiotropy) schizophrenia|| reaction time measurement GCST004974 schizophrenia|| reaction time measurement +Schizophrenia or verbal-numerical reasoning (pleiotropy) schizophrenia|| verbal-numerical reasoning measurement GCST004973 schizophrenia|| verbal-numerical reasoning measurement +"Schizophrenia, bipolar disorder and depression (combined)" unipolar depression|| mental or behavioural disorder|| bipolar disorder GCST000774 unipolar depression|| mental or behavioural disorder|| bipolar disorder +"Schizophrenia, schizoaffective disorder or bipolar disorder" schizophrenia|| bipolar disorder|| schizoaffective disorder GCST002254 schizophrenia|| bipolar disorder|| schizoaffective disorder +Sciatica caused by lumbar disc herniation (treated with microdiscectomy) lumbar disc herniation|| Sciatica|| LDH-related sciatica symptom severity measurement GCST004098 lumbar disc herniation|| Sciatica|| LDH-related sciatica symptom severity measurement +Sclerosing cholangitis and ulcerative colitis (combined) ulcerative colitis|| sclerosing cholangitis GCST001615 ulcerative colitis|| sclerosing cholangitis +Sleep traits (multi-trait analysis) sleep duration|| circadian rhythm|| excessive daytime sleepiness measurement|| insomnia measurement GCST003982 sleep duration|| circadian rhythm|| excessive daytime sleepiness measurement|| insomnia measurement +Smoking interaction in lung adenocarcinoma (1df test) smoking behavior|| lung adenocarcinoma GCST005909 smoking behavior|| lung adenocarcinoma +Smoking interaction in non-small cell lung cancer (1df test) smoking behavior|| non-small cell lung carcinoma GCST005910 smoking behavior|| non-small cell lung carcinoma +Smoking interaction in squamous cell lung cancer (1df test) smoking behavior|| squamous cell lung carcinoma GCST005911 smoking behavior|| squamous cell lung carcinoma +Social science traits (pleiotropy) (HIPO component 1) neuroticism measurement|| wellbeing measurement|| depressive symptom measurement GCST006665 neuroticism measurement|| wellbeing measurement|| depressive symptom measurement +Sotalol-induced IKr potassium channel inhibition (T wave peak and end interval change) response to sotalol|| TpTe measurement GCST005134 response to sotalol|| TpTe measurement +Sotalol-induced IKr potassium channel inhibition (ventricular repolarization duration change) response to sotalol|| ventricular repolarisation duration measurement GCST005140 response to sotalol|| ventricular repolarisation duration measurement +Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change) response to sotalol|| T wave amplitude GCST005135 response to sotalol|| T wave amplitude +Sotalol-induced IKr potassium channel inhibition (T wave morphology notching) response to sotalol|| T wave morphology measurement GCST005137 response to sotalol|| T wave morphology measurement +Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1) response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement GCST005139 response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement +Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2) response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement GCST005136 response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement +Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3) response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement GCST005138 response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement +Spherical equivalent (joint analysis main effects and education interaction) self reported educational attainment|| refractive error measurement GCST003455 self reported educational attainment|| refractive error measurement +Sphingolipid levels sphingolipid measurement|| blood metabolite measurement GCST002964 sphingolipid measurement|| blood metabolite measurement +Spine bone mineral density and alcohol drinking alcohol consumption measurement|| spine bone mineral density GCST003919 alcohol consumption measurement|| spine bone mineral density +Spontaneous preterm birth (maternal effect) spontaneous preterm birth|| parental genotype effect measurement GCST004845 spontaneous preterm birth|| parental genotype effect measurement +Spontaneous preterm birth (preterm birth) birth measurement|| spontaneous preterm birth GCST002751 birth measurement|| spontaneous preterm birth +Spontaneous preterm birth (preterm delivery) delivery measurement|| spontaneous preterm birth GCST002752 delivery measurement|| spontaneous preterm birth +Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) Stevens-Johnson syndrome|| toxic epidermal necrolysis GCST001239 Stevens-Johnson syndrome|| toxic epidermal necrolysis +Subcutaneous adipose tissue (sex interaction) subcutaneous adipose tissue measurement|| sex interaction measurement GCST005092 subcutaneous adipose tissue measurement|| sex interaction measurement +Suicide risk mental or behavioural disorder|| attempted suicide GCST000854 mental or behavioural disorder|| attempted suicide +Sulfasalazine-induced agranulocytosis drug-induced agranulocytosis|| response to sulfasalazine GCST004781 drug-induced agranulocytosis|| response to sulfasalazine +Susceptibility to persistent hepatitis B virus infection hepatitis B infection|| Susceptibility to viral and mycobacterial infections GCST003615 hepatitis B infection|| Susceptibility to viral and mycobacterial infections +Systemic lupus erythematosus and Systemic sclerosis systemic scleroderma|| systemic lupus erythematosus GCST002069 systemic scleroderma|| systemic lupus erythematosus +Systemic lupus erythematosus or rheumatoid arthritis rheumatoid arthritis|| systemic lupus erythematosus GCST003620 rheumatoid arthritis|| systemic lupus erythematosus +Systolic blood pressure (alcohol consumption interaction) systolic blood pressure|| alcohol drinking GCST002307 systolic blood pressure|| alcohol drinking +Systolic blood pressure (cigarette smoking interaction) smoking status measurement|| systolic blood pressure GCST006188 smoking status measurement|| systolic blood pressure +Systolic blood pressure (cigarette smoking interaction) systolic blood pressure|| smoking behaviour measurement GCST003365 systolic blood pressure|| smoking behaviour measurement +Systolic blood pressure (dietary potassium intake interaction) systolic blood pressure|| dietary potassium intake measurement GCST005204 systolic blood pressure|| dietary potassium intake measurement +Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) systolic blood pressure|| alcohol consumption measurement GCST006170 systolic blood pressure|| alcohol consumption measurement +Systolic blood pressure x alcohol consumption interaction (2df test) systolic blood pressure|| alcohol drinking GCST006434 systolic blood pressure|| alcohol drinking +Systolic blood pressure x smoking status (current vs non-current) interaction (1df test) smoking status measurement|| systolic blood pressure GCST006186 smoking status measurement|| systolic blood pressure +Systolic blood pressure x smoking status (current vs non-current) interaction (2df test) smoking status measurement|| systolic blood pressure GCST006195 smoking status measurement|| systolic blood pressure +Systolic blood pressure x smoking status (ever vs never) interaction (1df test) smoking status measurement|| systolic blood pressure GCST006189 smoking status measurement|| systolic blood pressure +Systolic blood pressure x smoking status (ever vs never) interaction (2df test) smoking status measurement|| systolic blood pressure GCST006192 smoking status measurement|| systolic blood pressure +Systolic blood pressure x sodium interaction (1df test) sodium measurement|| systolic blood pressure GCST006115 sodium measurement|| systolic blood pressure +Systolic blood pressure x sodium interaction (2df test) sodium measurement|| systolic blood pressure GCST006113 sodium measurement|| systolic blood pressure +TB-LM or TBLH-BMD (pleiotropy) bone density|| lean body mass GCST004771 bone density|| lean body mass +Total ventricular volume (Alzheimer's disease interaction) Alzheimer's disease|| brain volume measurement GCST000892 Alzheimer's disease|| brain volume measurement +Tourette's syndrome or obsessive-compulsive disorder obsessive-compulsive disorder|| Tourette syndrome GCST002682 obsessive-compulsive disorder|| Tourette syndrome +Triptolide cytotoxicity response to triptolide|| cytotoxicity measurement GCST003008 response to triptolide|| cytotoxicity measurement +Tumor necrosis factor receptor II (red blood cell fatty acid level interaction) fatty acid measurement|| tumor necrosis factor receptor II measurement GCST004817 fatty acid measurement|| tumor necrosis factor receptor II measurement +Type 1 diabetes and autoimmune thyroid diseases autoimmune thyroid disease|| type I diabetes mellitus GCST002876 autoimmune thyroid disease|| type I diabetes mellitus +Type 1 diabetes autoantibodies type I diabetes mellitus|| autoantibody measurement GCST001479 type I diabetes mellitus|| autoantibody measurement +Type 2 diabetes (dietary heme iron intake interaction) type II diabetes mellitus|| dietary heme iron intake measurement GCST001843 type II diabetes mellitus|| dietary heme iron intake measurement +Ulcerative colitis or Crohn's disease ulcerative colitis|| Crohn's disease GCST001118 ulcerative colitis|| Crohn's disease +Urate levels (BMI interaction) urate measurement|| body mass index GCST002827 urate measurement|| body mass index +Urate levels (BMI interaction) urate measurement|| body mass index GCST002826 urate measurement|| body mass index +Uveitis (juvenile idiopathic arthritis-associated) chronic childhood arthritis|| uveitis GCST006127 chronic childhood arthritis|| uveitis +Vaginal discharge (metrorrhagia) metrorrhagia|| vaginal discharge GCST006657 metrorrhagia|| vaginal discharge +Vascular brain injury vascular brain injury measurement|| vascular brain injury GCST002590 vascular brain injury measurement|| vascular brain injury +Ventricular ectopy or supraventricular ectopy (pleiotropy) premature cardiac contractions|| supraventricular ectopy|| ventricular ectopy GCST005935 premature cardiac contractions|| supraventricular ectopy|| ventricular ectopy +Visceral adipose tissue (sex interaction) visceral adipose tissue measurement|| sex interaction measurement GCST005086 visceral adipose tissue measurement|| sex interaction measurement +Visceral adipose tissue adjusted for BMI visceral adipose tissue measurement|| body mass index GCST006533 visceral adipose tissue measurement|| body mass index +Visceral adipose tissue adjusted for BMI visceral adipose tissue measurement|| body mass index GCST006534 visceral adipose tissue measurement|| body mass index +Visceral adipose tissue adjusted for BMI visceral adipose tissue measurement|| body mass index GCST003967 visceral adipose tissue measurement|| body mass index +Visceral adipose tissue adjusted for BMI visceral adipose tissue measurement|| body mass index GCST001523 visceral adipose tissue measurement|| body mass index +Visceral adipose tissue adjusted for BMI (sex interaction) visceral adipose tissue measurement|| sex interaction measurement GCST005088 visceral adipose tissue measurement|| sex interaction measurement +Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction) sex interaction measurement|| visceral:subcutaneous adipose tissue ratio GCST005090 sex interaction measurement|| visceral:subcutaneous adipose tissue ratio +Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI body mass index|| visceral:subcutaneous adipose tissue ratio GCST006554 body mass index|| visceral:subcutaneous adipose tissue ratio +Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI body mass index|| visceral:subcutaneous adipose tissue ratio GCST006553 body mass index|| visceral:subcutaneous adipose tissue ratio +Vitamin D levels (dietary vitamin D intake interaction) vitamin D measurement|| vitamin D dietary intake measurement GCST005366 vitamin D measurement|| vitamin D dietary intake measurement +Waist circumference (sex interaction) waist circumference|| sex interaction measurement GCST000931 waist circumference|| sex interaction measurement +Waist circumference adjusted for BMI (adjusted for smoking behaviour) smoking behavior|| BMI-adjusted waist circumference GCST004500 smoking behavior|| BMI-adjusted waist circumference +Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction) BMI-adjusted waist circumference|| physical activity measurement GCST004563 BMI-adjusted waist circumference|| physical activity measurement +Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction) smoking behavior|| BMI-adjusted waist circumference GCST004501 smoking behavior|| BMI-adjusted waist circumference +Waist circumference adjusted for BMI (physical activity interaction) BMI-adjusted waist circumference|| physical activity measurement GCST004561 BMI-adjusted waist circumference|| physical activity measurement +Waist circumference adjusted for BMI (smoking interaction) smoking behavior|| BMI-adjusted waist circumference GCST004502 smoking behavior|| BMI-adjusted waist circumference +Waist-to-hip circumference ratio (alcohol intake interaction) alcohol consumption measurement|| waist-hip ratio GCST004579 alcohol consumption measurement|| waist-hip ratio +Waist-to-hip circumference ratio (dietary energy interaction) diet measurement|| waist-hip ratio GCST004582 diet measurement|| waist-hip ratio +Waist-to-hip circumference ratio (ever vs never smoking interaction) smoking behaviour measurement|| waist-hip ratio GCST001754 smoking behaviour measurement|| waist-hip ratio +Waist-to-hip circumference ratio (recreational physical activity interaction) physical activity measurement|| waist-hip ratio GCST004583 physical activity measurement|| waist-hip ratio +Waist-to-hip circumference ratio (smoking years interaction) smoking behaviour measurement|| waist-hip ratio GCST004584 smoking behaviour measurement|| waist-hip ratio +Waist-to-hip ratio (sex interaction) sex interaction measurement|| waist-hip ratio GCST000928 sex interaction measurement|| waist-hip ratio +Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) smoking behavior|| BMI-adjusted waist-hip ratio GCST004505 smoking behavior|| BMI-adjusted waist-hip ratio +Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) BMI-adjusted waist-hip ratio|| physical activity measurement GCST004567 BMI-adjusted waist-hip ratio|| physical activity measurement +Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) smoking behavior|| BMI-adjusted waist-hip ratio GCST004507 smoking behavior|| BMI-adjusted waist-hip ratio +Waist-to-hip ratio adjusted for BMI (physical activity interaction) BMI-adjusted waist-hip ratio|| physical activity measurement GCST004566 BMI-adjusted waist-hip ratio|| physical activity measurement +Waist-to-hip ratio adjusted for BMI (smoking interaction) smoking behavior|| BMI-adjusted waist-hip ratio GCST004506 smoking behavior|| BMI-adjusted waist-hip ratio +Waist-to-hip ratio adjusted for BMI x age interaction BMI-adjusted waist-hip ratio|| age at assessment GCST005961 BMI-adjusted waist-hip ratio|| age at assessment +Waist-to-hip ratio adjusted for BMI x sex interaction BMI-adjusted waist-hip ratio|| sex interaction measurement GCST005959 BMI-adjusted waist-hip ratio|| sex interaction measurement +Waist-to-hip ratio adjusted for BMI x sex x age interaction BMI-adjusted waist-hip ratio|| sex interaction measurement|| age at assessment GCST005960 BMI-adjusted waist-hip ratio|| sex interaction measurement|| age at assessment +Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) BMI-adjusted waist-hip ratio|| sex interaction measurement|| age at assessment GCST005962 BMI-adjusted waist-hip ratio|| sex interaction measurement|| age at assessment +Waist-to-hip ratio adjusted for body mass index BMI-adjusted waist-hip ratio|| physical activity measurement GCST004576 BMI-adjusted waist-hip ratio|| physical activity measurement +White matter integrity (bipolar disorder risk interaction) white matter integrity|| bipolar disorder GCST001764 white matter integrity|| bipolar disorder +Whole body bone mineral density and alcohol drinking alcohol consumption measurement|| bone density GCST003921 alcohol consumption measurement|| bone density +Whole-brain volume (Alzheimer's disease interaction) Alzheimer's disease|| whole-brain volume GCST000895 Alzheimer's disease|| whole-brain volume +Resistance to antipsychotic treatment in schizophrenia schizophrenia|| response to antispychotic drug GCST004375 response to antispychotic drug schizophrenia \ No newline at end of file diff --git a/trait-representation-migration/study_background_traits-ALL.xlsx b/trait-representation-migration/study_background_traits-ALL.xlsx new file mode 100644 index 0000000..b54bf3f Binary files /dev/null and b/trait-representation-migration/study_background_traits-ALL.xlsx differ diff --git a/trait-representation-migration/study_background_traits-TEST.txt b/trait-representation-migration/study_background_traits-TEST.txt new file mode 100644 index 0000000..d6faca4 --- /dev/null +++ b/trait-representation-migration/study_background_traits-TEST.txt @@ -0,0 +1,19 @@ +DISEASE/TRAIT MAPPED_TRAIT MAPPED_TRAIT_URI STUDY ACCESSION Trait Background +3-hydroxy-1-methylpropylmercapturic acid levels in smokers "smoking behavior, 3-hydroxy-1-methylpropylmercapturic acid measurement" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_0007015" GCST002957 3-hydroxy-1-methylpropylmercapturic acid measurement smoking behavior +3-hydroxypropylmercapturic acid levels in smokers "smoking behavior, 3-hydroxypropylmercapturic acid measurement" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_0007014" GCST002956 3-hydroxypropylmercapturic acid measurement smoking behavior +6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction) "response to tenofovir, HIV infection, creatinine clearance measurement" "http://www.ebi.ac.uk/efo/EFO_0009279, http://www.ebi.ac.uk/efo/EFO_0000764, http://www.ebi.ac.uk/efo/EFO_0007934" GCST006070 "response to tenofovir, creatinine clearance measurement" HIV infection +6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction) "response to tenofovir, HIV infection, creatinine clearance measurement" "http://www.ebi.ac.uk/efo/EFO_0009279, http://www.ebi.ac.uk/efo/EFO_0000764, http://www.ebi.ac.uk/efo/EFO_0007934" GCST006072 "response to tenofovir, creatinine clearance measurement" HIV infection +Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis) "parietal cortex measurement, schizophrenia, white matter microstructure measurement, cingulate cortex measurement" "http://www.ebi.ac.uk/efo/EFO_0008420, http://www.ebi.ac.uk/efo/EFO_0000692, http://www.ebi.ac.uk/efo/EFO_0005674, http://www.ebi.ac.uk/efo/EFO_0007738" GCST004997 "parietal cortex measurement, white matter microstructure measurement, cingulate cortex measurement" schizophrenia +Acute graft versus host disease in bone marrow transplantation (donor effect) "acute graft vs. host disease, donor genotype effect measurement" "http://www.ebi.ac.uk/efo/EFO_0004599, http://www.ebi.ac.uk/efo/EFO_0007892" GCST003942 "acute graft vs. host disease, donor genotype effect measurement" +Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation "response to allogeneic hematopoietic stem cell transplant, acute graft vs. host disease" "http://www.ebi.ac.uk/efo/EFO_0007044, http://www.ebi.ac.uk/efo/EFO_0004599" GCST002958 acute graft vs. host disease response to allogeneic hematopoietic stem cell transplant +Acute kidney injury in coronary artery bypass surgery (creatinine rise) "coronary artery bypass, Acute kidney injury, serum creatinine measurement" "http://www.ebi.ac.uk/efo/EFO_0003776, http://purl.obolibrary.org/obo/HP_0001919, http://www.ebi.ac.uk/efo/EFO_0004518" GCST002982 "Acute kidney injury, serum creatinine measurement" coronary artery bypass +Acute kidney injury in critical illness "Acute kidney injury, illness severity status" "http://purl.obolibrary.org/obo/HP_0001919, http://www.ebi.ac.uk/efo/EFO_0007863" GCST003656 Acute kidney injury illness severity status +Acute-on-chronic liver failure in hepatitis B "acute-on-chronic liver failure, hepatitis B infection" "http://www.ebi.ac.uk/efo/EFO_0007949, http://www.ebi.ac.uk/efo/EFO_0004197" GCST004165 acute-on-chronic liver failure hepatitis B infection +Adult onset asthma in ever-smokers "smoking behavior, adult onset asthma" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_1002011" GCST004222 adult onset asthma smoking behavior +Adverse response to antithyroid drugs in Graves disease "Graves disease, response to anti-thyroid drug" "http://www.ebi.ac.uk/efo/EFO_0004237, http://www.ebi.ac.uk/efo/EFO_0007838" GCST006278 response to anti-thyroid drug Graves disease +Adverse response to chemotherapy (congestive heart failure) in breast cancer "response to bevacizumab, congestive heart failure, breast carcinoma, response to anthracycline-based chemotherapy" "http://www.ebi.ac.uk/efo/EFO_0005943, http://www.ebi.ac.uk/efo/EFO_0000373, http://www.ebi.ac.uk/efo/EFO_0000305, http://www.ebi.ac.uk/efo/EFO_0005257" GCST003939 "response to bevacizumab, congestive heart failure, response to anthracycline-based chemotherapy" breast carcinoma +Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia "spine bone mineral density change measurement, response to combination chemotherapy, acute lymphoblastic leukemia" "http://www.ebi.ac.uk/efo/EFO_0008474, http://www.ebi.ac.uk/efo/EFO_0007965, http://www.ebi.ac.uk/efo/EFO_0000220" GCST005214 "spine bone mineral density change measurement, response to combination chemotherapy" acute lymphoblastic leukemia +Bone mineral density x blood lead interaction in current smokers (1df test) "smoking behavior, blood lead measurement, bone density" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_0007040, http://www.ebi.ac.uk/efo/EFO_0003923" GCST006132 "blood lead measurement, bone density" smoking behavior +Bone mineral density x blood lead interaction in current smokers (2df test) "smoking behavior, blood lead measurement, bone density" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_0007040, http://www.ebi.ac.uk/efo/EFO_0003923" GCST006133 "blood lead measurement, bone density" smoking behavior +Bortezomib-induced peripheral neuropathy in multiple myeloma "peripheral neuropathy, multiple myeloma, response to bortezomib" "http://www.ebi.ac.uk/efo/EFO_0003100, http://www.ebi.ac.uk/efo/EFO_0001378, http://www.ebi.ac.uk/efo/EFO_0007808" GCST003964 "peripheral neuropathy, response to bortezomib" multiple myeloma || TEST +Bortezomib-induced peripheral neuropathy in multiple myeloma "peripheral neuropathy, multiple myeloma, response to bortezomib" "http://www.ebi.ac.uk/efo/EFO_0003100, http://www.ebi.ac.uk/efo/EFO_0001378, http://www.ebi.ac.uk/efo/EFO_0007808" GCST003438 "peripheral neuropathy, response to bortezomib" multiple myeloma \ No newline at end of file diff --git a/trait-representation-migration/study_background_traits.xlsx b/trait-representation-migration/study_background_traits.xlsx new file mode 100644 index 0000000..202161e Binary files /dev/null and b/trait-representation-migration/study_background_traits.xlsx differ